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Abstract  
Pancreatic ductal adenocarcinoma (PDA) is one of the leading causes of cancer-related deaths 
worldwide and the development of new treatment strategies for patients suffering from PDA is of 
crucial importance.  
Virotherapy uses natural or engineered oncolytic viruses (OVs) to selectively kill tumour cells. 
Although various OVs are being investigated as agents for pancreatic cancer treatment, due to the 
genetic heterogeneity of PDA cells and their consequent mixed permissiveness to viruses, 
virotherapy should not rely on a short list of possible candidates. As such, preliminary data from our 
group demonstrating the potent pro-apoptotic effect of the low pathogenicity avian influenza virus 
(LPAIV) H7N3 A/turkey/Italy/2962/03 in PDA cells, previously established to be resistant to other 
OVs, suggested that this virus might be effective against specific sub-classes of pancreatic cancer. 
Therefore, in the present studies, the avian isolate was selected for further development. 
Preferential replication of the H7N3 virus in IFN-deficient cells, a trait of the majority of PDA cell 
lines, was improved by the truncation of the viral NS1 protein (NS1-77), which compromised the 
virus’ ability to counteract the IFN-mediated antiviral response and, as bystander effect, enhanced 
the killing of uninfected cancer cells by stimulating IFN expression from healthy cells. 
Introduction of L75H mutation within the mitochondrial targeting sequence (MTS) of the viral 
protein PB1-F2 increased virus replication in permissive IFN deficient cells and also lessened PB1-
F2’s ability to counter the IFN response induced by overexpression of mitochondrial antiviral 
signalling protein (MAVS), further enhancing selectivity for PDA cells. 
Substitution of the genes expressing avian surface antigens haemagglutinin (HA) and neuraminidase 
(NA) with those of the well characterized human H1N1 A/Puerto Rico/8/1934 virus eliminated the 
potential risk of reassortment of the H7N3 virus with circulating human influenza strains that might 
result in a new pandemic virus, nonetheless, preserving the oncolytic properties of the parental 
isolate. 
Finally, to promote anti-tumour immunity, the newly generated PR8 H1/N1-2962 NS1-77 virus was 
“armed” to express the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene 
during infection. 
Taken together our data demonstrate the possibility to select an IAV from the avian reservoir on 
the basis of its strain-specific oncolytic skills in PDA cells and, through engineering, improve its 
selectivity, safety and tumour debulking activity.  
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Chapter 1. Introduction  
 
1.1 The Pancreas. 
1.1.1 Gross anatomy. 
The pancreas is an elongated, tapered retroperitoneal organ located behind the stomach, which 
can be subdivided in four main regions: the head, the neck, the body and the tail (Figure 1). The 
head lies in the curve of the second and third portion of the duodenum, while the remaining left 
side consisting of the neck and the body of the pancreas extends slightly upward and ends in the 
tail adjacent to the spleen.  
The distal end of the common bile duct passes through the head of the pancreas and joins the 
pancreatic duct entering the duodenum. The blood supply to the pancreas is from two major 
arteries supplying the abdominal organs, the celiac and superior mesenteric arteries. Venous 
drainage is via the splenic vein, which runs along the body of the pancreas, and the superior 
mesenteric vein draining into the portal vein (Pandol, 2010). 
 
 
Figure 1. Pancreas: gross anatomy and vascular system. Adapted from (Pandol, 2010). 
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1.1.2 Functional anatomy. 
The pancreas is a dual-function gland, which presents both endocrine and exocrine features and 
regulates two major physiological processes: glucose metabolism and digestion.  
The endocrine portion of the pancreas controls the homeostasis of glucose in the bloodstream. 
Blood glucose levels must be maintained within certain limits so that there is a constant supply of 
glucose to feed the cells of the body but not so much as to damage the kidneys and other organs. 
The part of the pancreas with endocrine function is made up of cell clusters, called islets of 
Langerhans, crisscrossed by a dense network of capillaries with which they are in direct contact 
(Figure 2). Their name was coined by Edouard Laguesse (1861-1927), a histologist working at the 
University of Lille, who deduced that they were involved in endocrine secretion and named them 
after Paul Langerhans (1849-1888), who in 1869 first described these clusters but was unable to 
attribute them with a specific function (Laguesse, 1893).  
Four main cell types exist in the islets and can be classified based on their secretions. Alpha (α) cells 
make up 30-45% of the human islet cells and are responsible for synthesizing and secreting the 
peptide hormone glucagon, which causes the liver to convert stored glycogen into glucose, thereby 
increasing the glucose level into the bloodstream (Baum et al., 1962). To counteract spikes in blood 
glucose concentrations beta (β) cells (55-70%) store and release the insulin hormone which reduces 
the glucose concentration in the blood by stimulating its uptake from skeletal muscles and fat tissue 
(Orci, 1986). Alpha and beta cell activity is finely regulated by somatostatin hormone which is 
produced by delta cells (Δ) and can inhibit or suppress the release of pancreatic hormones (Luft et 
al., 1974). Lastly, Γ (gamma) cells or (PP cells) secrete pancreatic polypeptide, which also 
contributes to self-regulate pancreatic endocrine and exocrine secretion activities. 
The pancreas as an exocrine gland is involved in the digestive process secreting a pancreatic fluid 
which contains digestive enzymes that reach the small intestine to further break down the 
carbohydrates, proteins and lipids in the chime (the semifluid mass of partly digested food expelled 
16 
by the stomach into the duodenum). The exocrine component of the pancreas comprises around 
85% of the total mass of the organ and its functional unit is composed of an acinus (from the Latin 
term meaning “berry in a cluster”) and its draining ductule (Figure 2).  
The acinar cells are specialized to synthesize, store, and secrete precursor form (or zymogen) of 
digestive enzymes. The major proteases secreted by the pancreas are trypsinogen and 
chymotrypsinogen and to a lesser degree pancreatic lipase and pancreatic amylase. In normal 
pancreas, the precursor enzymes are inactive in order to avoid autodegradation, which might lead 
to pancreatitis. However, once released in the intestine, the enzyme enteropeptidase (also called 
enterokinase) present in the intestinal mucosa activates trypsinogen by cleaving it to form trypsin 
(Kunitz, 1939). The free trypsin then cleaves the rest of the trypsinogen, as well as 
chymotrypsinogen to its active forms (Dreyer and Neurath, 1955).  
Control of the exocrine function of the pancreas is exerted via hormones gastrin, cholecystokinin 
and secretin, which are produced by cells in the stomach and duodenum, in response to distension 
and/or food and cause secretion of pancreatic juices (Williams, 2001).  
The basal region of the acinar cell contains the nucleus as well as abundant rough endoplasmic 
reticulum for protein synthesis, while the apical region contains zymogen granules and a store of 
digestive enzymes. Secretion of digestive enzymes occurs into the lumen of the acinus, which is 
directly connected to the ductal system. A ductule from the acinus drains the enzymes into the 
interlobular ducts, which in turn deliver them into the main pancreatic duct to finally reach the 
duodenum.  
Although, ductal cells represent a minor cell type in the adult pancreas (around 10% number and 
4% volume) they have two essential functions (i) forming a network that delivers enzymes from the 
acini into the digestive tract and (ii) producing bicarbonate ions (HCO3-), in response to the 
hormone secretin, to neutralize the acidic chime entering the duodenum from the stomach 
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(Githens, 1988). Because of the latter function their epithelium consists of cells that are cuboidal to 
pyramidal and contain abundant mitochondria necessary to produce energy for ion transport. 
 
 
Figure 2.Representation of the endocrine and exocrine components of the pancreas. A islet of Langerhans (clusters of pink 
cells) with endocrine function is surrounded by pancreatic acini producing digestive enzymes which are drain to the 
duodenum via a system of ducts. Adapted from (Bardeesy and DePinho, 2002) and (Logsdon and Ji, 2013). 
 
1.2 Pancreatic Cancer. 
1.2.1  Pancreatic ductal adenocarcinoma (PDA). 
Endocrine and exocrine cells form completely different types of tumours with distinct risk factors, 
symptoms, diagnostic tests, treatment, and survival rates (American Cancer Society, 2013).  
Endocrine tumours, also called islet cell tumours or pancreatic neuroendocrine tumours (PNETs or 
PanNETs), are less common than exocrine tumours, making up about 1% of pancreatic cancers. A 
pancreatic neuroendocrine tumour can be functioning, meaning it still makes hormones, or non-
functioning. A functioning neuroendocrine tumour is named based on the hormone the cells 
normally make such as for example insulinoma, glucagonoma and somatostatinoma (Yao et al., 
2007; Zhang et al., 2013). Non-functional tumours account for 85% of PanNETs and have a 
statistically significantly worse prognosis compared to functioning PanNETs, wherein a specific 
syndrome from hormone oversecretion is seen (Franko et al., 2010; Halfdanarson et al., 2008). 
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Exocrine tumours are the most common type of pancreatic cancer. About 95% of people with 
pancreatic cancer have adenocarcinoma (adeno "gland", karkínos "cancerous" and oma "tumor") 
arising from the exocrine component. Pancreatic ductal adenocarcinoma (PDA), derived from the 
ductal cells lining the ducts, is the most common primary malignancy of the pancreas, representing 
85-90% of all pancreatic neoplasms (Cubilla and Fitzgerald, 1984). Ductal adenocarcinomas are 
composed of infiltrating glands surrounded by dense, reactive fibrous connective tissue, which 
makes them highly invasive hard tumours with aggressive local growth and rapid metastases to 
surrounding tissues (Figure 3). PDA cells appear pleomorphic with variation in shape, lack of 
polarity, irregular nuclei and prominent nucleoli (Stathis and Moore, 2010). Because PDA are 
representative of the vast majority of tumours of the pancreas, the next part of the thesis will be 
focused on this type of neoplasm and within the text the acronym PDA will be used as synonym of 
pancreatic cancer.  
 
 
Figure 3. Histology of normal pancreas (A-B-C) and pancreatic ductal adenocarcinoma (PDA) (D-E-F) at different 
magnifications. Adapted from (The Human Protein Atlas). 
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1.2.2 PDA Risk Factors. 
Different factors affect the incidence and death rates of PDA, including sex, age and racial/ethnic 
group (Silverman et al., 2003). Although the exact etiopathogenesis remains unknown, many risk 
factors have been associated with PDA. 
Risk factors that a person can control are called modifiable risk factors. Among these, tobacco 
smoking is the most important known factor for pancreatic ductal adenocarcinoma. Approximately 
20% of PDA are attributable to cigarette smoking (Iodice et al., 2008) and the risk of developing 
pancreatic cancer is about twice as high among smokers as among those who have never been 
smokers. Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, N-acetyl- 
transferase, cytochrome P450 and DNA-repair genes (XRCC1, OGG1) may be genetic modifiers for 
smoking-related pancreatic cancer (Duell et al., 2002; Li et al., 2006).  
Obesity has also been fairly consistently linked to increased risk of PDA. Obese individuals have a 
20% higher risk of developing pancreatic cancer than those who are normal weight (Berrington de 
Gonzalez et al., 2003; Michaud et al., 2001). Enhanced risk in overweight patients has been linked 
to a positive association of Fat mass and obesity-associated (FTO) and Adiponectin (ADIPOQ) gene 
variants (Tang et al., 2011). Obesity during early adulthood may be associated with an even greater 
risk of pancreatic cancer and a younger age of disease onset (Li et al., 2009). 
Whether alcohol use causes PDA remains to be determined, since a positive association was found 
in several but not all studies (Genkinger et al., 2009). Accumulating evidence suggests that a 
moderate increased risk is limited to heavy alcohol users (Tramacere et al., 2010). 
Conversely to modifiable risk factors, non-modifiable risk factors are not dependent on the lifestyle 
of an individual and cannot be controlled or limited by his or her behaviour. 
Although rare in the human population, several hereditary syndromes linked to gene mutations 
represent non-modifiable risk factors associated with general increased risk of cancer, including 
pancreatic cancer. Hereditary breast ovarian cancer syndrome is associated with germ line mutation 
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in the breast cancer, early onset genes BRCA2 and BRCA1. BRCA2 and BRCA1 are tumour 
suppressor genes normally expressed in the cells of breast and other tissue, which are involved in a 
number of cellular pathways that maintain genomic stability and regulate transcription and 
apoptosis (Schlacher et al., 2011; Wu et al., 2010). Mutations in the BRCA2 gene are associated with 
an increased risk of pancreatic cancer and account for the highest proportion of known causes of 
inherited pancreatic cancer (Couch et al., 2007; Hahn et al., 2003).  
Patients with Peutz-Jeghers Syndrome (PJS), usually associated to mutations in the STK11 tumour 
suppressor gene (Jenne et al., 1998), also have a 11% to 36% chance of developing PDA during their 
lifetime (Giardiello et al., 2000); while the risk for those with hereditary pancreatitis linked to PRSS1 
mutations increase approximately to 40%-50% (Raimondi et al., 2010; Whitcomb et al., 1996). 
Moreover, Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, a rare hereditary 
syndrome characterized by multiple atypical nevi and an increased risk of melanoma due to 
mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumour suppressor gene, has 
also been associated with a 13- to 22-fold increased risk of PDA (Lynch et al., 2008).  
A number of studies have linked family history to an increased risk of pancreatic cancer. Generally, 
individuals with a family history of pancreatic cancer have a nearly 2-fold increased risk for 
developing pancreatic cancer, compared to those without such a history (Permuth-Wey and Egan, 
2009). Families with only one relative with pancreatic cancer or with multiple pancreatic cancers in 
more distant relatives are considered as sporadic. However, the risk increases to 7- to 9-fold for 
individuals with at least 1 first-degree relative (a parent or sibling) with pancreatic cancer and 17- to 
32-fold for individuals with 3 or more first degree relatives with pancreatic cancer (Klein et al., 
2004). 
Oncogenic transformation in the pancreas is currently understood to be a multistage process that 
involves the accumulation of inherited and acquired mutations of specific cancer-associated genes 
in premalignant lesions. The literature describes two main types of PDA precursor lesions: 
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pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). 
PanIN is by far the most common lesion in the small ducts and ductules in the pancreas, which 
growing evidence suggests that are the precursors to infiltrating ductal adenocarcinomas (Hruban 
et al., 2000b; McCarthy et al., 2001). Based on a number of studies that have correlated 
microscopic findings with genetic alterations, three grades of PanIN have been described as cells 
progress from low grade dysplasia (PanIN-1) to high grade dysplasia (PanIN-3) (Hruban et al., 2001) 
(Figure 4). 
Accumulating evidence suggests that also long-standing chronic pancreatitis is a strong risk factor 
for PDA, though pancreatitis may also be an early indicator of pancreatic cancer (Lowenfels et al., 
1993; Malka et al., 2002; Raimondi et al., 2010). Pancreatic cancer risk is almost threefold higher in 
people with chronic pancreatitis, compared with healthy controls (Duell et al., 2012). In addition, 
PDA risk is 40-120% higher in diabetics compared to non-diabetics since the diabetes itself may be 
the cause or an early manifestation of pancreatic cancer (Batabyal et al., 2014; Ben et al., 2011; 
Elena et al., 2013; Starup-Linde et al., 2013; Stevens et al., 2007). 
 
1.2.3 The genetics of PDA. 
Different mutations occur in PDA cells that mediate escape from the apoptotic pathway which will 
otherwise remove unwanted or damaged cells from multicellular organisms in an orderly, non-
inflammatory manner. The identification of signature gene mutations in pancreatic 
adenocarcinoma was recognized as a valuable starting point to study the progression of the 
disease. Alteration in the Kirsten rat sarcoma viral oncogene homolog gene (KRAS), cyclin-
dependent kinase inhibitor 2A gene (CDKN2A), Tumour suppressor protein p53 gene (TP53), and 
deleted in pancreatic carcinoma locus 4 gene (DPC4), also known as SMAD4, are considered 
hallmarks of PDA (Figure 4). 
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Figure 4. Genetic progression model of PDA. Pancreatic intraepithelial neoplasias (PanINs) seem to represent progressive 
stages of neoplastic growth that are precursors to pancreatic adenocarcinomas. The genetic alterations documented in 
adenocarcinomas also occur in PanIN in what seems to be a temporal sequence. The stage of onset of these lesions is 
depicted. Adapted from (Bardeesy and DePinho, 2002). 
 
Mutations in KRAS constitute the earliest genetic abnormalities underlying the development of 
pancreatic neoplasms (Feldmann et al., 2007; Maitra et al., 2006) (Figure 4). RAS protein produced 
by wild-type KRAS is important in normal growth, proliferation, and differentiation of cells, acting as 
a molecular switch, which is functionally characterized by the change from an inactive GDP-binding 
state to an active GTP-binding state. GTP-bound RAS can interact with more than 20 effector 
proteins to regulate various cellular responses including proliferation, survival and differentiation 
(Normanno et al., 2009). KRAS oncogene on human chromosome 12p12.1 is activated by point 
mutations in approximately 90% of PDA (Almoguera et al., 1988; Griffin et al., 1995; Grunewald et 
al., 1989; Shibata et al., 1990). 
Through the use of shared coding regions and alternative reading frames, cyclin-dependent kinase 
inhibitor 2A gene (CDKN2A), on chromosome 9p21, encodes two major proteins (p16 or INK4 and 
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p14 or ARF) involved in the control of the retinoblastoma (RB) and the p53 (TP53) cell cycle 
regulatory pathways (Robertson and Jones, 1999; Schutte et al., 1997). Like KRAS mutation, loss of 
function of the CDKN2A gene, brought by mutation, homozygous deletion or promoter 
hypermethylation, occurs in 80-95% of sporadic pancreatic adenocarcinomas (Rozenblum et al., 
1997) and is considered an early event in the progression of pancreatic neoplasm (Figure 4). 
In addition, homozygous deletions of the genetic material within chromosome arm 9p21, which 
lead to the CDKN2A gene inactivation, can also delete both copies of interferon alpha and beta 
(IFN-α/β) genes located in the same locus. This loss is responsible for the lack of IFN expression in 
nearly 80% of PDA cells (Chen et al., 1996; Ghadimi et al., 1999; Hruban et al., 2000a; Vitale et al., 
2007), although responsiveness to exogenous IFN is maintained in several cases (Booy et al., 2014; 
Murphy et al., 2012; Vitale et al., 2007). 
In approximately 50–75% of PDAs also the tumour suppressor gene TP53, on chromosome 17p13.1, 
has undergone bi-allelic inactivation generally by missense alterations of the DNA-binding domain 
(Rozenblum et al., 1997). The transcription factor p53, produced by TP53, responds to diverse 
cellular stresses formulated to regulate target genes participating in G1-S cell cycle checkpoint, cell 
cycle arrest, apoptosis, senescence and DNA repair (Redston et al., 1994). Studies suggest that loss 
of p53 function contribute to the genomic instability observed in pancreatic cancers (Hingorani et 
al., 2005) and that TP53 gene mutations constitute late events in pancreatic cancer progression 
(Maitra et al., 2003) (Figure 4).  
About 55% of human somatic pancreatic carcinomas show also allelic loss at chromosome locus 
18q21.1, where the DPC4 (also known as SMAD4) tumour suppressor gene is located (Schutte et al., 
1996). The loss of DPC4/SMAD4, infrequently in non-pancreatic cancers, interferes with the 
intracellular signalling cascades downstream from transforming growth factor beta (TGF-B), 
resulting in uncontrolled cell proliferation due to the loss of pro-apoptotic signalling or 
inappropriate G1/S transition (Massague et al., 2000). Like TP53, loss of DPC4/SMAD4 expression is 
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a late genetic event in pancreatic neoplasm progression and is considered a predictor of decreased 
survival for PDA patients (Feldmann et al., 2007). 
Interestingly, although a characteristic pattern of genetic lesions (KRAS, CDKN2A, TP53 and 
SMAD4/DPC4) plays a pivotal role in PDA progression (Bardeesy and DePinho, 2002), molecular 
research together with advances in sequencing technologies have identified many secondary 
genetic alterations in patients with pancreatic cancer revealing a marked genetic heterogeneity of 
individual tumours (Biankin et al., 2012; Yachida and Iacobuzio-Donahue, 2013). This heterogeneity 
can lead to various PDA sub-classes, as shown by various cancer-derived cell lines (Deer et al., 
2010), and appears to have substantial implications for differing responses to therapy (Biankin et 
al., 2012; Collisson et al., 2011). 
 
1.2.4 PDA prognosis and current treatments. 
Pancreatic ductal adenocarcinoma (PDA) is considered one of the most lethal malignancies with a 5-
year survival rate of merely 6% (American Cancer Society, 2013). The prognosis of PDA is largely 
determined by the stage of disease at diagnosis, which is based on the tumour’s size, lymph node 
involvement and the extent of spread locally and to distant organs. 
Whether the poor prognosis of patients with pancreatic cancer compared to others with different 
type of cancers is due to late diagnosis or early dissemination to distant organs is still debated. 
Previous studies split tumour progression in three intervals associated with (i) the time between 
tumour initiation to establishment of the founder parental clone (average 10 years, T1); (ii) the time 
between the appearance of the parental clone and the arise of subclones with metastatic potential 
(average 6.8 years, T2); and (iii) the time from metastatic dissemination to patient’s death (average 
2.7 years, T3) (Luebeck, 2010; Yachida et al., 2010). Unfortunately, the vast majority of PDA patients 
are diagnosed within the last two years of tumour development.  
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At present, surgery provides the best chance of prolonged survival for PDA patients, but due to the 
asymptomatic form of the early stage disease together with the lack of early detection methods 
only about 15% to 20% of diagnosed pancreatic cancer cases are eligible for surgery and even for 
patients with a tumour that has been surgically removed the 5-year survival is only about 20 to 25% 
(American Cancer Society, 2013). 
For advanced disease, chemotherapy is often offered and may lengthen survival. Nevertheless, in 
spite of numerous efforts, the 5-year survival rate for pancreatic cancer has not improved much for 
last few decades. One reason contributing to this is the lack of chemotherapeutic agents which 
would effectively improve the survival of patients (American Cancer Society, 2014).  
5-fluorouracil (5-FU), a pyrimidine analog which works as suicide inhibitor through irreversible 
inhibition of thymidylate synthase, has been used for half a century in advanced PDA. However, as a 
single agent, objective responses rates have typically been less than 10% and responses were 
usually for less than six months. In 1997, a randomized trial found Gemcitabine to have superior 
clinical effect when compared to 5-fluorouracil (Burris et al., 1997). 
Gemcitabine (2’, 2’- difluorodeoxycytidine or dFdC) is a difluoro analog of deoxycytidine and, at the 
time of this writing, is the first line chemotherapeutic agent used in the treatment of PDA. 
Gemcitabine enters the cell via human equillibrative nucleotide transporter 1 (hENT1) (Mackey et 
al., 1998) and therefore patients with detectable expression of hENT had significantly longer 
survival than patients with low levels or absence of this protein (Spratlin et al., 2004).  
In its triphosphate form (dFdCTP) Gemcitabine competes with deoxycytidine triphosphate (dCTP) to 
get incorporated into the DNA strand during replication blocking elongation and triggering 
apoptosis. In addition, the diphosphate metabolite (dFdCDP) inhibits the enzyme ribonucleotide 
reductase (RNR), responsible for the production of the deoxyribonucleotides, further preventing 
the formation of triphosphate nucleotide required for DNA replication and repair (Huang et al., 
1991). 
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Gemcitabine has been used either alone or in combination with other agents to inhibit the growth 
of cancer cells by interfering with specific molecules involved in tumor progression. In November 
2005, the FDA approved in combination with Gemcitabine the use of Erlotinib hydrochloride (trade 
name Tarceva), previously shown to be effective in lung cancer patients with epidermal growth 
factor receptor (EGFR) mutations (Kobayashi and Hagiwara, 2013), for treatment of locally 
advanced, unresectable, or metastatic pancreatic cancer. However, so far Erlotinib has failed to 
demonstrate a marked improvement in the treatment of advanced pancreatic cancer survival 
(American Cancer Society, 2014).  
Cisplatin, a platinum-based anti-neoplastic drug which binds to DNA causing cross-linkage and 
ultimately triggering apoptosis, has been also administered in combination with gemcitabine to 
treat advanced pancreatic cancer. However, although median overall survival was more favorable in 
the combination arm as compared with gemcitabine alone, the difference did not reach statistical 
significance (Heinemann et al., 2006). 
Drug resistance is one of the pivotal factors responsible for low survival rate of PDA patients. Cancer 
cells can acquire resistance against a drug through various mechanisms: (i) blocking the drug’s entry 
into the cell, (ii) increasing its exit from the cell, and/or (iii) enhancing its degradation or preventing 
its activation once inside the cell (Gottesman, 2002). Numerous studies over the past decades have 
suggested that PDAs are associated with various genetic alterations which contribute to its resistant 
characteristics (Shi et al., 2002; Tamburrino et al., 2013).  
Radiotherapy (RT) is commonly used together with chemotherapy for locally advanced pancreatic 
cancer. RT uses ionizing radiation that works by damaging the DNA of cancerous tissue leading to 
cellular death. However, normal cells around the cancer or where the radiation beams pass through 
the body can also be damaged, sometimes causing side effects. Radiotherapy, like chemotherapy, 
does not cure the cancer, but may help to control it and slow down its growth. 
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Because cancer therapies proven successful in other tumour types have shown little efficacy in 
treating pancreatic cancer, the development of new treatment strategies for patients suffering 
from PDA is of crucial importance. 
 
1.3 Virotherapy 
1.3.1 Oncolytic Viruses. 
Viruses began to be employed for cancer therapy at the end of the nineteenth century, but their 
use was not based on a particular theory of alternative treatment, rather it was the result of the 
observation that, occasionally, cancer patients who contracted an infectious disease went into brief 
periods of clinical remission. In the case of leukemia, it was well recognized that contraction of 
influenza sometimes produced beneficial effects as shown by an example dated 1896, in which a 
woman was reported to recover from “myelogenous leukemia” following a presumed influenza 
infection (Dock, 1904). The report was made 35 years before the etiological cause of influenza was 
first discovered in pigs by Richard Shope (Shope, 1931) and 37 years before the first isolation of the 
virus from humans by a group headed by Patrick Laidlaw (Smith et al., 1933). However, in 1912 the 
Italian physician Nicola De Pace presented findings that one of his female patients suffering from 
cervical carcinoma had undergone a complete spontaneous remission after receiving an inoculation 
of the live attenuated Pasteur-Roux rabies virus vaccine following a dog bite (De Pace, 1912). This 
was the first documented case of a tumour remission that was attributed to the lytic effects of a 
virus and began the field of oncolytic virotherapy. 
Oncolytic virotherapy is a treatment that uses natural or engineered oncolytic viruses (OVs) to 
selectively kill tumour cells. OVs exploit cancer-associated genetic aberrations to replicate and 
propagate selectively in tumour cells, thus leading to their lysis, while not affecting or displaying 
limited effect on surrounding normal cells. This behaviour may be attributed to the fact that many 
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of the hallmarks of cancer, such as blocks of apoptosis, deregulation of the cell cycle control and 
immune evasion, are also optimal cellular condition for successful viral replication. Tumour cells are 
therefore more susceptible to viral infection that normal cells.  
Virotherapy offers several advantages over the use of conventional small drugs as cancer 
therapeutics, including selectivity, potency and mechanism of cell killing. Cancer cell death through 
apoptosis triggered by OVs has been increasingly recognized as a promising therapeutic approach 
for many cancers as, differently from necrosis, the typical constituents of dying cells are not 
released into the extracellular environment (Brown and Attardi, 2005; Call et al., 2008; Guo et al., 
2008; Noteborn, 2009).  
Various naturally occurring or genetically engineered viruses are being investigated as oncolytic 
agents for cancer treatment (Table 1). The translational impact of this technique was strengthened 
by the approval of the first genetically-modified tumour killing adenovirus H101 for the treatment 
of head and neck cancer patients in China (Garber, 2006) and by the successful progression of other 
DNA viruses in advanced clinical trials, including the engineered herpes simplex virus Talimogene 
laherparepvec (T-Vec) for melanoma and the engineered vaccinia-vaccine-derived JX-594 (Pexa-
Vec) for colorectal carcinoma and liver cancer (Donnelly et al., 2013; Goins et al., 2014; Heo et al., 
2013). Beside DNA viruses, several RNA viruses have also entered the clinic displaying promising 
results. Reolysin, an unmodified reovirus type 3 Dearing strain, has probably been the most 
extensively studied among the oncolytic RNA viruses due to its natural replication preference in 
tumour cells and spontaneously transformed cells with overactive Ras pathway (Kelly et al., 2009). 
During the last decade more than 30 clinical trials have evaluated the oncolytic potential of locally 
or systemic administered Reolysin against different types of neoplasm. Multi-dose intravenous 
administration of Reolysin to patients with advanced cancers resulted in intratumoural localisation 
of reovirus with little toxicity (Vidal et al., 2008). Recently, Reolysin has completed a phase III clinical 
study in patients with metastatic or recurrent squamous cell carcinoma of the head and neck 
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designed to compare response rates following its intravenous administration in combination with 
paclitaxel and carboplatin versus the chemotherapy treatment alone (Table 1). 
The diversity and abundance of viruses available in nature has provided a constant basin from 
which to choose new oncolytic candidates, including viruses derived from the animal reservoir. 
Newcastle disease virus (NDV), a negative-sense single-stranded RNA virus with a natural avian host 
range, has been thoroughly investigated as oncolytic candidate for human disease (Elankumaran et 
al., 2010; Freeman et al., 2006; Hotte et al., 2007). Although, NDV can cause severe and lethal 
disease in poultry, infection is mostly asymptomatic in humans due to limited replication capacity in 
the cytoplasm of normal mammalian cells. Conversely, NDV displays selective replication in and lysis 
of tumour cells presumably because of their defective interferon (IFN) signalling pathways 
(Reichard et al., 1992; Wilden et al., 2009). In 2006 Freeman et al. presented the first clinical 
evaluation of a attenuated lentogenic isolate of NDV (HUJ) administered systemically and the first 
evaluation of any NDV strain in glioblastoma patients (Freeman et al., 2006) demonstrating  good 
tolerability and encouraging responses.  
Another example of a non-human virus is represented by Vesicular Stomatitis Virus (VSV), a non-
segmented negative-strand RNA virus that can infect insects, cattle, horses and pigs. VSV is also 
able to selectively infect and kill human tumour cells defective in type-I IFN production and 
responses (Barber, 2004; Lichty et al., 2004). At the time of this writing a Phase I clinical trial to 
evaluate the safety of intra-tumoural injections of an engineered VSV expressing human IFN-β in 
patients with liver cancer is recruiting (Table1). 
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Table 1. Selected examples of current clinical trials involving oncolytic viruses from different families. GM-CSF Granulocyte-
macrophage colony stimulating factor; hIFNβ, human interferon β, ICP, infected cell protein; IT, intratumoural; IV, 
intravenous;  MDA5, melanoma differentiation-associated protein 5; MV, measles virus ; NCT, national clinical trial; NIS, 
sodium-iodide symporter; PMID, PubMed identifier; Rb, retinoblastoma protein; SCCHN, squamous cell carcinoma of the 
head and neck; STAT1, signal transducer and activator of transcription 1; US, unique sequence; VSV, vesicular stomatitis 
virus. Adapted from (Miest and Cattaneo, 2014). 
 
Virus Family 
Phase and 
type of 
clinical trial 
Virus name Genetic changes 
Route/ 
Combination 
therapy 
NCT or PMID 
number 
DNA viruses 
Herpesviridae 
Phase III 
complete; 
melanoma, 
primary end 
point met. 
Talimogene 
laherparepvec 
(T-Vec)  
 Armed with GM-CSF  
 Tumour-specific 
replication; ICP 34.5 
deleted, US11 
altered 
 Enabled antigen 
presentation: ICP47 
deleted  
IT/ 
None 
NCT00769704 
Adenoviridae 
Phase II and 
III;  
Bladder 
cancer 
CG0070 
 Armed with GM-CSF 
 Preferential 
replication in Rb-
deficient tumours 
IT/ 
None 
NCT01438112 
 
Approved 
therapeutic 
(China); 
SCCHN 
Oncorine  
(H101) 
 Preferential 
replication in  
tumours: E1B-55K 
deleted 
IT/ 
Cisplatin 
PMID15601557 
Poxviridae 
Phase IIB; 
hepatocellular 
carcinoma 
JX-594  
(Pexa-Vec) 
 
 Armed with GM-CSF 
 Preferential 
replication in 
tumours: thymidine 
kinase deleted 
IT/ 
Cisplatin 
NCT01387555 
PMID23396206 
RNA viruses 
Paramyxoviridae 
Phase I; 
myeloma 
MV-NIS 
 Armed with human 
NIS 
 Preferential 
replication in 
tumours 
incompetent to 
block STAT1 and 
MDA5  
IV/ 
Cyclophosphamide 
NCT02192775 
NCT00450814 
Phase I/II; 
glioma  
NDV-HUJ None 
IV/ 
None 
PMID16257582 
NCT01174537 
Rhabdoviridae 
Phase I;  
hepatocellular 
carcinoma 
VSV-hIFNβ 
 Armed with human 
IFNβ 
IT/ 
None 
NCT01628640 
Retroviridae 
Phase I and II; 
glioma 
Toca 511 
 Armed with cytosine 
deaminase 
IT; IV; into 
resection cavity/ 
5-flurocytosine 
NCT01156584 
NCT01470794 
NCT01985256 
Reoviridae 
Phase III; 
SCCHN 
Reolysin None 
IV/ 
Carboplatin 
paclitaxel 
NCT01166542 
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Whether or not an oncolytic virus reaches the clinic, its development is constantly subject to 
improvement. The most important technical challenges for a successful oncolytic virus are the 
optimization and enhancement of (i) systemic virus delivery, (ii) tumour targeting, (iii) intra-
tumoural virus spread and (iv) anti-cancer immune response. 
 
1.3.1.1 Systemic virus delivery. 
When an oncolytic virus is delivered systemically through intravenous administration it can be 
rapidly cleared from the circulation due to neutralization by serum factors such as antibodies 
accumulated to a previous infection or administration and/or to sequestration by the mononuclear 
phagocytic system (MPS) in the liver and spleen (Underhill and Ozinsky, 2002) (Figure 5). Thus, 
different studies are focused on minimizing the impact of these barriers by changing or physically 
hiding the epitopes that are recognized by antibodies.  
Although several papers demonstrated the superior performances obtained by hiding oncolytic 
viruses inside carrier cells or through chemical modification of viral coat proteins by conjugation of 
biocompatible polymers (Croyle et al., 2004; Doronin et al., 2009; Ilett et al., 2009; Morrison et al., 
2008; Power and Bell, 2008), the most basic method of genetic shielding oncolytic viruses from pre-
existing immunity is serotype exchange, where a different serotype of the same virus species is 
engineered onto the core of an established virus. This strategy requires the availability of multiple 
serotypes for a given virus or of serotypes that humans have not previously encountered, with low 
homology between their surface-exposed glycoproteins or capsid proteins. Multiple engineering 
strategies that differ in the type and magnitude of modification have been applied to different virus 
families, but the result is always a chimeric virus with an engineered serotype that is not recognized 
by the pre-existing antibodies present in the target patient population (Kaufmann and Nettelbeck, 
2012; Miest et al., 2011; Roberts et al., 2006; Sarkioja et al., 2008). 
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Figure 5. Barriers to systemic delivery of oncolytic viruses. There are three main areas that must be addressed to enable 
systemic delivery of virus particles, namely (i) avoiding neutralisation by components of the bloodstream, (ii) avoiding 
premature scavenging by phagocytes, such as hepatic Kupffer cells, (iii) maximising extravasation within tumour 
vasculature and penetration to infect all viable tumour cells whilst avoiding other components of the interstitium. 
Adapted from (Tedcastle et al., 2012). 
 
1.3.1.2 Tumour targeting. 
Tumour selectivity can be enhanced either at the stage of virus entry in the target cells or post-
entry during replication.  
Virus retargeting can be achieved through different approaches; for example by making virus 
binding/entry dependent on proteases specifically secreted by tumour cells (Springfeld et al., 2006). 
Another common strategy involves fusion to the virus attachment protein of a single-chain antibody 
or a peptide known to bind a tumour-associated cell surface marker overexpressed in a wide variety 
of neoplasms (Coughlan et al., 2009; Jing et al., 2009; Nakamura et al., 2005) or specifically 
expressed by a particular type of malignancy (Grandi et al., 2010; Hasegawa et al., 2006; Liu et al., 
2009; Menotti et al., 2006).  
Post-entry targeting can be obtained by placing essential viral gene under the regulation of a 
specific promoter overactive in cancer cells (Doloff et al., 2011; Hardcastle et al., 2007; Kambara et 
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al., 2005; Lee et al., 2010), or by inserting in the viral genome sequences complementary to tissue 
specific miRNA which are downregulated in tumour cells (Hikichi et al., 2011; Ylosmaki et al., 2008). 
Oncolytic viruses can also be made tumour replication selective by mutating viral genes required for 
virus survival in normal cells but not in malignant cells. Deletion of adenovirus (Ad) E1A and E1B 
genes or vaccinia virus (VV) thymidine kinase (TK) genes restricts virus replication to cells with 
defects in retinoblastoma (Rb) and p53-controlled tumour suppressor pathways or in active 
proliferation, respectively (Fukuda et al., 2003; McCart et al., 2001). In the same manner 
impairment of influenza A virus NS1 gene limits virus growth in IFN competent cells, but does not 
affect viral replication in most cancer cells characterized by defective IFN expression or signalling 
pathway (Muster et al., 2004). 
 
1.3.1.3 Improving virus spread in tumours. 
Enhancement of intratumoural spreading also requires improvement, as the movement of viruses 
through tumour cells can be reduced or even blocked by dense intratumoural connective tissue 
(Sauthoff et al., 2003; Yun, 2008). Some oncolytic viruses are naturally well equipped to spread 
within and between tumours (Kirn et al., 2008; Patel et al., 2011), others require further 
engineering or synergy with drugs capable of enhancing the fluidity of the environment surrounding 
the tumour cell. Injection of hyaluronidase, an enzyme that catalyses the hydrolysis of hyaluronan, 
a key component of the tumour extracellular matrix (ECM), lowers the viscosity of the tumour 
environment, thereby increasing tissue permeability and enhancing the spread and efficacy of 
oncolytic adenoviruses (Ganesh et al., 2008). In the wake of this approach a hyaluronidase-
expressing oncolytic adenovirus was generated and displayed improved spread and activity in a 
human melanoma xenograft model (Guedan et al., 2010). More recently, Losartan (Cozaar), an 
angiotensin II receptor antagonist and antihypertensive agent, has been used to improve the 
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intratumoral spreading of HSV by disrupting transforming growth factor-β1 (TGF-β1) signalling, 
which decreases collagen production (Diop-Frimpong et al., 2011). 
 
1.3.1.4 Enhancing antitumor immunity.  
Immune evasion is one of the hallmarks of cancer. Tumours produce immunosuppressive cytokines 
and recruit immune inhibitory cells paralyzing any antitumor immune response (Melcher et al., 
2011; Yang et al., 2010). If stimulation of immune responses against oncolytic viruses represents a 
barrier to clinical success, immune response against cancer cells could help to achieve tumour 
destruction and potentially to prevent disease relapse. Oncolytic viruses may constitute a strategy 
for combining tumour lytic activity with a potent activation of adaptive and innate immune 
responses. Targeted infection of the tumour can lead to a localized inflammatory response, 
stimulating an immune storm directly within the malignancy, thereby facilitating immune 
recognition of cancer-specific antigens (Melcher et al., 2011). The understanding of the importance 
of the immune response stimulation in the final clinical outcomes has driven the design of new class 
of oncolytic viruses combining lytic infection and immunostimulatory transgene expression. To date 
the most successful strategy uses the expression by OVs of the granulocyte-macrophage colony-
stimulating factor (GM-CSF), a cytokine associated with the recruitment and differentiation of 
activating dendritic cells (DC) in the tumour microenvironment, which boosts adaptive immunity 
against tumour-associated antigens (Figure 6). Herpes simplex virus (HSV T-Vec), adenoviruses (Ad 
CG0070) and vaccinia viruses (VV JX-594) expressing GM-CSF have reached advanced clinical trials, 
repeatedly displaying efficacy, especially for malignancies that are sensitive to immune-therapy 
(Andtbacka et al., 2015; Breitbach et al., 2012; Burke et al., 2012; Cripe et al., 2014; Heo et al., 
2013). Another immune-modulatory gene often engineered within different OV scaffolds is the 
interferon-β (IFN-β) gene (Kirn et al., 2007; Li et al., 2010; Willmon et al., 2009). Interestingly, the 
initial aim of IFN-β expression by OVs was to restrict viral replication in normal tissue, thus 
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increasing direct oncolysis and the therapeutic index; further studies showed that the viruses 
worked via an enhanced immune response rather than via virus-mediated tumour lysis.  
OVs expressing other immune-modulatory signalling molecules (including IL-12, IL-24, IL-4, RANTES, 
CD80, IL-18, and IFN-α), which act on different immune pathways, have also been generated and 
tested for their oncolytic activity (Kaur et al., 2009). The success of current oncolytic viruses that 
express immunostimulatory transgenes, even in the absence of robust intratumoral proliferation, 
highlights the potential of new viruses characterized by high transcription rate and consequent high 
transgene expression to stimulate the immune response against the tumour microenvironment 
(Miest and Cattaneo, 2014). 
 
 
Figure 6. Mechanism of action of GM-CSF armed oncolytic viruses (Talimogene laherparepvec MOA). 
 
1.3.2 Virotherapy for PDA. 
Based on the promising results obtained for other type of malignancies, oncolytic virus therapy 
might be a feasible treatment for pancreatic cancer. Indeed, within the past decade, many OVs 
have been intensively studied as potential treatments for PDA and some of these, such as 
adenoviruses, herpesviruses and reoviruses, are currently under clinical trials.  
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At the time of this writing a phase I dose escalation study using a tumour-selective replication-
competent VCN-01 adenovirus, alone or in combination with Gemcitabine, in patients with 
advanced pancreatic cancer is currently recruiting (NCT02045589). VCN-01 virus harbours a T1 
mutation and expresses PH20 hyaluronidase. The T1 mutation consists of a single Adenine 
truncating insertion in the endoplasmic reticulum retention domain of the E3/19K protein (445A 
mutation), which relocates the protein to the plasma membrane and is responsible for enhanced 
virus release and virus anti-tumour activity when injected intra-tumorally or systemically in vivo 
(Gros et al., 2008). As previously discussed (see paragraph 1.3.1.3), the hyaluronidase technology 
improves intratumoral spread of oncolytic viruses increasing their debulking activity (Guedan et al., 
2010).  
Since KRAS is one of the most frequent mutations in PDA cells (80-95%) (Almoguera et al., 1988; 
Griffin et al., 1995; Grunewald et al., 1989; Shibata et al., 1990) reovirus has also been extensively 
studied for the treatment of pancreatic cancer and currently a clinical trial testing the use of 
Reolysin in combination with Gemcitabine in patients with advanced PDA is ongoing 
(NCT00998322). 
Besides agents that already have reached clinical trial stage, many different oncolytic candidates 
have been tested in preclinical studies for the treatment of PDA. For example, the oncolytic 
potential of attenuated VSV-∆M51-GFP and VSV-p1-GFP (Wollmann et al., 2010) was analyzed in a 
panel of 13 clinically relevant human PDA cell lines in vitro and in a xenograft model in comparison 
to conditionally replicative adenoviruses (CRAds), Sendai virus (SeV) and respiratory syncytial virus 
(RSV) (Murphy et al., 2012). Different NDV lentogenic strains were also evaluated for their oncolytic 
potential against PDA cells in vitro (Buijs et al., 2014; Walter et al., 2012). 
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1.4 Influenza A viruses.  
1.4.1 Classification. 
The word “virus” derives from Latin, for poison and other noxious substances. It was used in English 
for the first time in 1392 as a meaning of "agent that causes infectious disease" and then recorded 
in reference to venereal disease in 1728, a long time before the description of a non-bacterial 
pathogen infecting tobacco plants by Dimitri Ivanovsky in 1892 which led to the discovery the 
tobacco mosaic virus by Martinus Beijerinck in 1898.  
Influenza, commonly referred to as “flu”, is caused by a RNA viruses belonging to the 
Orthomixoviridae (ορθός, orthos, Greek for "straight"; μυξα, myxa, Greek for "mucus") family, 
which at the present consists of six genera: Influenza virus A, influenza virus B, Influenza virus C, 
Thogotovirus, Isavirus and Quaranjavirus (International Committee on Taxonomy of Viruses, 2014).  
The three genera of Influenza virus (A, B and C), which are identified by antigenic variations in their 
nucleoprotein (NP) and matrix protein (M1), show different tropism for vertebrates. While influenza 
B and C circulate almost exclusively in humans, influenza A viruses are established also in different 
animal species including horses, swine, and a wide variety of domesticated and wild birds. In 
humans influenza A and B viruses are the predominant cause of significant disease, whereas 
Influenza C virus infects primarily young children usually resulting in a mild respiratory illness 
(Gatherer, 2010; O'Callaghan et al., 1980) and is not included in the seasonal influenza vaccine.  
Genome organization and structural features suggest that influenza A, B, and C viruses had a 
common ancestor, which is distinct from those of other negative sense RNA viruses (Desselberger 
et al., 1980; Webster et al., 1992). Based on the same features, influenza A and B viruses appear to 
share more similarities than they do to influenza C, suggesting that the latter diverged before the 
split between influenza A and B viruses. Nevertheless, during the long human adaptation process, 
influenza B viruses accumulated increasing differences compared to influenza A viruses which 
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prevent potential intertypic reassortment. While Influenza B viruses can be further broken down 
only into lineages and strains, type A influenza viruses are divided into different subtypes based on 
the antigenic relationship of the surface glycoproteins, haemagglutinin (HA) and neuraminidase 
(NA). 
 
1.4.2 Morphology 
Influenza A virus (IAV) particles are pleomorphic, since many strains bud as spherical particles 
(approximately 100 nm in diameter) while others produce long filaments (up to 20 µm in length), 
depending on the virus strain, cell origin, passage history and Matrix protein (M1-M2) features 
(Elleman and Barclay, 2004; Roberts et al., 2013; Roberts et al., 1998) (Figure 7). Although it is 
unclear whether one morphology has advantages over the other, it is well established that serial 
passage of a filamentous strain in embryonated chicken eggs (ECE) results in selection of spherical 
particles (CHOPPIN et al., 1960), whereas the dominant morphology of viruses isolated from the 
upper respiratory tract (URT) of human patients is filamentous (CHU et al., 1949; KILBOURNE and 
MURPHY, 1960), suggesting that the latter phenotype might be clinically more relevant and may 
have a selective advantage in circulating strains.  
 
Figure 7. Different shapes of influenza A viruses. Spherical (A) (Noda et al., 2006) and filamentous (B) structures 
(Neumann et al., 2009). 
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1.4.3 Genome and structure. 
Influenza A virus (IAV) genome is composed of eight negative-sense single stranded RNA gene 
segments (-ssRNA) that encode 11 major proteins and several auxiliary peptides (Table 2). 
Production of infectious progeny virions requires incorporation of all eight vRNA segments and 
occurs at the apical membrane of infected cells (Wise et al., 2009). The eight vRNA molecules of 
varying sizes are individually packed and stabilized by wrapping around multiple copies of 
nucleoprotein (NP; ~56 kDa) (Compans et al., 1972; Ortega et al., 2000) (Figure 8A). The ends of 
each genomic segment are short complementary elements that form the viral promoter and are 
recognized by the viral RNA dependent RNA polymerase (RdRp), which is composed of the three 
subunits PB2, PB1 and PA (Fodor et al., 1994; Hagen et al., 1994; Hsu et al., 1987; Huang et al., 
1990; Lee et al., 2002). The polymerase complex together with the nucleoproteins (NP) and the 
RNA segment form the viral ribonucleoprotein complex (vRNP), which is responsible for virus mRNA 
synthesis and genome replication (Figure 8A). The eight vRNPs are located inside a shell of M1 
protein, that lines the viral lipid membrane derived from the plasma membrane of the infected cells 
during the budding process. Embedded in the membrane there are two surface glycoproteins the 
hemagglutinin (HA) and the neuraminidase (NA) and a membrane ion-channel (M2) (K.G. Nicholson, 
R.G. Webster & A.J. Hay, 1998) (Figure 8B).  
The HA is a glycosylated type I integral membrane protein which functions as both receptor-binding 
protein and fusion protein. NA is a type II integral membrane glycoprotein exerting the sialidase 
enzymatic activity required for cleavage of both host cell receptors and receptors on the virion 
surface to allow the release of the nascent virions preventing their aggregation. 
IAVs are subdivided by antigenic characterization of the HA and NA surface glycoproteins which are 
the major antigenic targets of the host humoral immune response.  At the time of this writing 
eighteen HA (H1-H18) and eleven NA (N1-N11) subtypes are known and can be found in numerous 
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different combinations (eg. H1N1, H3N2 H7N3, H7N1, H18N11, etcc) depending on the host 
(Fouchier et al., 2005; Tong et al., 2013). 
 
Table 2. Influenza A virus genomic segments and major proteins.  
Segment Protein Functions 
1 
Polymerase basic 
protein 2 (PB2) 
PB2 subunit is part of the viral RNA-dependent RNA polymerase (Fodor et al., 1994; 
Hagen et al., 1994; Hsu et al., 1987; Huang et al., 1990; Lee et al., 2002) and is involved 
in the recognition and binding of 5’-capped host pre-mRNAs (cap snatching) (Guilligay 
et al., 2008; Huang et al., 1990). 
2 
Polymerase basic 
protein 1 (PB1) 
PB1 subunit is part of the viral RNA-dependent RNA polymerase (Fodor et al., 1994; 
Hagen et al., 1994; Hsu et al., 1987; Huang et al., 1990; Lee et al., 2002). 
PB1-F2 
PB1-F2 induces mitochondria-associated apoptosis (Henkel et al., 2010; Zamarin et al., 
2005), exerts IFN atagonist properties by inhibing the activity of  Mitochondrial 
antiviral signaling protein (MAVS) (Varga et al., 2011) and interacts with PB1 
influencing the polymerase activity  (Mazur et al., 2008). 
N40 N40 maintains the balance between PB1 and PB1-F2 expression 
3 
Polymerase acidic 
protein (PA) 
PA subunit is part of the viral RNA-dependent RNA polymerase (Fodor et al., 1994; 
Hagen et al., 1994; Hsu et al., 1987; Huang et al., 1990; Lee et al., 2002) and is involved 
in the snatching of 5’-capped host pre-mRNAs providing RNA endonuclease activity 
(Dias et al., 2009).  
PA-X PA-X modulates the host response and viral virulence (Jagger et al., 2012). 
4 
Haemagglutinin  
(HA) 
HA is responsible for binding to sialic acid receptors on the cell surface and fusion with 
endosomal membrane (Skehel and Wiley, 2000). 
5 
Nucleoprotein  
(NP) 
NP is the major component of the viral ribonucleoprotein (RNP) complex and controls 
the nuclear transport of vRNPs (Portela and Digard, 2002). 
6 
Neuraminidase  
(NA) 
NA cleaves off sialic acid from cellular receptors of HA to enable progeny escape from 
infected cells and avoid virus aggregation (Palese et al., 1974). 
7 
Matrix protein  
(M1) 
M1 is the main component of the viral membrane; it underlies the viral envelope and 
plays multiple roles in virion assembly and infection (Ali et al., 2000; Rossman and 
Lamb, 2011). 
M1 is also involved in apoptosis by sequestrating cellular Hsp70 protein (Halder et al., 
2011). 
Matrix protein  
(M2) 
M2 is a membrane protein that forms a proton channel activated under endosomal pH 
conditions and has a pivotal role in virus uncoating and genome release in the 
cytoplasm of the infected cells (Helenius, 1992). 
8 
Non-structural 
protein  
(NS1)  
NS1 is a multifunctional protein that is involved in numerous virus – host interactions, 
but the major role ascribed to this protein is to antagonize the host IFN-mediated 
antiviral response (Hale et al., 2008). 
Nuclear Export 
Protein  
(NEP) 
NEP is a structural component of the viral particle and mediates vRNP export from the 
nucleus to the cytoplasm (Paterson and Fodor, 2012). NEP accumulation has been 
associated with the switch between transcription and replication of vRNAs (Robb et al., 
2009). 
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Figure 8. IAV genome and structure. A) Structural organization of influenza virus ribonucleoproteins (RNPs). The single-
stranded viral RNA (vRNA) molecule (black line) is coiled into a hairpin structure associated with nucleoprotein (NP) 
(yellow spheres). A short region of duplex vRNA (formed between the 5′ and 3′ ends) constitutes the binding site for the 
heterotrimeric RNA-dependent RNA polymerase. B) Schematic representation of IAV structure. Adapted from (Naffakh et 
al., 2008) and (Nelson and Holmes, 2007). 
 
1.4.4 Host Range. 
1.4.4.1 Birds. 
Although IAVs infect humans causing annual epidemics, economic loss and, occasionally, serious 
pandemics, the primary reservoir of the virus are wild aquatic birds (Figure 9). However, probably 
due to the asymptomatic form of most infections in birds, it was not until the mid-1970s that 
systematic investigations of IAVs in feral birds were undertaken. These studies revealed enormous 
genetic pools of the virus in the wild bird population (Alexander, 2007) from which subsequently 
sixteen HA (H1-16) and nine NA (N1-N9) subtypes were isolated (Fouchier et al., 2005).  
In addition to the classification based on HA and NA antigenic types, avian IAV can be further 
classified on the basis of their pathogenic properties. The proteolytic cleavage that is exerted by 
host proteases on the viral HA protein activates virus infectivity and has been shown to be an 
important determinant of influenza virus pathogenicity (Klenk and Garten, 1994; Steinhauer, 1999). 
The main characteristic of HA that determines its sensitivity to host proteases is the cleavage site, 
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which consists of either a single arginine (monobasic site) or an R-X-K/R-R motif (multibasic site) 
(Klenk and Garten, 1994). HAs containing monobasic cleavage sites are activated by trypsin or 
trypsin-like proteases (Klenk et al., 1975; Lazarowitz and Choppin, 1975) and thus IAVs bearing 
these glycoproteins are restricted to replication at sites in the host where these enzymes are found, 
such as the respiratory and intestinal tracts of birds (Steinhauer, 1999). Such viruses (Klenk and 
Garten, 1994; Steinhauer, 1999) display limited virulence and hence are called “low pathogenicity 
avian influenza” (LPAI) viruses. The introduction of basic amino acids into the hemagglutinin 
cleavage site allows HA activation in the trans-Golgi network by ubiquitous furin or related 
proprotein convertases (Morsy et al., 1994; Stieneke-Grober et al., 1992) resulting in virus 
spreading beyond the respiratory or gastrointestinal tract and causing an acute generalized disease. 
IAVs having multibasic cleavage sites, called “highly pathogenic avian influenza” (HPAI) virus, are 
highly virulent and induce systemic infection in their avian hosts with mortality rate as high as 100% 
(Webster and Rott, 1987).  
The highly pathogenic form of IAV, has been known since the end of the 19th century, when an 
Italian scientist, Edoardo Perroncito, reported what is believed to be the first documented evidence 
of “fowl plague” as a distinct disease (Perroncito, 1878). In August 2006, the Food and Agricultural 
Organization (FAO) estimated that, since a chain of outbreaks in late 2003, the HPAI H5N1 virus led 
to the death or destruction of more than 200 million birds worldwide, resulting in economic losses 
of over 20 billion dollars (Harris, August 2006). 
Interestingly, the HPAI viruses are found only in some H5 and H7 strains, whereas all the other avian 
influenza strains, including the H5 and H7 influenza A viruses with monobasic cleavage site, are LPAI 
viruses. It appears that most of the HPAI viruses arose by mutations after LPAI viruses were 
introduced into domestic poultry from the wild bird reservoir. Several mechanisms might be 
responsible for this mutation including duplications of purine triplets due to polymerase slippage 
(Garcia et al., 1996; Perdue et al., 1997) and recombination with cellular or viral RNAs (Maurer-
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Stroh et al., 2013). Nevertheless, the factors that determine mutation from LPAI to HPAI are still 
largely unknown. In some cases, the mutation seems to have taken place rapidly after introduction 
from wild birds; in others, the LPAI virus progenitor circulated in poultry for months before the 
mutation occurred. Although it is not possible to predict whether and when this mutation will 
happen, it is likely to assume that the longer the circulation of LPAI among poultry and domestic 
birds the higher the chance of the mutation to HPAI (Monne et al., 2014; Senne et al., 2006; Senne, 
2007). Thus the screening of the wild bird population and the monitoring of the domestic bird farms 
are essential condition to control the highly pathogenic form of the disease.  
 
1.4.4.2 Humans. 
Avian IAVs may, on occasion, be transmitted directly or indirectly to other host species such as 
domestic birds, pigs, horses, mink, marine mammals, and humans and either cause transient or 
endemic circulation of influenza A viruses in these new host populations (Webster et al., 1992). 
Zoonotic infections, in which a pathogen adapted to another animal species can cause disease in 
humans, may be sporadic, dead-end infections without adaptation to humans (eg. West Nile Virus). 
Other zoonotic infections can stably adapt to humans, leading to sustained person-to-person 
transmission (e.g. HIV and SARS). Influenza A viruses fall into both categories, displaying in the 
majority of the cases dead-end infections (eg. H5N1), but sporadically resulting in stable host switch 
events following adaptive mutations (eg. H1N1 “Spanish Flu”). Although 16 HA subtypes have been 
identified in wild birds, only H1, H2 and H3 subtypes have emerged in human population as a result 
of stable introduction of virus or viral genes from the avian reservoir following adaptive mutations 
(Neumann et al., 2009). The different subtypes showed cyclical appearance in humans: H3 viruses 
emerged around 1890, H1 in 1918, then H2 in 1957, H3 in 1968, and H1 in 2009 (Smith et al., 2009; 
Webster et al., 1992). Since these subtypes do not contain viruses with a multibasic cleavage site 
their infections in human usually result in localized replication within the respiratory tract and mild 
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symptoms, which include fever, cough, sore throat, muscle aches and conjunctivitis. Most people 
recover within a week without requiring medical attention, but influenza sometimes can cause 
severe illness or death especially in people at high risk, such as the elderly, immunocompromised 
subjects, children, pregnant women and patients with chronic medical conditions.  
Seasonal influenza occurs globally in humans with an annual attack rate estimated between 5%–
10% in adults and 20%–30% in children. Worldwide, these annual epidemics are estimated to result 
in about 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths (World Health 
Organization (WHO), March 2014). In temperate regions influenza epidemics show a marked 
wintertime seasonality, with circulation detected over a 2- to 3-month period between November 
and March in the Northern Hemisphere and between May and September in the Southern 
Hemisphere (Tamerius et al., 2013). Different factors are proposed to synergistically drive the flu 
epidemic seasonality. These include fluctuations in host immune competence mediated by seasonal 
factors, such as lower levels of vitamin D, an important activator of the innate immune response 
(antimicrobial activity and antigen presentation), due to reduced exposure to UV light during the 
winter (Cannell et al., 2006; Hewison, 2011). Seasonal changes in host behavior, such as school 
attendance or crowding indoors, have also been associated with enhanced virus spreading during 
inclement weather in winter. Moreover, winter environmental factors, such as typical low 
temperature and low humidity, have been shown to enhance the stability of infectious bioaerosols 
(Lofgren et al., 2007; Tamerius et al., 2011), allowing more transmission of influenza virus by the 
respiratory droplet or aerosol route (Lowen and Steel, 2014). 
 
1.4.4.3 Pigs. 
Three influenza A subtypes have become established in pigs: H1N1, H3N2, and H1N2 viruses. These 
swine viruses are antigenically and genetically different from their counterparts circulating in 
humans. Nevertheless, signs of disease in pigs are similar those observed in humans and include 
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nasal discharge, coughing, fever, breathing difficulties and conjunctivitis. Due to their susceptibility 
to infection by both human and avian IAVs, pigs are considered a mixing vessels for avian and 
human influenza A virus genes (Myers et al., 2007; Van Reeth, 2007) (Figure 9). Thus pigs can 
contribute to mammalian adaptation of avian influenza viruses or to the generation of new 
reassortant viruses between avian and human influenza strains that have the potential to cause 
pandemics (Brown, 2000). 
 
Figure 9. The reservoir of influenza A viruses (Institute of Medicine (US) Forum on Microbial Threats, 2005). Wild aquatic 
birds are the reservoir of influenza viruses for avian and mammalian species. Transmission of influenza has been 
demonstrated between pigs and humans and between chickens and humans (solid lines) but not between wild birds and 
humans (dotted lines).  
 
1.4.5 Replication cycle. 
1.4.5.1 Cell binding, entry and uncoating. 
Hemagglutinin (HA) is the major viral glycoprotein that exerts two main functions: (i) receptor 
binding and (ii) host membrane fusion. HA is a trimeric transmembrane glycoprotein (three 84-KDa 
subunits), in which each subunit consists of two disulfide-linked glycopolypeptides, HA1 (58 kDa) 
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and HA2 (26 KDa) (Doms and Helenius, 1986). The two subunits, HA1 and HA2, are generated from 
the precursor HA0 by proteolytic cleavage, which is exerted during the replication cycle by different 
host proteases depending on the amino acid composition of the cleavage site (see paragraph 
1.4.4.1).  
The cleavage of HA0 is required to allow the structural rearrangement of HA1 and HA2 subunits 
activating both the binding and fusion functions. Most of the HA1, involved in the binding process, 
folds into a globular domain containing the receptor binding site (RBS) at the top of the molecule; 
while the HA2, bearing the fusion peptide at its N-terminus, forms the stalk that projects the 
glycoprotein outward from the surface of the virus (Figure 10). 
IAV infection is initiated via viral attachment mediated by HA proteins binding to sialic acid (SA) (N-
acetylneuraminic acid) linked to sugars on the tips of host cell glycoproteins. The binding 
interactions are very weak, and high avidity is achieved by multiple bonds between HA molecules 
on the virus and SA receptors on the target cell (Matrosovich et al., 2009). After the binding, IAV 
entry and uncoating within the cells occurs exploiting the endocytic pathway (Figure 10). To achieve 
delivery of the viral genome into the cytoplasm, vRNPs must disconnect from the M1 layer and the 
viral shell must open up to the cytoplasm via membrane fusion (Bui et al., 2000; Martin and 
Helenius, 1991; Skehel and Wiley, 2000). Both membrane fusion and uncoating of influenza virus 
are driven by the low endosomal pH through two distinct steps involving different endosomal 
intermediates (Li et al., 2014). The first step, in early endosomes (EE), depends on the activity of the 
influenza virus M2 protein, which is a proton-selective ion channel protein present within the viral 
envelope (Schnell and Chou, 2008; Sugrue and Hay, 1991). In the EE (pH ~5.5–6.0), M2 begins to 
pump ions into the viral lumen acidifying the virus interior and allowing disruption of the M1-vRNP 
interaction and weakening of the M1 layer (Li et al., 2014). The dissociation of matrix proteins from 
the vRNPs has been shown to be important since otherwise M1 would down-regulate the nuclear 
import of vRNPs by directly inhibiting their binding to the nuclear pore complexes (NPCs) (Babcock 
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et al., 2004; Martin and Helenius, 1991). As the pH is further lowered in the late endosome (LE) (pH 
~5.0–5.5), the dissociation of M1 from the viral bilayer permits conformational change of HA and, 
eventually, membrane fusion (Li et al., 2014). Indeed, in the LE the pH decrease leads the HA2 
subunit, in which the N-terminus was hidden in the structure derived from the HA0 cleavage, to 
undergo a conformational change and to expose the fusion peptide. Once the fusion peptide is 
anchored in the endosome membrane the whole HA molecule can fold back allowing the merging 
of the two bilayers (Figure 10). 
After fusion the viral genome, consisting of the eight vRNPs, is released in the cytoplasm by 
diffusion (Babcock et al., 2004). The vRNPs gain access to the nucleus through the nuclear pore 
complexes (NPCs) by interacting with soluble nuclear import receptors (importin α/β transport 
system), which mainly recognize nuclear localization signals (NLSs) on the viral nucleoprotein NP 
(Cros et al., 2005; O'Neill et al., 1995; Wang et al., 1997).  
 
Figure 10. Influenza A virus binding, entry and uncoating. IAV binds via haemagglutinin 1 (HA1) to terminal sialic acids 
present on glycoproteins or on glycolipids (step 1). The virus is subsequently internalized by receptor-mediated 
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endocytosis into a low pH compartment (endosome). M2 ion-channel allows entry of H+ into the viral lumen decreasing 
the pH within the virion and triggering the dissociation of vRNPs from the Matrix protein (M1). As the pH is further 
decreased, HA2 undergoes a conformational changes that expose the viral fusion peptide and allow the fusion of the 
virus envelope with the endosomal membrane (step 2). Subsequently, the genomic ribonucleoprotein complex is 
transported to the nucleus to initiate transcription and replication of the viral genome (step 3). Adapted from (Bullough 
et al., 1994; Cross et al., 2001; Karlsson Hedestam et al., 2008; Weis et al., 1990). 
 
1.4.5.2 Genome transcription and replication. 
IAV transcription is initiated with the synthesis of positive-sense viral mRNAs(+) from the negative-
sense viral genome (vRNAs-) (Figure 11A). As for cellular mRNAs, IAV transcripts require a 7-
methylguanylate cap (m7G) at the 5’ terminus to promote nuclear export, to avoid degradation and 
to bind the ribosome for protein translation. Thus, viral mRNAs synthesis is primed using stolen 
fragments of cellular capped pre-mRNAs which are bound by the viral PB2 subunit (Guilligay et al., 
2008; Ulmanen et al., 1983) and then cleaved by the endonucleolytic domain of the polymerase 
subunit PA (Dias et al., 2009; Yuan et al., 2009) in a process called “cap snatching”. Conversely, 
polyadenylation of IAV mRNAs is independent of cellular 3’-end processing factors (Hay and Skehel, 
1979; Plotch and Krug, 1977) as all eight vRNA segments contain a stretch of uridines (U's) near the 
5' end which correspond to the polyadenylation site in viral mRNAs (Li and Palese, 1994; Robertson 
et al., 1981). 
The mature mRNAs generated from virus genome transcription exit the nucleus by recruiting the 
cellular nuclear export factor 1 (NXF1) through factors binding to the 5' cap structure or the 3' 
poly(A) tail (York and Fodor, 2013) and then undergo translation using the host cell machinery. 
Once expressed, the proteins are sorted based on their localization signals. While HA and NA signal 
peptides guide these glycoproteins to the plasma membrane, several of the viral proteins are 
targeted back into the nucleus by cellular NLS-mediated pathways. Nuclear import is observed for 
the three polymerase proteins (PB2, PB1 and PA) and NP, as well as for the matrix M1 protein, the 
non-structural NS1 protein and the nuclear export protein NEP (Smith et al., 1987) (Figure 11A). 
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The replication of the negative-sense IAV genome is a two-step process: (i) first a complementary 
positive-sense copy (cRNA+) of the vRNA- is produced and then (ii) the cRNA associates with NP and 
the polymerase complex to form a complementary ribonucleoprotein (cRNP) which directs the 
synthesis of a new vRNA- (Figure 11A). Although viral cRNAs and mRNAs are both positive strands 
derived from the same template, the fact that cRNAs do not present 5’cap and are full-length 
copies (including untranslated regions UTR) of the vRNA molecules (Park et al., 2003) suggests the 
existence of two distinct mechanisms to produce these RNAs (Jorba et al., 2009). Therefore, a 
proper timing between transcription and replication is of paramount importance for efficient virus 
production. To this end a major role in the regulation of the polymerase activity has been ascribed 
to the influenza nuclear export protein (NEP) (Bullido et al., 2001; Manz et al., 2012; Robb et al., 
2009). Previous publications showed that the expression of NEP during the replication cycle can 
regulate the accumulation of viral RNA species, leading to a switch from viral transcription during 
early viral replication to production of new vRNPs (Manz et al., 2012; Robb et al., 2009) (Figure 
11A). The importance of NEP in the regulation of viral replication was also emphasized by the 
observation that adaptive mutations within its N-terminus enhance the polymerase activity of avian 
polymerases in mammalian cell cultures (Manz et al., 2012). Beside NEP, the presence of 22 to 27 
nucleotides long small viral RNAs (svRNAs), synthesized from the 3’ end of cRNAs and 
corresponding to the 5’ ends of genomic vRNAs, has been associated with the switch from mRNA 
transcription to genome replication (Perez et al., 2010). Functional characterization indicates that 
svRNAs directly interact with the PA subunit and could provide a segment-specific guide for the viral 
polymerase to the cRNA templates, thereby promoting synthesis of genomic vRNAs which in turn 
will generate new vRNPs (Perez et al., 2012).  
The newly synthesized viral ribonucleoprotein complex (vRNP) is exported from the nucleus at late 
stage of infection. The current model of vRNP nuclear export implicates both the viral matrix 
protein M1 and the viral nuclear export protein NEP as crucial co-factors (Martin and Helenius, 
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1991; O'Neill et al., 1998). In this so called ‘‘daisy-chain’’ model the C-terminus of matrix protein 
(M1) binds strongly to the vRNP through interaction with NP (Baudin et al., 2001). Next the C-
terminus of NEP binds to the nuclear localization signal (NLS) on the N-terminal domain of the viral 
matrix protein M1 (Akarsu et al., 2003; Shimizu et al., 2011; Yasuda et al., 1993). Finally, the β-
importin Crm1 (chromosome region maintenance 1, also referred to as exportin1 or Xpo1) binds 
the N-terminal domain of NEP, and together with its cofactor GTPase Ran (Neumann et al., 2000) 
mediates nuclear export of the vRNP though the nuclear pore complex (NPC) (Figure 11B).  
 
Figure 11. Influenza A virus genome transcription, replication and nuclear export. A) The transcription and replication of 
influenza vRNPs. B) The daisy chain model for NEP-mediated nuclear export of influenza virus vRNPs. Crm1 mediates 
nuclear export of the vRNP complex by binding to the N-terminal domain of NEP, as well as to its cofactor, the small 
GTPase Ran. The C-terminus of NEP binds to the nuclear localisation signal (NLS) on the N-terminal domain of the viral 
matrix protein M1. The C-terminus of M1 in turn binds strongly to the vRNP through interaction with NP. Adapted from 
(Paterson and Fodor, 2012). 
 
1.4.5.3 Virus packaging and budding. 
Two models were originally proposed for the incorporation of the eight vRNPs into infectious IAV 
particles: the random incorporation model and the selective incorporation model (Hutchinson et 
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al., 2010) (Figure 12A). The random incorporation model, where the virus discriminates the vRNAs 
against cRNAs and other cellular RNAs but does not selectively incorporate one copy of each of 
eight segments into the new virion, implies the existence of a common feature in all the vRNAs. 
However, recent publications support the selective packaging model of the IAV segmented genome, 
which, beside common features, predicts also the existence of segment-specific signatures in each 
vRNA (Hutchinson et al., 2010). 
In the selective model, the packaging machinery must: (i) discriminate vRNAs embedded in vRNPs 
from positive-sense RNAs, which include viral cRNAs also packed into complementary RNPs (cRNPs), 
viral mRNAs and cellular RNAs; and (ii) discriminate between the eight vRNAs to ensure packaging 
of a complete and functional set of viral segments (Gerber et al., 2014).  
To discriminate vRNAs from all the other nonviral RNAs, signals that are common to all influenza A 
vRNAs are required. Sequences that match this criterion are the conserved U12 and U13 
sequences, which are located at the extreme termini respectively of 3’ and 5’ non coding regions 
(NCRs) of each vRNA segment and are selectively recognized by the viral polymerase (Arranz et al., 
2012; Moeller et al., 2012). U12 and U13 sequences has been shown to permit incorporation of the 
vRNAs into virus-like particles (VLPs) (Luytjes et al., 1989; Muramoto et al., 2006). 
Nuclear export might also represent an important step in discriminating  vRNAs as, unlike 5’ capped 
cellular RNAs and viral mRNAs, vRNPs are exported from the nucleus via a Crm1-dependent 
pathway (Hutchinson and Fodor, 2013). Discrimination between vRNAs and their positive-sense 
copy cRNAs may also rely on nuclear export since cRNPs are not exported from the nucleus due to a 
single bulged nucleotide in the cRNA termini, which determines differential recognition from viral 
polymerase and consequent variation in its conformation while bound to them (Tchatalbachev et 
al., 2001). Therefore, nuclear export together with U12 and U13, and possibly with the polymerase 
complex, could achieve the first level of selectivity.  
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The second level of recognition in the selective packaging appears to be carried out by both specific 
vRNA segment signatures and cytoplasmic trafficking. The transport of influenza vRNPs from the 
perinuclear region to the apical plasma membrane involves the Rab-11 positive recycling endosome 
system (van Ijzendoorn, 2006) together with an intact microtubule-organising centre (MTOC) for 
membrane targeting (Amorim et al., 2011; Avilov et al., 2012; Eisfeld et al., 2011; Momose et al., 
2011) (Figure 12B). Recent publications propose that, during late stage of infection, Rab-11 positive 
vesicles could serve as platforms for the vRNAs travelling in the cytoplasm to gather in close 
proximity, allowing segment-specific packaging regions, spanning from the 3’ and 5’ NCRs to part of 
the coding regions, to interact and form a core of vRNPs (Chou et al., 2013; Goto et al., 2013). The 
core complex might be constituted by a limited number of vRNPs in a virus strain-dependent 
combination as suggested by recent data confirming that vRNAs are exported neither individually 
nor all together from the nucleus. Viral RNA subcomplexes then would be further assembled on 
their way to the plasma membrane (Lakdawala et al., 2014). 
Influenza A viruses, like several other enveloped viruses, assemble and bud in the ‘‘budozone’’ 
(Schmitt and Lamb, 2004; Simons and Ikonen, 1997; Takeda et al., 2003; Zhang et al., 2000), which 
is a large, stabilized, liquid ordered, cholesterol-/sphingolipid-enriched domain in the plasma 
membrane normally implicated in membrane traffic and signal transduction. These microdomains, 
commonly called “lipid rafts” or “detergent-insoluble glycolipid-enriched complexes” (DIGs) 
(Rossman and Lamb, 2011; Schmitt and Lamb, 2005; Veit and Thaa, 2011), are targeted by influenza 
HA and NA glycoproteins via their transmembrane domains (TMD) (Barman and Nayak, 2000; 
Kundu et al., 1996; Scheiffele et al., 1997; Zhang et al., 2000). Lipid raft targeting appears a strategy 
to concentrate sufficient HA and NA proteins on the virus’ surface to guarantee efficient receptor 
binding, viral fusion and spread (Takeda et al., 2003). 
The viral M2 proton channel, the third viral transmembrane protein, is present in lower amount on 
the virion’s surface compared to HA and NA as it does not associate with lipid rafts when expressed 
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in the absence of other viral proteins (Thaa et al., 2010; Zhang et al., 2000). Nevertheless, M2 has 
been shown to cluster with HA in the plasma membrane independently of other virus proteins 
(Thaa et al., 2010) resulting in localization at the periphery of lipid raft which in turn will constitute 
the edge of the viral budding site (Thaa et al., 2011). 
The localization of the vRNA segments at the budozone level on the plasma membrane is driven by 
association of the viral matrix protein M1, bound to the newly synthesized vRNP (see paragraph 
1.4.5.2), to the cytoplasmic tails (CT) of HA, NA (Barman et al., 2001; Jin et al., 1997), and M2 (Chen 
et al., 2008; Wang et al., 2010). 
Upon assembly of all viral components in the budozone, budding proceeds by membrane bending 
and ultimately scission of the nascent virus particle is mediated by the viral transmembrane protein 
M2, which localizes to the base of growing filamentous viruses (Rossman et al., 2010a; Rossman et 
al., 2010b) and inserts its amphiphilic helix into the membrane to modify membrane curvature 
(Rossman et al., 2010b). 
Finally, influenza NA glycoprotein removes sialic acid from host cell glycol-conjugates and newly 
synthesized viral proteins allowing the release of the virions from the cell surface and preventing 
aggregation of the virus particles (Liu et al., 1995).  
 
Figure 12. Influenza A virus packaging and budding. A) Influenza virus random and selective models for genome 
packaging. B) Transport, selection, and packaging of vRNPs. Unlike viral and cellular mRNAs, vRNPs are exported via a 
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CRM1-dependent pathway; cRNAs are incorporated into cRNPs that are not exported out of the nucleus. In the 
cytoplasm, vRNPs concentrate close to the microtubule organizing centre (MTOC). They bind recycling endosomes via 
Rab11 and migrate along the microtubule network. Several vRNP species migrate together, and this process might 
favour the formation of a supramolecular complex held together by base pairing between vRNAs. Adapted from (Gerber 
et al., 2014; Hutchinson et al., 2010). 
 
1.5 Host defense mechanisms and influenza A virus countermeasures. 
1.5.1 The RIG-I like receptor (RLR) pathway. 
The innate immune system is a first line of defence against pathogen infection. The response to 
infection by the innate immune system of mammals is initiated with the detection of pathogen 
associated molecular patterns (PAMPs) by host pattern recognition receptors (PRRs). Viral RNA can 
be recognized on the cell surface and in the endosome by membrane-bound Toll-like receptors 
(TLRs) or in the cytoplasm by the cytosolic RIG-I-like receptors (RLRs). The latter group of receptors 
includes the retinoic acid inducible gene 1 (RIG-I, also known as DDX58) and the melanoma 
differentiation associated antigen 5 (MDA5, also known as IFIH1 or Helicard) (Kawai and Akira, 
2006; Seth et al., 2006). RIG-I and MDA5, which belong to the superfamily 2 (SF2) helicases or 
ATPases (Gorbalenya et al., 1988; Hopfner and Michaelis, 2007), display a unique domain structure, 
consisting of two N-terminal caspase activation and recruitment domains (CARDs), a central SF2 
type DECH box ATPase domain, and a C-terminal regulatory domain (CTD or RD) (Cui et al., 2008). 
Despite similarity in their structure, the two helicases sense different viruses (Kato et al., 2006; 
Schlee, 2013) as they recognize diverse viral RNA patterns. Indeed, while MDA5 detects long 
double-stranded RNAs (more than 2 kb), RIG-I recognizes short 5′ triphosphate (5’-ppp) dsRNAs (up 
to 1 kb) (Kato et al., 2008; Schlee et al., 2009; Schmidt et al., 2009) including those belonging to 
influenza A viruses. Although the partially complementary 5′- and 3′-ends of influenza virus ssvRNA 
form a short double stranded structure, called the “panhandle” (Hsu et al., 1987), the major PAMP 
detected by RIG-I is the 5′-ppp (Hornung et al., 2006; Pichlmair et al., 2006) which arises during 
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replication and is absent in cellular cytosolic RNAs due to cleavage or capping modifications 
(Fromont-Racine et al., 2003; Shatkin and Manley, 2000; Singh and Reddy, 1989).  
The exact mechanism at the basis of RIG-I/vRNA recognition and signal transduction is still debated; 
however different studies involving crystal structure analysis and NMR identified a basic binding 
cleft within the CTD of RIG-I (amino acids 802–925) as the crucial 5’-pppRNA binding structure that 
determines ligand specificity. Based on these studies, the binding of the 5’ppp-dsRNA to the CTD 
would induces a conformational change in the enzyme which would allow the displacement of the 
N-terminal auto-inactivated CARDs from binding to the DECH box domain (Cui et al., 2008; 
Kolakofsky et al., 2012; Takahasi et al., 2008).  
Once exposed the amino-terminal CARDs of RIG-I undergo robust Lys63-linked ubiquitination on 
Lys172 by tripartite motif 25 (TRIM25) ubiquitin E3 ligase (Gack et al., 2007) (Figure 13). The 
ubiquitination of CARDs activates RIG-I, which then rapidly binds the N-terminal CARD-like domain 
of the mitochondrial antiviral signalling protein MAVS (also called IPS-1, Cardif or VISA) on the 
mitochondrial membrane (MM). This interaction induces MAVS to recruit other MAVS molecules on 
the mitochondrial surface to form larger polymers (Hou et al., 2011). MAVS-mediated antiviral 
signalling is propagated through assembly of a MAVS “signalosome” containing TRAF3, TRAF6, TRAF 
family member-associated nuclear factor κB (NF-κB) activator (TANK), and TNFR1-associated death 
domain protein (TRADD). The formation of a MAVS signalling complex results in the 
phosphorylation and nuclear translocation of interferon regulatory factor 3 and 7 (IRF3 and IRF7) by 
TANK binding kinase 1 (TBK1) and/or IKKε, as well as activation of NF-κB to induce expression of 
type I interferons (IFNs) and pro-inflammatory cytokines (West et al., 2011). 
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Figure 13. Schematic representation of RIG-I receptor pathway. 
 
1.5.2 Interferon-stimulated genes (ISGs). 
IFN-α or IFN-β, induced by the RLR pathway, are soluble cytokines that can act in both autocrine 
and paracrine manner to up-regulate the expression of more than 300 IFN-stimulated antiviral 
genes (ISGs) (Randall and Goodbourn, 2008a).  
A key regulator of antiviral activities induced by IFN is the Protein kinase RNA-activated (PKR). In 
non-stimulated cells, PKR is present at a basal level that can vary depending on the tissue type and 
the degree of differentiation. However, IFN expression up-regulates the levels of PKR, allowing a 
robust response to a viral infection (Kuhen and Samuel, 1999). Human PKR is a latent 
serine/threonine kinase of 551 amino acids with two consecutive N-terminal dsRNA-binding motifs, 
a linker domain, and a C-terminal kinase domain (Meurs et al., 1990). Activation of PKR requires 
binding to dsRNA (Gabel et al., 2006) or, alternatively, to ssRNA molecules presenting internal 
dsRNA structure (Dauber et al., 2009; Katze et al., 1987) (Figure 14A). The binding to dsRNA leads to 
auto-phosphorylation of PKR on multiple sites (Galabru and Hovanessian, 1987; Samuel, 2001) and 
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its subsequent dimerization. PKR dimer blocks cellular and viral protein synthesis by 
phosphorylating the α subunit of the Eukaryotic Initiation Factor 2 (eIF2α) (Farrell et al., 1977) 
required for the initiation of translation (Samuel, 1993); thus playing a central role in host defence 
against viral infection (Gale and Katze, 1998).  
Other key ISGs important in the antiviral state stimulated by IFN expression include the human 2'-5'-
oligoadenylate synthetases (OAS) family, consisting of OAS1, OAS2, OAS3, and OASL (Baglioni et al., 
1978). OAS proteins are synthesized in an inactive form and binding to viral dsRNA triggers their 
allosteric activation (Figure 14B). Active OAS oligomerizes ATP through an unusual 2’-5’ 
phosphodiester linkage, generating 2’- 5’-oligoadenylates [2-5A or pppA(2’p5’A)n] which in turn 
binds to and activates the Latent RNase (RNase L). Upon activation, RNase L dimerizes and begins to 
degrade all RNAs within infected cells, both viral and cellular (Clemens and Williams, 1978; Dong 
and Silverman, 1997), thus preventing protein translation and shutting down viral replication. 
Among the many antiviral factors upregulated by IFNs, the dynamin-like large GTPase Mx proteins 
expressed from the myxovirus resistance gene (MX1) are key effector molecules inhibiting different 
RNA viruses in many species (Haller et al., 1980; Haller et al., 2010; Haller and Kochs, 2011). With 
respect to IAV the murine Mx1 protein, present in the majority of wild type mice but mutated and 
functionally absent in most inbred laboratory strains (Haller et al., 1987; Staeheli et al., 1988), 
accumulates in the cell nucleus and inhibits virus primary transcription by targeting the viral 
ribonucleoprotein complex to degradation pathways (Haller and Kochs, 2002). In contrast to the 
murine counterpart, human MxA protein localizes in the cell cytoplasm in association with the 
smooth endoplasmic reticulum (ER) (Figure 14C). This localization has been shown to confer MxA 
the ability to exert its antiviral effect before virus primary transcription by preventing the input 
vRNPs from being transported into the nucleus (Matzinger et al., 2013; Xiao et al., 2013). A current 
model proposes that, upon viral infection, MxA recognizes the incoming vRNPs and starts to self-
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assemble into rings around the viral nucleocapsid structure, resulting in a higher-order oligomeric 
complex that prevents vRNPs from entering the nucleus (Gao et al., 2011). 
The identification and functional characterization of other ISGs that control influenza virus 
replication such as the recently described IFITM3 gene (Everitt et al., 2012), are a matter of current 
research in several laboratories. 
 
Figure 14. Activity of selected interferon stimulated antiviral genes (ISGs). A) Protein kinase RNA-activated (PKR), B) 2',5'-
oligoadenylate synthetase 1 (OAS1), C) MxA protein. Adapted from (Sadler and Williams, 2008). 
 
1.5.3 Apoptosis. 
Apoptosis or programmed cell death is a highly regulated natural process of eliminating unwanted, 
redundant, or damaged cells from an organism without eliciting a major host inflammatory and/or 
immune response. Morphologically, cells are subject to cytoplasmic shrinkage, plasma membrane 
blebbing, DNA fragmentation, and chromatin condensation. Finally, the cells form cell fragments, 
termed apoptotic bodies, and are removed by phagocytic cells. The main difference from necrosis is 
the absence in the extracellular environment of constituents of the dying cells, which can induce 
unwanted inflammatory response (Raff, 1998). 
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Apoptosis is triggered through two signalling pathways: the intrinsic pathway (also known as the 
mitochondrial pathway) and the extrinsic pathway (also known as the death receptor pathway) 
(Figure 15). 
The intrinsic pathway can be triggered by any stimulus that causes oxidative stress, DNA damage or 
mitochondrial disturbances. The involvement of the mitochondria in apoptosis first came to light 
when it was discovered that one of the critical factors required for the activation of programmed 
cell death was cytochrome c (cyt c) (Li et al., 1997). Indeed, mitochondrial damage can cause 
permeabilization of the outer mitochondrial membrane which facilitates cyt c release into the 
cytoplasm (Figure 15). Once released, cyt c binds the caspase adaptor protein Apaf-1 (apoptotic 
protease-activating factor-1), which then activates procaspase 9 forming a complex termed the 
“apoptosome”. This complex in turn activates several downstream effector caspases, such as 
caspases 3, 6 and 7, leading to DNA fragmentation and cell death (Iannolo et al., 2008; Oliver and 
Vallette, 2005). 
In contrast to the intrinsic pathway, the extrinsic pathway is induced by ligand binding to death 
receptors (Figure 15). The ligand-death receptor system includes different receptors such as the 
tumour necrosis factor receptor 1 (TNF-R1), the Fas ligand-Fas receptor (also known as CD95) 
(Mollinedo and Gajate, 2006) or TRAIL-TRAIL receptor (including TRAIL-R1, also termed DR4, and 
TRAIL-R2, also termed DR5). Binding of respective ligands leads to receptor oligomerization and 
recruitment of death signal adaptor proteins. Fas ligand (Fas-L) binding on the outer cellular 
membrane, for example, leads to Fas receptor oligomerization and a subsequent conformational 
change which activates its cytoplasmic death domains to recruit FADD protein (Fas-associated 
protein with death domain) (Iannolo et al., 2008) (Figure 15). Recruitment determines activation of 
FADD N-terminal death effector domain (DED) and consequent enrolment and activation of 
procaspase 8. The oligomerized receptors together with the recruited FADD and the initiator active 
60 
caspases 8 form a complex termed DISC (death-inducing signalling complex) which propagates the 
signal by activating effector caspases 3 and 7, hence leading to apoptotic events. 
During the last decade it has become clear that, besides playing an important role in the 
development and maintenance of tissue homeostasis, apoptosis is also important for preventing or 
limiting viral replication during infections. Two types of virus-host interactions should be considered 
in this respect. First, apoptosis may be induced in infected cells by the endocrine or intrinsic 
pathway. Second, infected cells may trigger paracrine or extrinsic apoptosis in non-infected 
neighbouring cells through release of signalling molecules, such as IFNs (Zhirnov and Klenk, 2007). 
Indeed, another important function of IFNs is to establish a pro-apoptotic state in target cells, which 
can help to restrain the infection. Both IFN-α and IFN-β have been shown to be capable to induce 
apoptosis in various systems, although whether their effect is mainly exerted via extrinsic or 
intrinsic pathway is still unclear (Barber, 2001; Clemens, 2003; Randall and Goodbourn, 2008b). 
Probably it would involve both, as suggested by the different mechanisms proposed for PKR 
(Balachandran et al., 1998) and OAS (Ghosh et al., 2001) triggered cell death in response to viral 
infections.  
Regardless of the pathway involved, the central players in the unfolding of apoptotic events are the 
caspases. These cysteine-dependent, aspartate-specific family of proteases, which are normally 
expressed as inactive precursors (zymogens) in the cytoplasm, are activated by proteolytic cleavage 
immediately downstream the two independent initiator pathways (Taylor et al., 2008). Activation of 
the effector caspases triggers different events, which can vary in the timeline depending on cell line 
or tissue examined, apoptosis-inducing agent, stimulus intensity and/or exposure time, but 
eventually they will determine an orderly cell death.  
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Figure 15. Schematic representation of the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways. 
Adapted from (MacFarlane and Williams, 2004). 
 
Different assays are available to detect and to study the biochemical changes that occur during 
apoptosis. The annexin V assay is based on morphological changes that occur in apoptotic cells. 
Under normal physiological conditions, a cell displays an asymmetric distribution of phospholipids 
in the two leaflets of the cellular membranes with phosphatidylserine (PS) facing the cytosolic side 
(Higgins, 1994). However, during the early stages of apoptosis this membrane asymmetry is rapidly 
lost, without concomitant loss of membrane integrity, resulting in externalization and exposure of 
PS on the outer leaflet of the plasma membrane, which serves as a label for recognition and 
subsequent removal of the dying cell by phagocytosis (van Engeland et al., 1998).  
Annexin V is a 35-36 KDa phospholipid-binding protein, which was initially discovered for its strong 
anticoagulant properties (Reutelingsperger et al., 1985). This protein binds to phospholipids in a 
Ca2+ dependent manner (Raynal and Pollard, 1994), presenting higher preference for phospholipid 
62 
species such as PS, (Andree et al., 1990), while displaying minimal binding to phospholipid species 
such as phosphatidylcholine and sphingomyeline constitutively present in the outer leaflet of 
plasma membrane. Thus, fluorescein labelled annexin V represents a powerful probe to detect early 
apoptosis, characterized by PS externalization, in dying cells (Vermes et al., 1995).  
DNA fragmentation is another key feature of apoptosis. The enzyme responsible for this 
fragmentation is the Caspase-Activated DNase (CAD), which is normally inhibited by another 
protein, the Inhibitor of Caspase Activated DNase (ICAD), in non-apoptotic growing cells. However, 
during apoptosis, the effector caspase 3 cleaves ICAD causing CAD activation (Enari et al., 1998). 
Because the double-stranded DNA of the nucleosomes is tightly complexed with the core histones 
and is thus protected from cleavage by CAD, the active endonuclease can only exert its activity at 
the most accessible internucleosomal linker region, generating mono- and oligonucleosomes 
bearing DNA fragments which are roughly discrete multiples of 180-bp (360, 540 etc.) (Skalka et al., 
1976). This effect can be used to reveal apoptosis either via DNA laddering (Wyllie, 1980) on 
agarose gels or via enzymatic immunoassay detection of cytoplasmic histone-associated DNA 
fragments several hours before plasma membrane breakdown (Duke and Cohen, 1986; Terui et al., 
1995). 
Poly [ADP-ribose] polymerase 1 (PARP-1) cleavage is also a hallmark of caspase-dependent apoptosis 
(Aredia and Scovassi, 2014). Since apoptosis is an energy-dependent process (Wyllie et al., 1980), 
intracellular level of ATP is considered the crucial discriminant for activating the apoptotic pathway 
or dying through less regulated mechanisms, i.e. necrosis (Nicotera et al., 1998). In normal cells, 
genome integrity is assured in response to DNA damage/cellular stress by activation of PARP-1, 
which allows DNA repair by synthesizing poly(ADP-ribose) (PAR) through NAD consumption (Aredia 
and Scovassi, 2014). However, in cells undergoing apoptosis, PARP-1 activity would dramatically 
increase in the attempt to repair the damage caused by caspase-triggered DNA fragmentation. This 
would have a deleterious impact on cell metabolism, depleting the intracellular energy pool (Herceg 
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and Wang, 1999; Nicotera et al., 1998) required to support the ATP-consuming sequential steps of 
programmed cell death. Thus, during apoptosis caspase 3 and 7 inactivate PARP-1 by proteolytic 
cleavage. These proteases recognize and cleave a motif in the nuclear localization signal of PARP-1 
separating a 24 KDa fragment (p24) zinc finger domain required for DNA binding from a 89 kDa 
fragment (p89), which includes the auto-modification domain and catalytic domain (Chaitanya et 
al., 2010; Lazebnik et al., 1994; Nicholson et al., 1995). 
Cleaved PARP-1 protein fragments also inhibit any remaining functional PARPs by binding 
irreversibly to damaged DNA. The existence of this feed-back loop in caspase-mediated PARP-1 
inactivation suggests that blocking PARP-1 activity is pivotal for the proper function of the apoptotic 
machinery.  
 
1.5.4  Influenza A virus NS1-protein: antagonizing IFN-mediated antiviral response. 
Influenza A virus NS1 protein is encoded on a collinear mRNA derived from vRNA segment eight, 
which upon splicing results in the synthesis of the nuclear export protein (NEP) mRNA (Lamb and 
Choppin, 1979). Both NS1 and NEP mRNA species share 56 nucleotides at the 5’ end, resulting in 
NS1 and NEP proteins sharing 10 N-terminal amino acids (Lamb and Lai, 1980). In infected cells, the 
amount of spliced NEP mRNA was found to be only approximately 10% that of unspliced NS1 mRNA 
but this may vary depending on the strain (Lamb et al., 1980).  
The NS1 protein has a strain-specific length of 219–237 aa (Hale et al., 2008), an approximate 
molecular mass of 26 kDa and it is notionally divided into two distinct functional domains: an N-
terminal double-stranded RNA (dsRNA)-binding domain (RBD; aa 1-73) and a C-terminal effector 
domain (ED; aa 88-C teminus), which are connected via a short inter-domain linker region (LR) 
(Bornholdt and Prasad, 2008; Hale, 2014). Unlike NEP, NS1 protein is not considered a structural 
component of the virion, although recent proteomics analysis suggest it may in fact be present 
(Hutchinson et al., 2014). Nevertheless, NS1 is expressed at high levels in infected cells (Krug and 
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Etkind, 1973) where it exerts a plethora of different activities involved in regulation of viral RNA 
replication, viral protein synthesis, and general host-cell interaction (Hale et al., 2008). Despite its 
multiple activities, the major role ascribed to NS1 is to antagonize the host IFN-mediated antiviral 
responses at different levels. Although the IFN-antagonistic properties of NS1 proteins are strain-
specific (Geiss et al., 2002; Hayman et al., 2006; Kochs et al., 2007), different studies demonstrated 
NS1 can limit IFN-β induction by pre-transcriptional and/or post-transcriptional mechanisms (Figure 
16) . 
Pre-transcriptional limitation of IFN induction occurs in the cytoplasm of infected cells and is 
performed by sequestrating viral RNAs from the cellular cytoplasmic pattern recognition receptor 
RIG-I (Donelan et al., 2003; Talon et al., 2000) and by blocking the multimerization of TRIM25, 
which is required for the ubiquitination and activation of RIG-I (see paragraph 1.5.1). Residues Arg-
38 and Lys-41 within the NS1 RBD are mainly involved in pre-transcriptional limitation of IFN 
induction since a R38A/K41A mutant results defective both in sequestering viral RNA from 
molecular sensors and in suppressing TRIM25-mediated RIG-I ubiquitination (Donelan et al., 2003; 
Gack et al., 2009). However, a contribution in blocking TRIM25-triggered antiviral response has 
been also reported for residues E96 and E97 within the NS1 ED (Gack et al., 2009) (Figure 16). 
Interestingly in mouse cells, NS1 inhibited the activation of murine RIG-I in a TRIM25-independent 
manner by binding another ubiquitin E3 ligase called Riplet, which has also been shown important 
for RIG-I ubiquitination (Oshiumi et al., 2010; Rajsbaum et al., 2012). 
Post-transcriptional limitation of IFN-β induction occurs in the nucleus and involves the C-terminal 
ED that binds directly to two zinc-finger regions in the 30 kDa subunit of Cleavage and 
Polyadenylation Specificity Factor (CPSF30) (Nemeroff et al., 1998; Noah et al., 2003; Twu et al., 
2006) and interacts with Poly(A)-Binding Protein II (PABPII) (Chen et al., 1999). The NS1–CPSF30 
complex prevents CPSF30 from binding cellular pre-mRNAs, thereby inhibiting normal cleavage and 
polyadenylation of the 3’- end of host-cell mRNAs (Nemeroff et al., 1998). Binding to CPSF30 
65 
appears to require Phe-103 and Met-106 as the influenza virus strain H1N1 A/Puerto Rico/8/34 
(PR8) is unable to interact with CPSF30 due to amino acid substitutions in these positions (Kochs et 
al., 2007). Polyadenylation of influenza A virus mRNAs is independent of cellular 3’-end processing 
factors (see paragraph 1.4.5.2), therefore viral mRNAs are not affected by CPSF30 inhibition (Figure 
16). 
Besides limiting IFN expression in infected cells, NS1 can also directly block the functions of the 
cytoplasmic ISG antiviral proteins 2’-5’-oligoadenylate synthetase (OAS) (Min and Krug, 2006) and 
PKR (Li et al., 2006), which, as previously discussed (see paragraph 1.5.2), are key regulators of viral 
transcription/translation processes and play additional roles in other innate defences such as IFN 
induction and apoptosis (Garcia et al., 2006; Silverman, 2007). The RBD of NS1 protein out-
competes OAS for interaction with dsRNA, thereby inhibiting this host antiviral strategy (Min and 
Krug, 2006), while NS1 interaction with PKR is suggested to occur in a RBD-independent manner, via 
residues 123–127 within the ED (Li et al., 2006; Min et al., 2007). In addition, the ED also interacts 
with other cellular proteins such as PI3K/Akt (Shin et al., 2007b) and Scribble (Liu et al., 2010) 
implicated in the apoptotic pathway. 
Influenza A virus is a cytolytic virus that induces cell death in most cell types by apoptosis (Fesq et 
al., 1994; Hinshaw et al., 1994; Mori et al., 1995) and, only in certain cells, by necrosis (Arndt et al., 
2002; Zhirnov and Klenk, 2003). Different publications suggest that the role of apoptosis in 
influenza virus replication can be seen from two perspectives. From one point of view apoptosis is 
seen as a host defence mechanism, which aims to limit virus replication (Barber, 2001; Kurokawa et 
al., 1999), on the other hand, apoptotic factors, such as caspase 3 and NF-kB/ Fas/Trail, promote 
influenza virus replication (Stray and Air, 2001; Wurzer et al., 2003; Wurzer et al., 2004). Therefore, 
a proper timing in apoptosis might be of paramount importance for virus replication. Accordingly, 
NS1 has been reported to have both anti and pro-apoptotic functions (Ehrhardt et al., 2007; Lam et 
al., 2008; Schultz-Cherry et al., 2001; Shin et al., 2007a; Stasakova et al., 2005; Zhirnov et al., 2002). 
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Indeed, the activation of the anti-apoptotic program early during infection eliminates an important 
defence mechanism of the host and, thus, provides conditions for efficient virus replication. Once 
this has been accomplished, apoptosis is up-regulated at the final stage of the viral life cycle to 
promote nuclear release of vRNPs and phagocytic clearance of infected cells, which might 
otherwise stimulate cell-mediated cytotoxic responses (Zhirnov and Klenk, 2007). 
To interact with so many different host proteins and exert its multifunctional activity, NS1 has been 
suggested to adopt different quaternary conformations in infected cells on a concentration and 
spatial-dependent basis (Hale, 2014). Various papers report that at low concentrations NS1 protein 
is present as a dimer, which formation is likely mediated by the stable self-association between 
RBDs (Aramini et al., 2011; Kerry et al., 2011). However, at later time-post infection following 
increasing protein concentration, higher-order multimerization of NS1 can be observed (Aramini et 
al., 2011; Bornholdt and Prasad, 2008; Carrillo et al., 2014). Cell-based assays indicate that such 
multimerization is dependent upon the ED (Nemeroff et al., 1995) with the highly conserved 
tryptophan-187 (W187) exerting a crucial role (Aramini et al., 2014). This mutimerization have been 
proposed to enhance the NS1 affinity to dsRNA via cooperative binding of different monomers 
linked to one another by alternating stable RBD–RBD and ED–ED ‘helix–helix’ interactions (Hale, 
2014). In line with spatial importance of dsRNA binding activity and concentration progression of 
NS1 protein, while dimers are mainly localized in the nucleus, higher-order multimerization occurs 
in the cytoplasm (Hale, 2014).   
In addition to different quaternary structures, NS1 has also been shown to undergo post-
translational modifications commonly occurring for different cellular proteins, such as 
phosphorylation and sumoylation of specific residues, which can affect in a strain-dependent 
manner protein interaction, protein activity and/or protein stability (Hsiang et al., 2012; Santos et 
al., 2013; Xu et al., 2011). 
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Figure 16. Influenza virus NS1 protein: pre- and post-transcriptional limitation of IFN expression in infected cells. 
 
1.5.5  Influenza A virus PB1-F2 protein: apoptosis inducer. 
As discussed in the previous paragraph, temporal regulation of both anti- and pro-apoptotic 
mechanisms is critical for the virus during its normal replication cycle. To counteract apoptosis 
during early infection, NS1 protein has been shown to modulate anti-apoptotic proteins (Liu et al., 
2010; Shin et al., 2007b). However, in a later stage of infection, expression and localization of PB1-
F2 viral protein, encoded by the +1 alternative ORF in the PB1 gene, at the mitochondrial 
membrane (MM) results in dissipation of membrane potential (ΔΨm), release of cytochrome c (cyt 
c) and activation of caspase-9-mediated intrinsic apoptotic pathway (Gibbs et al., 2003; Henkel et 
al., 2010; Zamarin et al., 2005) (Figure 17). A region near the C-terminus of PB1-F2 called 
Mitochondrial Targeting Sequence (MTS) (aa 65-87) is necessary and sufficient for its inner MM 
localization (Gibbs et al., 2003). PB1-F2 MTS mimics the most common type of mitochondrial 
targeting signal in cellular proteins, consisting of a terminal extension termed the presequence, 
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characterized by enriched positively charged, hydroxylated and hydrophobic residues, which have 
the potential to form an amphiphilic α helix (Pfanner, 2000). In a helical wheel projection, the 
positively charged residues localize to one side of the helix, while the opposite side is uncharged 
and hydrophobic (Roise and Schatz, 1988; von Heijne et al., 1989). Inside the MTS specific amino 
acids bearing hydrophobic side chains, such as Leucine (Leu or L) residues, appear crucial for 
mitochondrial targeting (Chen et al., 2010; Gibbs et al., 2003), which involves direct recognition and 
subsequent translocation into the intermembrane space (IMS) via the translocase of outer 
membrane 40 (TOM 40) (Melin et al., 2014; Yoshizumi et al., 2014). Following translocation, PB1-F2 
assembles into a highly ordered oligomer (Yoshizumi et al., 2014) and triggers permeabilization of 
the MM likely by forming a nonselective ion channel (Henkel et al., 2010) or through interaction 
with proteins constituting the permeability transition pore complex (PTPC), such as the adenine 
nucleotide translocator 3 (ANT3) in the inner mitochondrial membrane and the voltage-dependent 
anion channel 1 (VDAC1) in the outer mitochondrial membrane (Zamarin et al., 2005). Although the 
exact mechanism of MM permeabilization is still debated, the final outcome consists in 
depolarization of membrane potential (ΔΨm) and release of cyt c which in turn activates the 
intrinsic apoptotic pathway. 
In addition to its role in inducing apoptosis, localization at mitochondrial level of PB1-F2 was shown 
to exert IFN antagonist function by impairing the activity of the mitochondria antiviral signalling 
protein (MAVS), which, as a downstream adaptor protein for RIG-I, plays a central role in virus-
triggered IFN-β induction (see paragraph 1.5.1). Different mechanisms can modulate MAVS 
expression and signalling. These include protein–protein interactions, alterations in mitochondrial 
dynamics, and/or post-translational modifications as previously reviewed by Jacobs and Coyne 
(Jacobs and Coyne, 2013). Among the alterations in mitochondrial dynamics, the membrane 
potential (ΔΨm) is essential for MAVS-mediated IFN-α/β induction (Koshiba et al., 2011). As such, 
PB1-F2 exerts its IFN antagonist function, at mitochondrial level, through the dissipation of the 
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membrane potential (ΔΨm) (Varga et al., 2012), which in turn results in inhibition of MAVS activity 
and consequent decrease of IFN expression (Varga et al., 2011) (Figure 17). Thus, PB1-F2 protein 
enhances influenza virus replication in two different ways: (i) it increases virion release by 
promoting apoptosis at late stage of infection, and (ii) it contributes to the inhibition of IFN 
expression therefore blocking the activation of paracrine IFN-mediated antiviral response. 
Interestingly, beside mitochondria localization, PB1-F2 has also been found in the cytoplasm and in 
the nucleus of infected cells (Chen et al., 2010; Gibbs et al., 2003). The presence of the protein in 
the nucleus may allow for its proposed interaction with PB1, affecting viral polymerase activity 
(Mazur et al., 2008). 
 
 
Figure 17. Pro-apoptotic and IFN-antagonist activities of influenza virus PB1-F2 protein at late stage of infection. Adapted 
from (Varga et al., 2012). 
 
1.6 Influenza A virus evolution. 
1.6.1 Antigenic Drift and Antigenic Shift. 
Change is a conditio sine qua non for a virus since it allows escape from the host pre-existing 
immunity, enhancement of viral fitness during infection and adaptation to new host species. IAVs 
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are constantly changing through two different mechanisms called antigenic drift and antigenic shift 
(Figure 18).  
“Antigenic drift” consists of selective amino acidic mutations in the antigenic portions of the surface 
glycoproteins HA and NA. These mutations are the results of small changes in viral genes that 
happen continually over time during virus replication. As in all RNA viruses, mutations in influenza 
occur frequently because the virus' RNA polymerase lacks exonuclease proofreading capability, 
resulting in an error rate between 1×10−3 and 8×10−3 substitutions per site per year during viral 
genome replication (Chen and Holmes, 2006). Random mutations can be rapidly selected from a 
viral population depending on the evolutionary pressures applied, (Murphy and Clements, 1989) 
and can accumulate over time resulting in antigenically different viruses, leading to immune 
response evasion (Smith et al., 2004) and/or drug resistance (Ong and Hayden, 2007). The numbers 
and locations of mutations in the surface proteins, allowing the virus to elude host immunity, have 
been characterized by different studies (Bush et al., 1999; Fitch et al., 1997; Smith et al., 2004) since 
these genetic changes are the main reason why people can get the flu more than one time during 
their lifetime and why the flu vaccine composition must be reviewed each year, and updated as 
needed to keep up with evolving viruses. 
The other type of change consists in an abrupt, major variation in the IAV genetic constellation. 
Because the IAV genome consists of eight distinct RNA segments, co-infection of one host cell with 
two different IAVs can result in progeny viruses containing a mix of gene segments from both 
parental viruses (Figure 18). When this process of genetic reassortment involves the gene segments 
encoding the HA and/or NA surface glycoproteins it has been termed “antigenic shift”. While IAVs 
are changing by antigenic drift all the time, antigenic shift happens only occasionally; nevertheless 
reassortment has been shown to be both common and important in IAV evolution (Holmes et al., 
2005) and host switch events (Garten et al., 2009; Scholtissek et al., 1978). Because antigenic shift 
results in a new influenza A subtype or a virus with a hemagglutinin or a 
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hemagglutinin/neuraminidase combination that has emerged from an animal population that is so 
different from the same subtype in humans, most people are completely naïve to the new virus, 
which can then rapidly spread and in some cases cause pandemics.  
In 1957, an H2N2 “Asian” strain emerged bearing HA, NA, and PB1 genes from an avian IAV and the 
remaining five genes from the human H1N1 strain circulating at the time (Kawaoka et al., 1989). 
Because the human population had not previously experienced infection with H2 antigenic type, 
the entire world was susceptible to infection and the virus spread rapidly. The Asian flu virus killed 
between 1 million and 4 million people becoming the most frequent subtype circulating among 
humans until a new H3N2 subtype was introduced in 1968. This latter virus, called “Hong Kong” 
pandemic virus, was also the result of antigenic shift comprising H3 and PB1 gene segments of 
avian origin and the remaining six segments from previously circulating human H2N2 strain 
(Scholtissek et al., 1978). The H3N2 pandemic virus replaced the H2N2 subtype, claiming around 2 
million human lives. 
In 2009 a new pandemic H1N1 virus, characterized by a novel H1, was stably introduced into 
human population. The pH1N1-09 virus, also called “swine flu”, because the origin of the virus was 
initially thought to be in pig farms in Mexico, arose through a multiple-reassortment process 
combining avian-origin PB2 and PA, human PB1, classical swine HA, NP and NS and Eurasian swine 
NA and M segments (Garten et al., 2009; Novel Swine-Origin Influenza A (H1N1) Virus Investigation 
Team et al., 2009; Smith et al., 2009). The virus exhibited a remarkable transmissibility between 
humans most of whom had very little pre-existing immunity against this novel strain. Age 
distribution of morbidity during 2009 H1N1 pandemic was different from that of the two seasonal 
influenza epidemic viruses (H1N1 and H3N2) as the proportion of under-60s among influenza 
deaths was markedly higher (Lemaitre and Carrat, 2010). pH1N1-09 became the most frequent H1 
subtype among humans and since then has been included in the seasonal trivalent and quadrivalent 
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vaccine formulations together with the drifted version of the previous H3N2 virus and influenza B 
viruses (World Health Organization (WHO), 20 February 2014). 
  
 
Figure 18. Influenza virus antigenic shift and antigenic drift. 
 
1.6.2 Adaptation  
Although wild birds are the natural reservoir of IAVs, mammals are often infected with influenza 
viruses of avian origin. The zoonotic transmissions can result in severe disease in different mammals 
including cats, dogs, horses, pigs and humans due to the lack of pre-existing immunity to the new 
influenza strain. In most of the cases the results are dead-end infections and are not further 
transmitted within the new host. However, on rare occasions, IAVs can pass the species barrier and 
establish an entirely new virus lineage in a mammalian species, as shown by the 1918 pandemic 
when the introduction into human population of an H1N1 subtype (called “Spanish flu”) directly 
from the avian reservoir, following a small number of adaptive mutations (Reid et al., 2004; 
Taubenberger et al., 2005), caused between 20-50 million deaths worldwide. Although the death 
73 
toll was very likely increased by historical and environmental factors such as the gathering of troops 
to the frontline, poor hygienic conditions and the lack of antibiotics available, the spillover of avian 
IAVs into human population represents a constant threat for the global health. Fortunately, 
different adaptive mutations are required for avian viruses to stably spread among humans, 
including those involved in the HA SA receptors binding and fusion activities, the polymerase 
efficiency and the ability of the virus to overcome cellular restriction factors.  
 
1.6.2.1 Receptor binding and endosomal membrane fusion.  
The HA protein has been widely associated with a major role in the host-range restriction of 
influenza A virus (Matrosovich et al., 2000; Rogers and Paulson, 1983). Indeed, one of the primary 
barriers to adaptation is the rather poor binding avidity of avian influenza virus HA for the 
predominant human receptors. IAVs have HAs with different specificities for the disaccharide 
consisting of SAs and the penultimate sugar (galactose or N-Acetylgalactosamine [GalNAc]) with 
different glycosidic bond isomerization. Avian IAVs have an HA receptor-binding specificity for α-2,3 
SA mainly expressed on avian respiratory and enteric cells, while HAs from IAVs adapted to humans 
have higher specificity for α-2,6 SA abundantly present on the surface of the cells of the human 
upper respiratory tract (URT) (Figure 19). Therefore, a pre-requisite for an avian IAV to be stably 
transmitted from human-to human is adaptive mutations in the HA receptor-binding domain (RBD) 
to enhance or shift the binding preference to α-2,6 SA receptors. In line with this consideration, 
while the RBD is quite conserved in avian IAV HAs, those belonging to IAVs adapted to humans have 
mutations in several key residues, which have been linked to increased binding specificity to α-2,6 
SA (Herfst et al., 2012; Imai et al., 2012).  
However, enhanced binding to α-2,6 SA is not a requirement for human infections since the 
majority of H5N1 virus dead-end infections have occurred in viruses with RBD specificity for α-2,3 
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(Taubenberger and Kash, 2010). Moreover the receptor binding switch is sometime insufficient 
alone for a stable host switch of an avian IAV to humans,  
Endosomal membrane fusion at the optimal pH is also crucial for efficient transmission between 
mammals (Imai et al., 2012). After binding to cellular receptors, influenza viruses are internalized by 
endocytosis. As the pH is progressively decreased from early endosome to late endosome, a 
threshold is reached at which the HA surface protein undergoes irreversible structural changes that 
facilitate fusion of the viral envelope with the endosomal membrane (see paragraph 1.4.5.1). 
Threshold pH values differ among influenza viruses, and a change in the pH of fusion of the HA 
protein can help influenza viruses to adapt to different cell lines (Lin et al., 1997) and host species 
(Giannecchini et al., 2006). In general, a high pH of HA protein activation could result in influenza 
virus inactivation in the environment or during transport to the cell surface. On the other hand, a 
low pH of HA protein activation could result in late uncoating or even degradation in the lysosome 
as the pH of the endocytic pathway decreases from early endosomes to late endosomes to 
lysosomes (Reed et al., 2010). Experimental infection in ducks and chickens infected with H5N1 
influenza viruses, demonstrated that the highest levels of virus replication and pathogenesis 
correlated with HA activation at pH values that range between 5.6 and 6.0, while HA activation at 
pH values lower than 5.6 attenuated replication and pathogenesis. In contrast, replication of 
attenuated or reassorted H5 viruses in the URT of mice and ferrets was enhanced by mutations that 
decreased the H5 protein pH activation values to 5.6 or lower (Zaraket et al., 2013). Therefore, for 
efficient propagation within a biological host, an IAV should also have an optimal range of pHs of 
activation for the HA protein (Imai et al., 2012). 
 
1.6.2.2 Temperature and polymerase activity. 
In addition to the switch in receptor specificity, efficient virus production from the cell of the 
respiratory tract is also required for stable transmission of an avian-origin IAV in the human 
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population. One of the major barriers for the replication of avian IAVs in human cells consists in the 
different temperature at which replication occurs. Avian IAVs, which replicate at temperatures 
around 41°C in the intestinal tract of birds, need to adapt their polymerase activity at the much 
lower temperature of the human URT (33°C). To this end amino acid substitutions in the 
polymerase proteins have been shown to be of paramount importance to determine host range 
and transmission (Mehle and Doudna, 2009; Van Hoeven et al., 2009) (Figure 19). 
The amino acid substitution Glu627→Lys627 (E627K) in the polymerase complex protein PB2 has 
been widely studied for its association with increased virus replication in mammalian cells at lower 
temperatures (de Wit et al., 2008; Subbarao et al., 1993). More recently, also PB2 residues S590 
and R591 have been reported as responsible for efficient activity of the pH1N1-09 virus polymerase 
in human cells, which retains the avian signature 627E (Mehle and Doudna, 2009). Due to the 
proximity displayed by residues 590-591 to position 627 in the structural model (Tarendeau et al., 
2008), it is likely that they contact the same human co-factor. However, cellular factors involved in 
PB2 627K mediated host adaptation and pathogenicity still remain poorly understood and 627 
amino acid specific binding of any cellular component has yet to be demonstrated. 
In several H5N1 viruses isolated from humans or other mammals, the PB2 gene does not contain 
E627K substitution but displayed a D701N mutation within the PB2 nuclear localization signal (NLS), 
which has been shown to enhance nuclear import of PB2 by importin-α in mammalian cells but not 
in avian cells (Gabriel et al., 2008; Gabriel et al., 2011). Mutation D701N can compensate for the 
absence of 627K signature, enhancing transmission from birds to mammals and between mammals 
(Gao et al., 2009; Steel et al., 2009). Another mammalian adaptive mutation at the level of PB2 is 
T271A, which is found in many human influenza viruses compared to the avian counterparts. This 
mutation, increases viral growth in human cells and is in part responsible for the pH1N1-09 high 
levels of polymerase activity (Bussey et al., 2010).  
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Figure 19. Influenza A viruses tropism and adaptation. Avian IAVs bind preferentially to α-2,3-SA, which is found on 
receptors in the gut and respiratory tract of birds. By contrast, human-adapted IAVs have a higher affinity for α-2,6-SAs, 
which are expressed in the upper respiratory tract of humans. The swine trachea contains receptors with α-2,3-linked 
and α-2,6-linked sialic acid (α-2,3-SA and α-2,6-SA) moieties that allow for binding of both avian and human viruses, 
leading to the idea that pigs can serve as the 'mixing vessel' in which reassortment of human and avian viruses can 
occur. Beside the HA binding site, also the activity of the viral RNA-dependent RNA polymerase needs to adapt to the 
different temperature of the new hosts, to this end mutation within the PB2 protein has been widely characterized. 
(Medina and Garcia-Sastre, 2011). 
 
1.6.2.3 vRNPs nuclear import and the cellular restriction factor MxA. 
Besides mutations that enhance interaction with positive cellular factors, and promote viral 
replication, other adaptive mutations allow IAVs to escape cellular restriction factors that otherwise 
would inhibit virus replication in the new hosts. The human interferon (IFN) system represents a 
major innate defence against zoonotic viruses. As previously described (see paragraph 1.5.2), 
among the many IFN-induced antiviral factors capable of inhibiting influenza A virus replication, the 
human Myxovirus resistance gene A (MxA) has been thoroughly characterized. The influenza virus 
nucleoprotein (NP) has been shown to be the viral target of MxA protein (Manz et al., 2013; 
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Zimmermann et al., 2011) and a direct interaction between human MxA and influenza NP has been 
observed (Turan et al., 2004). In line with these findings, MxA protein has been reported to exert its 
antiviral function in the cytoplasm of infected cells by binding NPs associated within the vRNPs, 
blocking influenza A virus replication before primary transcription, and preventing also newly 
translated NPs from entering the nucleus to participate in secondary transcription (Matzinger et al., 
2013; Pavlovic et al., 1992; Xiao et al., 2013). Because MxA antiviral activity depends on appropriate 
binding sites on the viral NP, IAV strains differ in their sensitivity to MxA depending on the origin of 
the NP protein (Dittmann et al., 2008). In general, avian IAVs are more sensitive to MxA than human 
strains (Dittmann et al., 2008). This is likely the result of the absence of selective pressure exerted 
by Mx gene in avian species, where this ISG was previously shown to lack antiviral activity against 
different strains of IAVs (Schusser et al., 2011). Therefore, MxA contributes to a natural barrier to 
transmission of IAVs from avian reservoirs and avian IAVs stably introduced in mammals often 
acquire adaptive mutations on the NP protein to allow them to escape this restriction factor 
(Dittmann et al., 2008; Manz et al., 2013; Zimmermann et al., 2011). Among these mutations 
isoleucine at position 100 (100I), proline at position 283 (283P) and tyrosine at position 313 (313Y) 
have been reported to be essential for reduced Mx sensitivity in mammalian cell culture and in vivo, 
while asparagine at position 52 (52N) has been shown to partially compensate the absence of some 
of the previous amino acids (Riegger et al., 2015).  
 
1.6.3 Reverse Genetics 
The use of reverse genetics, to facilitate the generation of virus entirely from cloned cDNA, is a 
common practice nowadays to study IAV in laboratories worldwide. However, it took almost 20 
years to set up this tool since the advent of recombinant DNA technology opened the door for 
conversion of viral RNA genomes into cDNA clones back in the late 1970s.  
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The de novo synthesis of a positive-sense RNA virus, in which naked RNA is infectious, was first 
reported for the bacteriophage Qβ (Taniguchi et al., 1978) in 1978 and then followed by many 
other positive-sense RNA viruses (Boyer and Haenni, 1994). 
However, it took many years to adapt the techniques for the recovery from cDNAs of negative-
sense RNA viruses, which possess genomes complementary to mRNA in their orientation and 
therefore rely on viral RNA-dependent RNA polymerases for transcription. In fact the generation of 
a nonsegmented negative-sense RNA virus entirely from cloned cDNA was not achieved until 1994, 
when Schnell et al. (Schnell et al., 1994) produced a recombinant rabies virus. In this system a 
plasmid containing full length copy of the viral antigenome, controlled by bacteriophage T7 RNA 
polymerase promoter, was transfected into cells that expressed T7 RNA polymerase. The 
components of the viral polymerase complex and NP protein were provided from protein 
expression plasmids, all controlled by generation of T7 RNA polymerase promoter. Although this 
work was soon followed by the generation of other nonsegmented negative-sense RNA viruses 
belonging to different families, the production of segmented negative-sense RNA viruses from 
cloned cDNA was even more challenging because it required the transfection of more than one 
genomic RNA at the same time. Only in 1996 did Bridgen and Elliot manage to generate a member 
of the Bunyaviridae family, characterized by a genome consisting of a three segments of negative-
sense viral RNA, entirely from cloned cDNA (Bridgen and Elliott, 1996).  
Influenza A virus was finally generated entirely from plasmids in 1999 by two different groups using 
a similar approach (Fodor et al., 1999; Neumann et al., 1999). Neumann et al. cloned cDNA 
encoding all eight segments of IAV in negative orientation between RNA polymerase I promoter and 
terminator sequences, which after transfection of human embryonic kidney (HEK 293T) cells, 
transcribed negative-sense vRNAs. The proteins required for transcription and replication of the 
vRNAs (PB2, PB1, PA and NP) were provided from co-transfected protein expression plasmids, 
controlled by chicken β-actin promoter (Figure 20A). Fodor et al. 1999 reported a similar system, 
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where all eight vRNAs were synthesized from plasmids containing the RNA polymerase I promoter 
and hepatitis delta ribozyme following transfection of African green monkey kidney (Vero) cells; 
while the NP and polymerase proteins were generated from expression constructs. Hence both 
approaches required 12 plasmids (Neumann and Kawaoka, 2004). 
Later, Hoffmann et al. (Hoffmann et al., 2000) devised a modified RNA polymerase I system that 
reduced the number of plasmids required for influenza virus generation from 12 to 8. In this 
approach, cDNAs encoding viral RNAs were inserted in positive-sense orientation between an RNA 
polymerase II promoter and a polyadenylation signal. This cassette was then inserted in negative 
sense orientation between the RNA polymerase I promoter and the terminator sequence. Hence, 
capped and polyadenylated mRNAs for the expression of proteins and negative-sense vRNAs were 
generated from the same template. Although the RNA polymerase I/II system may be proved 
advantageous for virus generation in cell lines that cannot be efficiently transfected with 12 
plasmids, the flexibility of virus generation is reduced, because both protein expression and vRNA 
synthesis are achieved from the same template. Nevertheless, regardless of the reverse genetics 
systems employed, the ability to alter the genomes of segmented negative-sense RNA viruses had a 
dramatic impact on the understanding of viral replication steps and on the virulence factors 
associated with viral fitness, transmission and host adaptation, and also facilitating the production 
of reassortant viruses, which can now be used as inactivated or live attenuated vaccines. 
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Figure 20. The 12 (A) and 8 (B) plasmids reverse-genetics methods for generating segmented negative-sense RNA influenza 
A viruses. Adapted from Neumann et al., 1999 and Hoffmann et al., 2000. 
 
1.7 Rationale and scope of the thesis 
Observational studies and pathological findings in animals naturally and experimentally infected 
with avian-origin IAVs revealed extensive replication of the virus in the pancreas, implying an 
enhanced tropism for this organ. The predilection of both highly pathogenic and low pathogenicity 
IAVs for the pancreas was previously reported in domesticated avian species and migratory 
waterfowl following experimental or natural infection (Bertran et al., 2011; Kwon et al., 2010; 
Mutinelli et al., 2003; Shinya et al., 1995). In mammals, spread of the infection through the 
pancreas was reported in ferrets following exposure of digestive system to highly pathogenic IAVs 
(Lipatov et al., 2009), while pancreatic post-mortem lesions ranging from inflammation to necrosis 
were observed in infected cats (Reperant et al., 2009; Rimmelzwaan et al., 2006; Yingst et al., 
2006). In addition, in the wake of the 2009 pandemic, different publications reported pancreatic 
damage in humans cases associated with pH1N1-09 IAV infection (Blum et al., 2010; Cano et al., 
2010; Nenna et al., 2011; Watanabe, 2011) and in a more recent study, using in vitro and ex vivo 
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models, human-origin pancreatic cells were shown sensitive to both IAV infection and induced cell 
death (Capua et al., 2013). Therefore, although the pancreas is not considered a typical site of 
replication after standard infection, IAV seems to be capable of infecting and damaging pancreatic 
cells in severe infections.  
Although IAV infections are well studied because they represent a considerable health burden, the 
oncolytic potential of this virus has not been investigated as thoroughly as for some other viruses. 
However, IAVs present some features compatible with those required for OVs: (i) they induce 
apoptosis in numerous cell types in vitro (Fesq et al., 1994; Lowy, 2003; Takizawa et al., 1993) and in 
vivo (Ito et al., 2002; Mori et al., 1995; Mori and Kimura, 2000); (ii) they present different serotypes 
with typically low homology between their surface-exposed glycoproteins, which can be exploited 
to avoid host pre-existing immunity (Fouchier et al., 2005; Hay et al., 2001) (see paragraphs 1.3.1.1 
and 1.4.3) and (iii) they have a genome structure that can be easily manipulated, since the 
introduction of reverse genetics (see paragraph 1.6.3), in order to modulate virus selectivity and 
pathogenicity. 
Based on these observations, we set out to further evaluate the sensitivity of different human PDA 
cell lines to a panel of avian-origin IAVs. As reported in chapter 2, PDA cell lines were found to be 
sensitive to infection by human and avian IAV isolates. Investigation of cell viability and apoptosis 
induction following infection of PDA cell lines and a non-transformed pancreatic ductal cell line 
demonstrated the promising oncolytic potential of some avian-origin IAV isolates for virotherapy 
treatment. Based on these data the low pathogenicity avian influenza (LPAI) virus H7N3 
A/turkey/Italy/2962/03, which displayed high levels of apoptosis in different PDA cell lines and 
beneficial effect in xenograft model (Kasloff et al., 2014), was selected for further development.  
Using this work as a starting point, the aim of the present project was to engineer the avian-origin 
H7N3 influenza A virus to enhance its selectivity, safety and oncolytic activity for PDA treatment. 
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Specific aims of the presented study were: 
1. Understand the mechanism by which the virus leads to high levels of cell death in PDA cell 
lines. 
2. Generate a reverse genetics system for the H7N3 avian influenza virus suitable for 
engineering to improve its oncolytic potential. 
3. Enhance the selectivity of the H7N3 virus to IFN-deficient cells, such as the majority of PDA 
cells (see paragraph 1.2.3). 
4. Optimize the balance between levels of apoptosis induced and productive H7N3 virus 
replication in PDA cells to achieve the best therapeutic effect (see paragraph 1.5.4 and 
1.5.5). 
5. Enhance the safety of the avian isolate for clinical use by reducing the risk associated to 
antigenic shift with human circulating strains that may result in a potentially pandemic virus 
(see paragraph 1.6.1). 
6. “Arm” the virus by engineering expression of the granulocyte-macrophage colony-
stimulating factor (GM-CSF) gene during infection to increase potential potency of the 
treatment through stimulation of anti-tumour adaptive immunity (see paragraph 1.3.1.4).  
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Chapter 2. Oncolytic activity of avian-origin influenza A viruses in 
human pancreatic ductal adenocarcinoma cell lines. 
 
2.1  Introduction 
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of human cancer mainly 
due to the lack of early methods of detection and to the asymptomatic form of the disease at the 
initial stages. Cancer therapies proven successful in other tumour types have shown little efficacy in 
treating PDA, thus development of new treatment strategies for pancreatic cancer patients is of 
crucial importance. Building on the observation that avian influenza A viruses (IAVs) appears to have 
a tropism for the pancreas in vivo (see paragraph 1.7) and human derived pancreatic cells are 
sensitive to IAV infection, investigations were undertaken to test the potential of different origin 
IAVs as oncolytic agents for PDA virotherapy treatment.  
 
2.2  Results 
2.2.1 Susceptibility of human PDA cell lines to avian-origin influenza A virus infection.  
Preliminary data generated at the Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe – 
Padova, Italy) using flow cytometry (FACS) with fluorescent labelled lectins specific for alpha-2,3 
and alpha-2,6-linked sialic acids, demonstrated the presence of receptors for both human and avian 
influenza A viruses (see paragraph 1.6.2.1) on the surface of different human PDA cell lines (Table 3) 
(Kasloff et al., 2014). To further confirm the capability of avian IAVs to utilize receptors on the 
human PDA cells, a variety of cell lines were transduced with lentiviral pseudotypes bearing HA and 
NA glycoproteins of the avian influenza A virus A/Viet Nam/1194/2004 (H5N1). HA mediated entry 
of pseudotypes was monitored by the expression of GFP encoded from the packaged lentiviral 
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genome (Figure 21A). Bearing in mind that each cell line was transduced with an equal titre of 
pseudotypes, it appeared that the BxPC3 PDA line was the most susceptible to infection via the 
influenza H5 HA protein (Figure 21B). 
Results generated at IZSVe demonstrated active viral RNA replication in all PDA cell lines (data not 
shown) infected with a panel of different IAVs of human or avian origin and of different subtypes 
(Table 4). This was detected both by accumulation of vRNA by RT-PCR from infected cells, and also 
by increases in virus titres released from the cells, although the infectious titres recorded were less 
than might have been expected, likely due to suboptimal proteolytic activation (Kasloff et al., 2014). 
Interestingly, MTT assay, an indicator of cell viability, which measures tetrazolium reduction by 
metabolically active and proliferating cells, highlighted different levels of virus-induced cell death in 
PDA cells depending on both the cell line and the virus isolate tested (Kasloff et al., 2014). The 
lowest levels of cell death were displayed by PANC-1 cells, and the highest by BxPC-3 and CFPAC-1 
cell lines. Influenza A virus isolates H7N3 A/turkey/Italy/2962/03 and the H7N7 
A/macaw/England/626/80 caused the greatest loss of cell viability across the panel of cell lines 
tested. The H7N3 isolate, in particular, triggered higher cell loss in BxPC-3 and CFPAC-1 cells than in 
the normal human pancreatic duct epithelial cell line HPDE6 (Kasloff et al., 2014). 
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Table 3. Genotype of selected PDA cell lines used in this study with respect to the four most common mutations in 
pancreatic cancer. Adapted from (Deer et al., 2010). a KRAS mutations involve amino acids that interfere with the GTPase 
function. In pancreatic cancer, mutations are essentially seen only at the twelfth position, (codon or amino acid 12), with 
rare exceptions seen at codon 13. The majority of KRAS mutations in pancreatic cancer change a glycine at codon 12 to a 
valine or aspartate. b Most of TP53 mutations consist of single amino acid change, which leads to the production of an 
altered version of the p53 protein that cannot bind effectively to DNA thus preventing the cell from undergoing apoptosis 
in response to DNA damage. WT—wild type, Δ—deletion, bp—base pair, HD—homozygous deletion 
CELL LINE DERIVATION KRASa CDKN2A TP53b SMAD4/DPC4 
AsPC-1 
62-year-old woman with 
adenocarcinoma of the head 
of the pancreas. 
12 Asp 
Δ2 bp; 
HD 
135 Δ1 bp WT 
BxPC-3 
61-year-old woman with 
adenocarcinoma of the body 
of the pancreas. 
WT HD 220 Cys HD 
CFPAC-1 
Adenocarcinoma of the 
head of the pancreas 
derived from 26-year old 
male with cystic fibrosis.  
12 Val 
WT; 
Promoter 
methylation 
242 Arg HD 
Mia 
paca2 
65-year-old man with 
adenocarcinoma of the body 
and tail of pancreas. 
12 Cys HD 248 Trp WT 
PANC-1 
56-year-old male with an 
adenocarcinoma in the head 
of the pancreas. 
12 Asp HD 273 His WT 
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Figure 21. Influenza A virus pseudotypes structure and entry into PDA cells. A) Generation of pseudotypes bearing avian 
signature HA and NA glycoproteins of A/VietNam/1194/2004 (H5N1). B) H5N1 pseudotype entry into PDA cells. AsPC-1, 
BxPC-3, CFPAC-1, and PANC-1 cell lines were transduced with fluorescent HA- and NA-bearing IAV pseudotypes as 
described in material and methods and visualized following 48 h of incubation. Human Embryonic Kidney (HEK or 293T) 
cells were included as positive control. Monolayers (left), GFP reporter gene expression (middle), and the merging of 
these two images (right) are shown for each cell line at a ×10 magnification. Cells were visualized with a Zeiss Axiovert 
40 CFL, fluorescence, phase-contrast, inverted microscope equipped with an HBO50 mercury short-arc lamp.  
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Subtype Strain Species HA cleavage site  
H5N1 A/mallard/Italy/3401/05 Avian Monobasic  
H7N3 A/turkey/Italy/2962/V03 Avian Monobasic  
H1N1 A/Puerto Rico/8/34 Human Monobasic  
H4N8 A/cockatoo/England/72 Avian Monobasic  
H7N7 A/macaw/England/626/80 Avian Monobasic  
 
Table 4. Influenza A viruses subtypes and strains used in the preliminary experiments. 
 
The ability of Influenza A viruses to induce apoptosis in PDA cells was further evaluated in infected 
cells through annexin-V staining (see paragraph 1.5.3). The immortal human pancreatic duct 
epithelial cell line (HPDE6), which retains a genotype similar to pancreatic duct epithelia and is non-
tumorigenic in nude mice (Furukawa et al., 1996; Ouyang et al., 2000), was employed as a “benign” 
control cell line.  As a positive control treatment for apoptosis, cells were subject to a high 
concentration gemcitabine and cisplatin (gem+cisp), two commonly used chemotherapeutic agents 
(see paragraph 1.2.4).  
Levels of apoptosis were highly variable between cell lines and virus isolates, ranging from only 5% 
of H7N7-infected PANC-1 cells to over 60% of H7N3-infected BxPC-3 cells by 16 hours post-
infection (hpi) (Figure 22A). Surprisingly, BxPC-3, a PDA cell line previously shown “resistant” to 
other oncolytic viruses including Vesicular Stomatitis Oncolytic Virus (VSV), Conditionally Replicative 
Adenoviruses (CRAds), Sendai Virus (SeV) and Respiratory Syncytial Virus (RSV) (Murphy et al., 
2012), was the most sensitive among the PDA cell lines to IAV-induced apoptosis, followed by AsPC-
1, CFPAC-1, MIA paca 2 and PANC-1. Interestingly, the human H1N1 PR8 strain, whose oncolytic 
potential has been previously appraised for other tumour types (Bergmann et al., 2001; Muster et 
al., 2004), induced far less apoptosis compared to the avian isolates. Consistent with results from 
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MTT assays, the H7N3 A/turkey/Italy/2962/03 virus was the most potent inducer of apoptosis in the 
majority of PDA cell lines examined (Figure 22A). Replication of this avian strain in PDA cell lines was 
confirmed by quantitative Real-Time PCR and Western Blot targeting viral Matrix gene (M) and NP 
protein respectively (Figure 22 B-C). In line with results previously reported by Kasloff et al. (Kasloff 
et al., 2014), PDA cell lines displayed higher permissiveness to IAV replication than benign-like 
HPDE6 cell line. 
 
Figure 22. Influenza A viruses apoptosis induction and replication in PDA cell lines. A) Comparative induction of apoptosis 
in PDA cells following infection with different origin IAVs. Cells infected at MOI=1 with IAV or cultured with gemcitabine 
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(2 mM) plus cisplatin (0.8 μM) were assessed for induction of apoptosis at 16 hpi (black bars) and 24 hpi (grey bars) by 
Alexa Fluor 647-labelled Annexin V binding and flow cytometry. Results are normalized to uninfected controls and 
represent means plus standard deviation of two (Gem + Cisp treatment) or three (virus infections) independent 
experiments. Statistically significant differences between virus-induced and Gem + Cisp induced apoptosis at 16 hpi are 
indicated. Note - Severe cell death induced in H7N3-infected CFPAC-1 cells (X) prevented proper Annexin V cell labelling 
at time points examined. Virus-induced apoptosis is determined by subtracting the percentage of annexin V-positive 
control cells from infected cells. Adapted from (Kasloff et al., 2014). B) Real-time PCR results obtained targeting IAV’s M 
gene in different pancreatic cell lysates at 1, 5 and 10 hours post-infection with H7N3 A/turkey/Italy/2962/03 virus. C) 
Western blot analysis for the detection of viral nucleoprotein NP (56 KDa) in pancreatic ductal adenocarcinoma cells 
(MIA-PaCa-2, BxPC-3, AsPC-1, PANC-1) and human pancreatic ductal epithelial cell lines (HPDE6) infected with H7N3 
A/turkey/Italy/2962/03. NP and Beta actin (46 KDa) were evaluated in cell lysates collected at 1, 5 and 10 h post-
infection. 
 
2.2.2 The H7N3 A/turkey/Italy/2962/03 virus triggers high level of apoptosis in tumour 
BxPC-3 cells but not in “benign” HPDE6 cells. 
 Since some of the IAVs displayed high levels of apoptosis induction in BxPC-3 cells, a PDA cell line 
that was previously shown “resistant” to other oncolytic viruses (Murphy et al., 2012), we decided 
to focused on this line, together with the HPDE6 employed as a “benign” control (Furukawa et al., 
1996; Ouyang et al., 2000), to further elucidate the mechanisms of IAV-induced PDA cell death.  
Immunocytochemistry (ICC) targeting active caspase-3 was performed in BxPC-3 and HPDE6 cells at 
16 and 24 hours post infection with the avian H7N3 A/turkey/Italy/2962/03 virus or with the human 
H1N1 A/Puerto Rico/8/1934 (PR8). The combination of gemcitabine and cisplatin was included as 
positive control treatment for apoptosis.  
Acting at the cross-road between extrinsic and intrinsic pathway (see paragraph 1.5.3), caspase-3 
can be considered as a general marker of apoptosis. Staining for activated caspase-3 revealed more 
positive cells after infection with H7N3 than for PR8 virus or the chemotherapeutic agents in BxPC-3 
cells (Figure 23A-B). However, the effect of the H7N3 virus was much lower in the benign HPDE6 
cells where it triggered levels of caspase-3 activation similar to those derived from infection with 
PR8 virus or treatment with the drugs (Figure 23A-C).  
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Figure 23. Immunocytochemistry (ICC) targeting active effector caspase-3 in BxPC-3 and HPDE6 cells following infection 
with IAVs. (A) Semi-confluent monolayers of BxPC-3 and HPDE6 cells grown on glass chamber slides were infected with 
H1N1 A/Puerto Rico/8/34 (PR8) and H7N3 A/turkey/Italy/2602/2003 at an MOI of 1 and then tested by 
immunocytochemistry (ICC) for expression of cleaved caspase-3 at 16 and 24hours post-infection. Gemcitabine (2 mM) 
and cisplatin (0.8 μM) were included as positive controls. Quantification of BxPC-3 (B) and HPDE6 (C) cells positive to 
active caspase-3 in ICC. Results are means plus standard deviations for 10 repeat counts of 500 cells each, with 
significance shown for virus compared to gemcitabine plus cisplatin at 16 and 24 hours post-infection (*** p<0.001). 
 
HPDE6 cells resistance to Vesicular Stomatitis virus (VSV) oncolytic activity was previously suggested 
by Moerdyk-Schauwecker et al., 2012 as the result of constitutive high-level expression of IFN-
stimulated antiviral genes (ISGs). BxPC-3 cells were not characterized in that paper. Therefore, in 
order to understand the differences in apoptosis recorded in the two cell lines, we investigated by 
RT-PCR the expression of IFNs and IFN-stimulated antiviral genes in BxPC-3 and HPDE6 cells mock 
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infected or infected with the H7N3 A/turkey/Italy/2962/03 virus. RT-PCR, using primers with 
sequence derived from those published by Moerdyk-Schauwecker et al. (Moerdyk-Schauwecker et 
al., 2012), confirmed that RIG-I and MAVS genes were expressed in both cell lines and the 
expression increased after infection (Figure 24). In contrast, while MxA and IFNα/β genes were 
constitutively expressed at low levels in HPDE6 cells, and their expression was increasing during 
infection, no expression was detected at all in BxPC-3 cells either constitutively (mock) or after 
infection with H7N3 virus. Thus differences in expression of and/or response to IFN, might account 
for the different infection rate and ensuing oncolytic ability displayed by H7N3 virus in BxPC-3 and 
HPDE6 cells.  
 
 
Figure 24. mRNA expression of IFN related genes in BxPC-3 and HPDE6 at 16 hours post-infection. Cells were mock 
infected or infected with H7N3 A/turkey/Italy/2962/03 influenza viruses at M.O.I of 0.1. At 16 h post-infection cells were 
harvested and mRNA was reverse transcribed and analysed by PCR using the primers previously published (Moerdyk-
Schauwecker et al., 2012). Amplified mRNA and corresponding product sizes are indicated on the left and on the right 
respectively. 
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2.2.3 The H7N3 A/turkey/Italy/2962/03 virus induces apoptosis in tumour BxPC-3 cells 
mainly by affecting the intrinsic apoptotic pathway. 
Although BxPC-3 cells remain sensitive to exogenous IFN (Murphy et al., 2012; Vitale et al., 2007), 
the lack of endogenous IFNα/β expression suggests that the cell death induced by IAV in this cell 
line was mainly a direct consequence of the virus activity (intrinsic pathway) rather than the result 
of paracrine cell signalling (extrinsic pathway). To confirm this hypothesis immunocytochemistry 
(ICC) targeting caspases 9 and 8, markers of the intrinsic and extrinsic apoptotic pathway 
respectively (see paragraph 1.5.3), was performed in BxPC-3 and HPDE6 cells infected with H7N3 or 
PR8 viruses. Treatment using Gemcitabine and Cisplatin was included as positive controls of 
apoptosis.  
Most of the apoptosis driven by H7N3 virus in BxPC-3 cells was through the intrinsic pathway, since 
the percentage of caspase-9 positive cells at 16 hours post-infection was approximately double the 
number of those positive for caspase-8 (Figure 25A). The same trend was not observed in the case 
of PR8 virus for which caspase-8 and 9 positive cells reached comparable levels (Figure 25A). 
Conversely, HPDE6 cells infected with H7N3 virus tended to die more from apoptosis driven by the 
extrinsic pathway as showed by the higher levels of caspase-8 positive cells in comparison to those 
stained for caspase-9 (Figure 25B). Considering the data of IFNs and IFN-stimulated antiviral gene 
expression previously obtained (Figure 24), these results confirm that in BxPC-3 cells, unable to 
mount an IFN-mediated antiviral response, the H7N3 virus would more likely trigger apoptosis 
during its replication by direct targeting. Conversely, in HPDE6 cells the same virus, hindered in its 
replication by expression of IFN and ISGs such as MxA, would drive cell death mainly through IFN 
mediated cellular signalling. Taken together this finding emphasizes the H7N3 strain-specific ability 
to trigger high levels of cell death in tumour permissive BxPC-3 cells by activating the intrinsic 
apoptotic pathway.  
 
93 
 
Figure 25. Immunocytochemistry (ICC) targeting active caspases 8 and 9 in BxPC-3 (A) and HPDE6 (B) cells at 16 hours 
post-infection. Semi-confluent monolayers of BxPC-3 and HPDE6 cells were infected with H7N3 A/turkey/Italy/2602/2003 
and H1N1 A/Puerto Rico/8/34 (PR8) at an M.O.I of 1 and then tested by ICC for expression of initiator caspases 8 and 9 
at 16 hours post-infection. ICC results are normalized to uninfected controls of each cell line. All data represent means ± 
standard deviations (SD) of one representative experiment (n=10). Statistical significance was determined using Two-
way ANOVA followed by Tukey’s multiple comparison test. 
 
2.2.4 Oncolytic effects of H7N3 A/turkey/Italy/2962/03 influenza virus in mouse 
xenograft model.  
The high level of apoptosis observed in BxPC-3 cells infected with H7N3 A/turkey/Italy/2962/03 
virus in vitro appeared not to be due to the ability of the virus to infect these cells more efficiently 
than other isolates (Kasloff et al., 2014), but rather to its strain-dependent capability to induce cell 
death (Figure 22A-23B) by affecting mainly the intrinsic pathway (Figure 25A).  
Aiming to confirm the H7N3 activity in vivo in a xenograft model, we firstly appraised the ability of 
human BxPC-3 cells to establish tumours in SCID-B17 mice. A group (n=5) of six-week-old female 
SCID-B17 mice were subcutaneously injected with 5 x 106 BxPC-3 cells in a volume of 100 μL into 
the right flank and observed for the development of a palpable tumour. All animals were sacrificed 
when the tumor volume had reached more than 1,000 mm3. Post-mortem examination revealed 
solid hard tumours without involvement of other organs or evidence of metastasis (Figure 26A).  
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We next proceeded to test the H7N3 virus oncolytic activity in SCID mice (n=6) bearing BxPC-3 
derived solid tumours. Following four successive virus inoculations into palpable BxPC-3 tumours 
over seven days (between day 8 and 15 post-implantation), the oncolytic effect of IAV on tumour 
reduction was compared to a PBS control group (Figure 26B). Overall, H7N3 treatment resulted in 
reduction of tumour growth in comparison to the control group, and all tumours collected from 
H7N3-treated mice sacrificed upon termination of the experiment yielded a positive result for IAV 
RNA by Real-Time RT-PCR targeting influenza virus Matrix (M) gene (Figure 26C). 
 
 
Figure 26. Oncolytic effects of H7N3 A/turkey/Italy/2962/03 influenza virus in SCID xenograft model. A) BxPC-3 derived 
solid tumour in SCID-B17 mice.  B) Oncolytic effect of H7N3 A/turkey/Italy/2962/03 virus in BxPC-3 xenograft mouse 
model. Twelve Six-week-old female SCID mice were subcutaneously implanted with 5 x 106 BxPC-3 cells in a volume of 
100 μL into the right flank. At 8 days post-implantation palpable tumour became established, and mice were randomly 
divided in two groups (n=6 each), receiving either four intra-tumoural injections of 2.4 x 104 pfu of low pathogenic H7N3 
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virus (triangles) between day 8 and day 15 or four injections of PBS (squares). Caliper measurements of tumour 
dimensions were taken on indicated days post-implantation for calculation of tumour volumes. Data shown represent 
means of tumour volume + SEM. C) Real-time RT-PCR detecting influenza virus’ Matrix (M) gene in tumour collected 
from different mice. Based on diagnostic procedures in place at IZSVe the Ct value of 35 is considered the threshold 
between a weak positive sample and a negative sample.  
 
2.3 Discussion and conclusion 
The present data demonstrate that avian influenza A virus can infect, replicate in and induce 
apoptosis in several human PDA cell lines. Characterization of the receptor profiles of a panel of 
human PDA cell lines shown that these cells contained both α-2,6- and α -2,3-sialic acid linkages, 
explaining their susceptibility to infection by both avian and mammalian viruses. While the upper 
respiratory tract (URT) is the primary site of infection for human influenza viruses as a result of high 
levels of α-2,6-linked SAs, the expression of α-2,3-linked SAs has been detected in other human 
tissues, including endothelial cells of the heart, brain, intestines, and liver as well as nonciliated cells 
in the lungs (Yao et al., 2008). Although all PDA cell lines expressed both types of SA receptors on 
their surfaces, differences in expression levels were noted (Kasloff et al., 2014). Such heterogeneity 
in the levels of SA expression in different cell lines was not surprising, as altered levels of expression 
of sialyltransferases and fucosyltransferases have been demonstrated in different types of tumors, 
including pancreatic, breast, colon, gastric, cervical, and renal cancers (Mas et al., 1998; Peracaula 
et al., 2005). 
Annexin V staining results demonstrated that levels of IAV-induced apoptosis in PDA cells varied 
depending on the virus isolate and cell line tested (Figure 22A). While several of the isolates tested 
showed a significantly enhanced ability to induce apoptosis compared to the treatment with 
gemcitabine and cisplatin, the H7N3 A/turkey/Italy/2962/03 isolate repeatedly outperformed the 
others, including the human PR8 virus currently tested as oncolytic virus for other tumour types, in 
terms of the rapidity and potency of cell death induced. Although it is not possible to completely 
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rule out an especial efficient ability of the H7N3 virus to bind and thus infect PDA cells, the results 
appear in line with the strain-specific variations in apoptotic induction previously documented in 
primary cultures and established cell lines in the cases of human, avian, and swine influenza viruses 
(Choi et al., 2006; Mok et al., 2007). These observations about the H7N3 isolate led us to further 
investigate its oncolytic potential.  
Among the different tumour cell lines tested, we focused on BxPC-3, a PDA cell line previously 
shown “resistant” to other oncolytic viruses including Vesicular Stomatitis Oncolytic Virus (VSV), 
Conditionally Replicative Adenoviruses (CRAds), Sendai Virus (SeV) and Respiratory Syncytial Virus 
(RSV) (Murphy et al., 2012), but which surprisingly appeared to be highly sensitive to IAV infection 
(Figure 22A). 
Immunocytochemistry (ICC) for the expression of effector caspase-3 in BxPC-3 and HPDE6 infected 
cells, confirmed the higher sensitivity of the tumour cell line over the resistant “benign” line (Figure 
23A-B-C). Since KRAS mutations are known to increase resistance to apoptosis (Guerrero et al., 
2000), the fact that BxPC-3 cells contain a wild-type KRAS (Table 3) may partially explain the higher 
levels of cell death observed in this tumour cell line compared to the others. However, the facts 
that non-transformed HPDE6 cells also contain wild-type KRAS and display a resistant phenotype 
suggests that other contributing factors are at play. Among these factors, the lack of expression of 
functional IFN and MxA (Figure 24) antiviral genes might exert a pivotal role. As discussed in chapter 
1 (see paragraph 1.5.2), IFN expression can act in autocrine and/or paracrine manner to heighten 
the cell anti-viral defences; while MxA can counteract virus replication by preventing nuclear import 
of the vRNPs especially in the case of viruses presenting nucleoproteins (NPs) of avian origin (see 
paragraph 1.6.2.3). Thus the lack of expression of IFN and MxA genes, even at basal level, might 
contribute to the permissive phenotype displayed by BxPC-3 cells infected with the avian origin 
H7N3 A/turkey/Italy/2962/03 virus compared to the resistant HPDE6 cells.  
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Further ICC studies targeting initiator caspases 8 and 9 in infected BxPC-3 cells, demonstrated that 
H7N3-induced apoptosis was mainly the result of a strong strain-dependent activation of the 
intrinsic pathway (Figure 25A).  
Building on results observed in vitro, an experiment using a SCID mouse xenograft model was 
performed to examine the oncolytic activity of the H7N3 A/turkey/Italy/2962/03 virus in vivo. As 
reflected by in vitro sensitivity, BxPC-3-derived tumours showed significantly reduced growth 
following H7N3 treatment compared to growth after treatment with PBS alone (Figure 26B). The 
presence of viral RNAs in neoplasm homogenates of all H7N3-treated animals sacrificed at the end 
of the experiment confirmed that all tumours were successfully infected with IAV (Figure 26C). 
Given the reduced ability of the LPAI viruses to undergo multiple rounds of replication in PDA cells 
in vitro (Kasloff et al., 2014), most likely due to protease-limiting conditions, the H7N3 virus was not 
expected to display numerous rounds of infection in BxPC-3 xenograft model. However, detection 
of viral RNAs in treated tumours up to 1 week following the final injection suggests that virus 
replication did occur within the tumour microenvironment. Indeed, previous papers 
immunohistochemically demonstrated the presence of mild to marked immunoreactivity to 
pancreatic trypsinogen in 75% of the 23 surgically resected pancreatic ductal adenocarcinomas 
(Ohta et al., 1994), reporting also that some human pancreatic ductal cancer cells, including BxPC-3, 
express and secreted pancreatic cationic-type tripsinogen in vitro, which can be spontaneously 
converted into active trypsin at acid pH of tumour microenvironment (Ohta et al., 1998). Thus it 
may well be that BXPC-3 cells can support multiple rounds of influenza virus infection because they 
secret activating proteases that can cleave the HA protein, a necessary step in the virus replication 
cycle. 
In any case, the selective pro-apoptotic effect of the virus observed in tumour BxPC-3 cells, 
previously shown resistant to other oncolytic viruses, strengthen the idea that research in the area 
of oncolytic virology should not be focused on a short list of candidates, but rather on a broad 
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range of viruses characterized by specific cancer cell permissiveness, and that influenza virus could 
play a role in further studies on treatment of PDA. To this purpose the H7N3 A/turkey/Italy/2962/03 
virus, which shown the highest oncolytic activity in PDA cells, was selected and the corresponding 
reverse genetics backbone was generated for additional development. 
 
 
Chapter 3. NS1-77 truncation: enhancing IAV selectivity and 
oncolytic potential by reducing control of host antiviral response. 
 
3.1  Introduction 
Based on the sensitivity to IAVs displayed in preliminary results (see paragraph 2.2.1), our research 
focused on BxPC-3, a PDA cell line that was previously shown “resistant” to other oncolytic viruses 
including Vesicular Stomatitis Oncolytic Virus (VSV), Conditionally Replicative Adenoviruses (CRAds), 
Sendai Virus (SeV) and Respiratory Syncytial Virus (RSV) (Murphy et al., 2012). Like many PDA cells, 
BxPC-3 present homozygous deletion of genetic material within chromosome arm 9p21, where 
interferon alpha and beta (IFN-α/β) genes are located (see paragraph 2.2.2). Indeed, this loss has 
been shown to determine lack of functional IFN expression in nearly 80% of PDA cells, although 
responsiveness to exogenous IFN can be maintained in some cases (Murphy et al., 2012; Vitale et 
al., 2007). As such we reasoned that OV selectivity to these cells could be enhanced by creating 
viruses defective in IFN antagonism, which should not replicate efficiently if at all in interferon 
competent cells but can still replicate and trigger apoptosis in cells deficient in IFN induction or 
response. 
Influenza A virus non-structural protein 1 (NS1) is a 219-237 amino acid protein expressed at very 
high levels in infected cells. Although it is a multi-functional protein, the major role ascribed to NS1 
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is to antagonize host IFN-mediated antiviral responses (see paragraph 1.5.4). Due to its role in 
counteracting host type I IFN expression, an IAV that lacks NS1 protein expression (ΔNS1) fails to 
replicate efficiently in normal cells. However, in cancer cells with deficient IFN responses, such 
mutants have been shown to be able to replicate and cause cell death (Bergmann et al., 2001; 
Muster et al., 2004). Moreover, a recombinant NS1 truncated influenza virus that has intermediate 
attenuation characteristics between ΔNS1 and wild-type viruses showed superior beneficial effect 
in mice due to an improved attenuation/replication balance (Muster et al., 2004). 
Thus, to obtain a virus that could replicate efficiently in IFN deficient PDA cells but not in healthy 
IFN competent cells, we decided to introduce mutations within the IAV NS1 gene to create a 
premature termination codon and produce a protein of only 77 amino acids (NS1-77), resulting in 
complete loss of the effector domain (ED), which interacts with a variety of different cellular protein 
to mitigate host IFN expression and apoptosis (Figure 27A) (see paragraph 1.5.4). Position aa 77 was 
selected for the termination codon as mutations at this site did not affect the coding of the nuclear 
exporting protein (NEP), which is also expressed from viral RNA segment 8 (Figure 27B) (see 
paragraph 1.5.4). Furthermore, the truncation occurs within the linker region (LR) and thus should 
not change the folding of the RNA binding domain (RBD) (Figure 27C) or its ability to self-associate 
in dimers, although the loss of the ED domain might also reduce the dsRNA binding efficiency of the 
N-terminal domain by preventing higher-order multimerization of NS1 dimers (Hale, 2014).  
Thus, we generated a complete reverse genetics system for the recovery of recombinant virus 
based on the backbone of the low pathogenicity avian influenza virus (LPAIV) H7N3 
A/turkey/Italy/2962/03, which triggered high levels of apoptosis in different PDA cell lines (see 
paragraph 2.2.1) and displayed beneficial effect in mouse model (see paragraph 2.2.4). Using this 
system, a mutated virus bearing truncated NS1-77 gene was generated and propagated in Npro-
MDCK cells that express NPro gene of Bovine Viral Diarrhea Virus (BVDV) and thus lack of IFN 
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expression. We then compared the H7N3 NS1-77 properties with those of the isogenic recombinant 
wild type virus bearing a full length NS1.   
 
Figure 27. The H7N3 NS1-77 truncation. A) Linear schematic representation of the NS1 domain layout (yellow) and host-
proteins interaction sites (red). NS1 can be divided into three distinct regions: the N-terminal RNA-binding domain (RBD), 
the linker region (LR) and the effector domain (ED) which include also the “C-terminal tail”. Interaction sites for NS1 to 
form homo-multimers are present in both the RBD (triangular cut-outs) and ED (W187). Adapted from (Hale, 2014). B) 
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Nonsense mutations introduced to obtain the H7N3 NS1-77 protein. The NS1 truncated protein possesses the RBD, but 
not the ED. The introduced mutations do not affect the NEP open reading frame, because they occur in a region that 
undergoes splicing during NEP mRNA synthesis. C) Cartoon representation of the NS1 structure as viewed looking across 
the main a-helix of the RBD (aquamarine). The ED is coloured green, and the linker region (LR) orange. Red arrow 
indicates the aa position 77. Adapted from (Bornholdt and Prasad, 2008) 
 
3.2  Results 
3.2.1 NS1-77 truncation determines faster progression of apoptosis in infected BxPC-3 
cells.  
To check whether NS1-77 truncation might have a detrimental effect on the apoptosis levels 
previously displayed by the wild type H7N3 virus, annexin V assay was performed in BxPC-3 and 
HPDE6 cells infected with full length or truncated NS1 viruses. Specific Cell Death (SCD%), defined 
as described in material and methods, was measured at 16 and 24 hours post-infection. Incubation 
of the cells with Gemcitabine and Cisplatin was included as positive control for apoptosis.  
BxPC-3 and HPDE6 cells were equally susceptible to the treatment with chemotherapeutic agents 
(Figure 28A-B). However, in line with previous results (see paragraph 2.2.1), influenza virus 
induction of apoptosis was far more selective to tumour cells than to benign HPDE6 cells at both 16 
and 24 hours post-infection (Figure 28A-B).  
Interestingly, in permissive BxPC-3 cells, apoptosis induced by the NS1 truncated virus reached its 
peak at 16 hours post-infection, displaying significantly more cell death than the wild type at this 
time-point (Figure 28C). However, this effect was not maintained at later time post-infection (24h) 
when the levels of apoptosis triggered by the H7N3 NS1-77 virus were not further increased and 
the wild type reached similar SCD (Figure 28C). These data suggest that the NS1 truncation does not 
improve the pro-apoptotic skills of the virus in infected cells but rather allows the progression of 
cell death, once primed, to occur faster due to the loss of anti-apoptotic functions. The finding is 
consistent with previous publications showing that the NS1 ED can interact with cellular proteins 
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such as PKR (Li et al., 2006), PI3K/Akt (Shin et al., 2007b) and Scribble (Liu et al., 2010) implicated in 
the apoptotic pathway, contributing to delayed apoptosis during infection.  
 
Figure 28. H7N3 and H7N3 NS1-77 annexin V results in BxPC-3 and HPDE6 cells. Specific cell death (SCD) triggered by 
apoptosis in BxPC-3 and HPDE6 cells at 16 (A) and 24 (B) hours post-infection with H7N3 and H7N3 NS1-77 influenza 
virus (m.o.i.= 0.1). Treatment with Gemcitabine and Cisplatin was used as positive control for apoptosis. C) Time-course 
analysis of BxPC-3 SCD following infection with the different mutant viruses and chemotherapeutic agents. All data 
represent means ± standard deviations (SD) of two independent experiments. Statistical significance was determined 
using Two-way ANOVA followed by Tukey’s multiple comparison test. 
 
3.2.2 H7N3 NS1-77 virus infection triggers high levels of IFN expression in benign cells. 
Because of the strain-specific characteristics of NS1 protein, to investigate the effect of the 
truncation on the protein’s ability to limit host IFN response during infection, a second pair of full 
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length NS1 or NS1-77 truncated IAVs were also generated using the genetic backbone of the well-
studied laboratory human strain H1N1 A/Puerto Rico/8/34 (PR8).  
The ability of the two pairs of IAVs to counteract the host IFN-mediated antiviral response was first 
assessed in A549-IFNLuc cells, a human lung cell line expressing a reporter construct in which the 
luciferase gene is downstream of an IFN-β promoter (Hayman et al., 2006). A549-IFNLuc cells were 
infected with the different engineered viruses at equal multiplicity (M.O.I. = 1) and after an eight 
hour infection they were lysed and measured for luciferase activity (Figure 29A). The resulting 
luciferase signal was an indirect measure of IFN expression and therefore it was inversely 
dependent on the virus ability to counteract IFN. Results showed that the H7N3 wild type virus 
efficiently controlled IFN induction as no difference was observed compared to the mock infection 
(Figure 29A). However, the H7N3 NS1-77 virus induced a significantly higher luciferase signal than 
the mock infection or the infection with the H7N3 wild type virus. Interestingly, while the truncation 
of the NS1 ED in this avian isolate led to a strong reduction of the ability to limit IFN induction, the 
difference in the IFN expression induced by human PR8 viruses with full length or truncated NS1 
proteins was less pronounced.  
To test the extent to which each of the recombinant influenza viruses would induce IFN in 
pancreatic cells, an indirect method was used (Figure 29B). Pancreatic ductal adenocarcinoma 
BxPC-3 cells and “benign” HPDE6 cells (Furukawa et al., 1996; Ouyang et al., 2000) were infected 
with an equal multiplicity of each recombinant IAV. Eight hours after infection, supernatants that 
would contain any induced secreted cytokines were collected, and any viruses present were 
inactivated under a germicidal lamp. The treated supernatants were transferred onto 293T cells 
previously transfected with ISG54Luc plasmid, which encoded the firefly luciferase gene driven by 
the interferon-inducible ISG54 promoter. A RenillaLuc plasmid encoding the renilla luciferase as 
transfection control was also included. The firefly luciferase signal from the ISG54 promoter was an 
indirect measure of IFN expression from BxPC-3 or HPDE6 cells during viral infection and as such it 
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was inversely dependent on the virus’ ability to counteract IFN in these cells. Consistent with our 
preliminary data (see paragraph 2.2.2) and with previous publications reporting the lack of IFN-α/β 
expression in BxPC-3 cells due to chromosomal aberrations (see paragraph 1.2.3), the results 
showed no significant differences in the ISG54 stimulation between the supernatants derived from 
BxPC-3 cells infected with any of the influenza viruses and the mock infection (Figure 29B). 
However, supernatants from infected HPDE6 cells triggered luciferase signals from the ISG54 
promoter and to a different extent depending on the virus used to infect. The trend was the same 
as previously shown in the A549-IFNLuc assay. The H7N3 NS1-77 bearing a truncated NS1 protein 
did not efficiently limit the IFN expression whereas parental H7N3 with full length NS1 gene did 
(Figure 29B). Recombinant PR8 NS1-77 virus was not affected as much as H7N3 NS1-77 by the 
truncation, since it did not show any significant difference in ISG54 stimulation compared to its wild 
type virus counterpart. 
The likely explanation for the profound effect of H7N3 NS1 truncation on the virus’ ability to control 
interferon compared to the same mutation in the PR8 virus is that the way in which different NS1 
proteins can limit IFN expression differ between the influenza virus strains. Most NS1 protein can 
work to inhibit IFN at two different levels: first pre-transcriptionally by inhibiting RIG-I recognition of 
viral PAMPs and/or RIG-I ubiquitination by TRIM25, and second post-transcriptionally by binding to 
CPSF30 and inhibiting processing of induced host cell mRNAs such that they are not expressed (see 
paragraph 1.5.4). Previous studies showed that the NS1 protein of H1N1 A/PR/8/34 (PR8) limits pre-
transcriptional events associated with IFN-β expression, but is apparently unable to block post-
transcriptional processing of IFN-β pre-mRNAs due to amino acid substitutions in position 103 and 
106 that block the interaction with the cleavage and polyadenylation specificity factor (CPSF30) 
(Kochs et al., 2007; Steidle et al., 2010). To appraise the ability of H7N3 NS1 to limit host gene 
expression, the NS1 proteins were cloned into pCAGG expression plasmids so they could be 
expressed in the absence of other viral proteins. To monitor expression of a gene that is transcribed 
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by host polymerase II, 293T cells were transfected with pCAGGLuc plasmid, which directs 
polymerase II mediated expression of firefly luciferase (Figure 29C). In addition, to measure the 
effect of NS1, one of the following plasmids: pCAGG/PR8 NS1, pCAGG/H7N3 NS1, pCAGG/H7N3 
NS1-77 and empty pCAGG (K-) was co-transfected. The expression of luciferase in 293T was 
dependent on the ability of the different NS1 proteins to interfere with the maturation of the 
luciferase pre-mRNA. When full length PR8 NS1 protein was expressed, the levels of luciferase 
activity were comparable with those obtained if the empty pCAGG plasmid were transfected (Figure 
29C). Conversely, the presence of full length H7N3 NS1 blocked luciferase expression, suggesting 
that the protein possesses the capability to interact with CPSF30. However, the truncation of the ED 
(NS1-77) resulted in the loss of this capability and restored luciferase expression to a level 
comparable with that measured with PR8 NS1 or empty pCAGG. 
Western Blot results showed that all the NS1 proteins were expressed, although different levels of 
expression were observed (Figure 29C). During an infection the polyadenylation of IAV mRNAs is 
independent of cellular 3’-end processing factors (see paragraph 1.4.5.2); therefore in the context 
of the virus infection viral mRNAs are not affected by CPSF30 inhibition. However, in this assay the 
NS1 protein was encoded by a plasmid that underwent post transcriptional processing as a regular 
host cell mRNA. As a consequence the production of an NS1 protein efficiently able to interact with 
CPSF30 should limit its own expression. Accordingly, H7N3 NS1 protein showed lower levels of 
expression compared to PR8 NS1, but truncation of the ED restored expression of H7N3 NS1-77 
protein to similar high levels as the PR8 NS1. Taken together, the luciferase assay and the western 
blot results also demonstrate that a small amount of functional H7N3 NS1 protein can trigger a high 
inhibition of host cell pre-mRNA processing. 
106 
 
Figure 29. Strain specific effect of NS1-77 truncation on IFN expression in infected cells. A) IFN-β expression in A549-IFNLuc 
cells infected with H7N3 and PR8 reverse genetics viruses bearing full length or truncated NS1 protein. Results are shown 
as raw data and expressed as RLU (relative light units). B) ISG54 expression induced by supernatant obtained from 
HPDE6 or BxPC-3 cells infected with recombinant IAVs. HPDE6 and BxPC-3 cells were infected with H7N3 or PR8 reverse 
107 
genetics viruses bearing full length or truncated NS1 protein. At 8 hours post-infection, the supernatants were collected, 
inactivated under ultraviolet radiation and transferred on 293T cells previously transfected with ISG54Luc plasmid, 
encoding the firefly luciferase gene driven by the inducible promoter ISG54, and RenillaLuc, encoding the renilla 
luciferase. After 24 hours 293T cells were washed, lysed and tested for luciferase activity. Results are shown as 
Luciferase/Renilla ratio. C) Luciferase expression in 293T cells co-transfected with pCAGGLuc, stably expressing firefly 
luciferase, and pCAGG/H7N3 NS1, pCAGG/H7N3 NS1-77, pCAGG/PR8 NS1 or empty pCAGG (K-). Results are shown as 
raw data and expressed as RLU (relative light units).  Western Blot targeting SV5 tag was performed to confirm NS1 
protein expression in the cell lysates following transfection of pCAGG plasmids encoding different NS1 genes. Vinculin 
was used as a loading control. All data represent means ± standard deviations (SD) of one representative experiment 
(n=3). Statistical significance was determined using One-way ANOVA followed by Bonferroni’s multiple comparison test. 
 
3.2.3 H7N3 NS1-77 virus shows diminished replication in IFN-expressing targets. 
Having proved that truncation of H7N3 NS1 protein significantly reduced the virus ability to 
antagonize the interferon response, we next tested whether this conferred a degree of preference 
for the virus to replicate in IFN deficient systems, representing the majority of PDA cells. 
Replication of H7N3 and H7N3 NS1-77 viruses was monitored over a 72 hour time-course in IFN-
competent HPDE6 cells and IFN-deficient BXPC-3 cells. Results confirmed that, although viral 
growth in either cell line was not high, overall, replication levels were higher in permissive tumour 
BxPC-3 cells than in HPDE6 cells (Figure 30A-B).  
In IFN deficient BxPC-3 cells viral titres showed significant increase at 72 hours compared to those 
at 24 hours post-infection for both viruses and no significant differences between full length and 
truncated NS1 virus was observed at any given time-point (Figure 30A). Conversely, in IFN-
competent HPDE6 cells only the wild-type virus showed significant growth between 24 and 72 
hours post-infection, with the NS1-77 truncated virus displaying appreciable lower replication 
ability (Figure 30B). Although the results are in line with the data generated using direct and 
indirect IFN assay and seem to confirm that H7N3 NS1-77 virus had restricted replication in IFN 
expressing systems compared to the corresponding full length NS1 virus, we have to acknowledge 
that the truncation only appears to attenuate H7N3 virus in HPDE6 cells by about 2-fold, which is 
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extremely modest by virological standards. Because this might be due to suboptimal levels of 
proteases available (see paragraph 2.2.1) or to higher sensitivity of avian IAV isolates to mammalian 
ISGs (see paragraph 1.6.2.3), we decided to test the effect of NS1 truncation also in Embryonated 
Chicken Eggs (ECE), which represent a more standard laboratory medium for propagating avian 
influenza viruses.  
The susceptibility of ECE to many viruses may change during the embryonic or neonatal 
development. Baron and Isaacs (Isaacs and Baron, 1960) first suggested that increasing resistance 
of the chicken embryo to certain viruses might be due to increased ability of older embryonic 
tissues to produce and respond to interferon. Morahan and Sidney (Morahan and Grossberg, 1970) 
showed that different viruses including IAV, VSV and NDV grew to lower titres in cells derived from 
older chicken embryos, capable of mounting a mature IFN response, than in those derived from 
younger embryos. Based on these reports, the growth of full length and truncated NS1 H7N3 
viruses in 7 and 14 days old ECE was used to compare their replication in IFN impaired and 
competent systems.  
Ten specific pathogen free (SPF) ECE of either 7 or 14 days of age were infected with 103 pfu/egg of 
recombinant H7N3 NS1-77 or full length NS1 viruses. Eggs were then incubated at 37°C and candled 
daily to monitor the embryo death for 5 days. Allantoic fluids harvested from all eggs were 
screened by rapid haemagglutination test and those positive in each group were pooled together. 
Viral titre of the pooled fluids was measured by haemagglutination assay (HA). Results showed that 
the two viruses reached the same HA titre in 7 day old ECE, whereas the HA titre of the wild type 
H7N3 virus was 3log2 higher than the truncated virus in fully IFN competent 14 day old ECE (Figure 
30C). These data confirm that H7N3 NS1-77 virus have restricted replication in IFN expressing 
systems compared to the corresponding full length NS1 virus, but displays the same growth as an 
otherwise isogenic wild type virus in IFN deficient systems. 
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Figure 30. Replication kinetics of H7N3 and H7N3 NS1-77 IAVs in BxPC-3 and HPDE6 cell lines. H7N3 and H7N3 NS1-77 
virus replication was monitored over a 72 hour time-course in IFN-deficient BxPC-3 (A) and IFN-competent HPDE6 (B) 
cells. Cells were infected at an M.O.I. of 0.001 and virus titres of the supernatants were determined via plaque assay on 
MDCK-NPro cells at 24, 48 and 72 hours post-infection. Results represent means plus standard deviation (SD) of three 
independent experiments. Statistical differences for each virus at different time-points were determined using Two-way 
ANOVA followed by Tukey’s multiple comparison test; while difference between the two viruses at each time-point were 
evaluated using Bonferroni post-test. C) H7N3 and H7N3 NS1-77 virus growth in 7 and 14 day old embryonated chicken 
eggs (ECE). PBS antibiotic solution containing each virus was inoculated into the allantoic cavity of 7 and 14 day-old ECE. 
The eggs were incubated at 37°C and candled daily for 5 days (120 h). For each group, the allantoic fluid of any eggs 
positive to rapid hemagglutination test after embryo’s death or at the end of the incubation period were pooled together 
and the virus titre was measured using haemagglutination assay (HA assay).  
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3.2.4 The immunostimulatory activity of H7N3 NS1-77 virus in infected healthy cells 
enhances its oncolytic effect via IFN-mediated cell killing of neighbouring 
uninfected PDA cells.  
Different studies demonstrated the efficacy of IFN-α and β in the treatment in vitro and in vivo of 
several tumours types (Lindner et al., 1997; Vitale et al., 2006). Although IFN-α and β are 
multifunctional cytokines that binds the same receptors (IFNAR1 and IFNAR2), the latter possesses 
greater anti-tumour effect (Damdinsuren et al., 2003; Johns et al., 1992; Rosenblum et al., 1990; 
Vitale et al., 2006). In line with this considerations, as previously discussed (see paragraph 1.3.1.4), 
oncolytic viruses armed to express IFN-β are currently under clinical trials. 
Vitale et al. (Vitale et al., 2007), showed that also in PDA cells, which often retain sensitivity to 
exogenous IFN (see paragraph 1.2.3), IFN-β is significantly more effective than IFN-α in inhibiting 
tumour cell growth by inducing more potent cell cycle arrest and apoptosis activation at very low 
doses, particularly in tumours with a high expression of IFNAR-1 and IFNA-2c receptors. A later 
publication by Tomimaru et al. (Tomimaru et al., 2011) demonstrated that IFN-β is able to act 
synergistically with gemcitabine to reduce the cell growth of pancreatic cancer cells, even in cell 
lines that are nonresponsive to IFN-α and have a low IFNAR-2 expression. In line with these 
observations, a recent study evaluating the effects of IFN-α and β in 11 human pancreatic cancer 
cell lines, showed that the expression level of the type I IFN receptor (IFNAR-1 and IFNAR-2c) is of 
predictive value for the direct antitumor effects of IFN-α, but not of IFN-β (Booy et al., 2014). 
Indeed IFN-β induced a potent antitumor effect at low concentrations and its activity was less 
dependent on IFN receptor expression, making it a more promising therapeutical agents than IFN-α.  
Local production of IFN-β was shown to induce a strong anti-tumour effect on PANC02-H7 cells, a 
highly metastatic mouse pancreatic adenocarcinoma cell line, successfully transfected with a vector 
containing a murine IFN-β gene (Wang et al., 2001). Thus, having demonstrated that the H7N3 NS1-
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77 virus induces higher levels of IFN-β expression in IFN competent cells compared to the wild type 
(see paragraph 3.2.2), we hypothesized that by stimulating the antiviral response in healthy cells, 
which in a real situation are in contact with the tumour, the truncated virus might indirectly trigger 
a significant IFN-mediated killing of neighbouring uninfected PDA cells. 
To test this hypothesis, confluent monolayers of IFN-competent HPDE6 cells, which present a near 
normal genotype and phenotype, were infected in 12 well plates with H7N3 and H7N3 NS1-77 at 
M.O.I=1 or mock infected (Figure 31A). After 24 hours supernatants were collected and treated 
under germicidal lamp to inactivate potential infectious particles in the suspension as confirmed by 
subsequent plaque assay. The VeriKine Human IFN-β ELISA kit (pbl Assay Science) was then used for 
quantitative measurement of IFN-β in the supernatants derived from HPDE6 infections (Figure 31A). 
Next different monolayers of PDA and HPDE6 cells were incubated with the conditioned media 
derived from previous infection. After 16 hours incubation the media was discharged and cells were 
tested for the presence of cytoplasmic histone-associated DNA fragments, a hallmark of apoptosis 
progression (see paragraph 1.5.3), using the Cell Death Detection ELISAPLUS photometric enzyme 
immunoassay (Roche – Life Science) (Figure 31A).  
Human IFN-β ELISA results showed higher concentration of the soluble cytokines in the HPDE6 
supernatants derived from H7N3 infection than in those from mock infection (Figure 31B). This 
result slightly differed from the data obtained in the previous plasmid-based assays, where no 
significant difference was observed between these two conditions (Figure 29B), but this was likely 
due to the later time post-infection of the sampling (8h vs 24h). Nevertheless, consistent with 
previous results (Figure 29B), IFN-β concentration in the media from H7N3 NS1-77 virus infection 
was significantly higher compared to the supernatant from full length NS1 virus infection.  
Cell death results (Figure 31C) showed that infectious particle-free HPDE6 cell supernatants 
containing IFN-β were capable of inducing apoptosis in various PDA cell lines to different extents. 
Indeed diverse degrees of sensitivity to exogenous IFN-β, depending on the PDA cell line, have been 
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previously reported (Booy et al., 2014; Vitale et al., 2007). Consistent with these publications, in 
comparison to the cell death triggered by supernatants derived from mock infection, BxPC-3 and 
AspC-1 cell lines displayed the highest sensitivity to conditioned media that contained IFN, followed 
by CFPAC-1 and by the more resistant Mia Paca-2. Benign HPDE6 cells were not affected by 
conditioned media, although it is not possible to exclude that longer incubation period might have 
also increased the amount of apoptosis occurring in this cell line.  
In addition and even more interesting, the results showed that HPDE6 cell supernatants derived 
from H7N3 NS1-77 infection provoked significantly higher levels of cell death in all the PDA cells 
tested than those derived from full length NS1 virus infection. Thus, taken together, these data 
suggest that H7N3 NS1-77 virus might trigger higher apoptosis in uninfected PDA cells as 
consequence of a stronger stimulation of IFN production from infected neighbouring healthy cells, 
which would be also more resistant to this effect. 
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Figure 31. Sensitivity of PDA cells to exogenous IFN. A) Schematic representation of the experiment. HPDE6 cells were 
infected at M.O.I = 1 pfu/cell with H7N3, H7N3 NS1-77 virus or mock infected. After 1 h absorption, the media were 
replaced with 3% FBS RPMI 1640 without trypsin, and the cells were incubated for further 24 hours. Next the 
supernatants were collected and exposed to the ultraviolet radiation from a germicidal lamp for 10 minutes in order to 
inactivate any infectious virus. Quantitative measurement of IFN-β in the supernatants was performed using the VeriKine 
Human IFN Beta ELISA kit (pbl Assay Science). The inactivated supernatants were then placed on different PDA and 
HPDE6 cells and incubated for 16 hours. Apoptosis triggered by conditioned media in the different cell lines was 
measured using Cell Death Detection ELISAPLUS photometric enzyme immunoassay (Roche – Life Science). B) Human IFN-
β ELISA kit results for HPDE6 cell supernatants collected at 24h post-infection with H7N3, H7N3 NS1-77 viruses or mock 
infected. For each group absorbance values at 450 nm are represented (left Y axis) and the correspondent IFN-β 
concentration (pg/ml) can be obtained by comparison with the standard curve values (right Y axis). All values represent 
means ± standard deviations (SD) of one representative experiment (n=3). C) Enzyme immunoassay targeting 
cytoplasmic histone-associated DNA fragments in PDA and HPDE6 cells after 16h incubation with virus-free supernatants 
derived from HPDE6 cells infected with H7N3, H7N3 NS1-77 virus or mock infected. Value represents means of 
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Absorbance450nm-Absorbance490nm ± standard deviations (SD) of one representative experiment (n=4). Statistical 
significance was determined using Two-way ANOVA followed by Tukey’s multiple comparison test.  
 
To further investigate the contribution of the immunostimulatory activity on the IAV’s oncolytic 
potential, we tested the effect of infecting a confluent monolayer mix (ratio 1:1) of HPDE6 cells and 
a luciferase expressing BxPC-3 cell line derived from the original PDA cells, which was generated as 
part of this project and termed BxPC-3Luc. The mixture of HPDE6/BxPC-3Luc cells was infected with 
H7N3 or H7N3 NS1-77 viruses at different M.O.I or mock infected. Because the infection was 
performed in absence of exogenous trypsin and the media was enriched with foetal bovine serum 
(FBS), which possesses proteases inhibitory activity (Schultze et al., 1955), viral replication in both 
cell lines of the mix was limited to a single cycle. The virus ability to trigger BxPC-3Luc cell death in 
this experimental setting was evaluated through the decrease of luciferase activity compared to 
mock infection at 24 hours post-infection, a time-point at which the two viruses displayed similar 
levels of apoptosis by direct lysis (Figure 28C). 
In this mixed scenario (Figure 32A), while IAV infection of BxPC-3Luc cells should trigger cell death 
via direct lysis, in HPDE6 cells it would result in a high levels of IFN-β production (see figure 31B), 
which, besides increasing the resistance of this cell line to virus infection (see paragraph 2.2.2), 
might also enhance the killing of IFN sensitive uninfected PDA cells (see figure 31C).  
Results showed that reduction of luciferase activity following virus infection was detectable at 24h 
post-infection compared to mock infection and the extent of this decrease was overall greater at 
higher M.O.I (Figure 32B). Moreover, at equal M.O.I the amount of BxPC-3Luc cell death was higher 
for H7N3 NS1-77 virus infection than for the full length NS1 virus and the extent of this difference 
tended to increase at lower M.O.I. These data are in line with the mechanism of action proposed in 
which at high M.O.I. the lytic effect triggered by direct virus infection outcompetes the 
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immunostimulatory activity exerted on IFN competent cells. However at lower M.O.I., as the ratio 
between virus and cells decrease, the effect of the IFN induction became appreciable. 
To confirm that PDA cell killing was at least partly due to the effect of virus infection of the HPDE6 
cells, we repeated the test using confluent monolayers of BxPC-3Luc cells alone (Figure 32C).  
Luciferase expression results at 24 hours post-infection showed significant difference at higher 
M.O.I only between virus treatments and the negative control (mock infection) (Figure 32D). 
However, no significant difference was observed in the decrease of luciferase activity between the 
H7N3 and H7N3 NS1-77 viruses at any M.O.I. used.  
Taken together this results suggests that the NS1 truncated virus might have superior beneficial 
effect compared to the wild type virus in a clinical situation, by adding to the direct virus-mediated 
lysis of infected PDA cells a powerful immunostimulatory effect on healthy cells, which can trigger 
killing of uninfected tumour cells. 
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Figure 32. Evaluation of H7N3 viruses’ immunostimulatory activity. A) Proposed mechanism of IAVs action in a mixed 
monolayer of benign IFN-competent HPDE6 cells and tumour IFN-deficient BxPC-3Luc cells stably expressing the 
luciferase gene. Besides triggering direct lysis of infected BxPC-3Luc cells, IAV stimulates IFN production from HPDE6 
cells, which in turn can promote cell death of uninfected IFN sensitive PDA cells enhancing the overall oncolytic activity of 
the virus. B) Luciferase activity results in mixed monolayers of HPDE6 and BxPC-3Luc cells at 24 hours post-infection with 
H7N3 and H7N3 NS1-77 viruses at different M.O.I. or following mock infection. The luciferase signal is expressed in 
relative light units (RLU) and provides a direct measurement of BxPC-3Luc cell viability. C) Proposed mechanism of IAV 
action in monolayers of tumour BxPC-3 cells. Since BxPC-3 cells lack of IFN expression, in monolayers of this cell line 
alone there will not be any contribution of the virus’ immunostimulatory activity on the cell death, which will be 
exclusively the result of the direct virus-mediated lysis of infected cells. D) Luciferase activity in monolayers of BxPC-3Luc 
cells alone at 24 hours post-infection with H7N3 and H7N3 NS1-77 viruses at different M.O.I. or following mock 
infection. Luciferase signal (RLU) provides a direct measurement of BxPC-3Luc cell viability. All data displayed in panel B 
and D represent means + standard deviations (SD) of representative experiments (n=4 for each M.O.I). Statistical 
significance was determined using Two-way ANOVA followed by Tukey’s multiple comparison test. 
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3.2.5 H7N3 NS1-77 virus showed a beneficial effect in PDA xenograft mice model. 
To further confirm the superior oncolytic activity of H7N3 NS1-77 virus compared to the 
corresponding wild type, we tested the efficacy of each virus in the treatment of SCID mice bearing 
BxPC-3Luc derived solid tumours.  
Equal numbers of BXPC-3Luc cells were injected subcutaneously into the right flank of SCID mice. 
After the mice developed palpable tumours, they were divided equally into three groups (n=5). A 
control group received injections of PBS whilst the other two groups received four 5x104 pfu/50 µl 
injections of H7N3 or H7N3 NS1-77 viruses around the tumour mass as described in material and 
methods. The amount of virus used in the present experiment for each injection was almost 3 log10 
lower than in trials previously performed for other tumour types using PR8 strain (Sturlan et al., 
2010). Such low virus dose was chosen to appraise the contribution of both lytic and 
immunostimulatory activity of the viruses. The mice were monitored for signs of distress and 
tumour size was measured twice a week from the beginning of the treatment using a microcaliper. 
The mean percentage of volume increase compared to the beginning of the treatment (day 9) was 
calculated for each group at any given time-point (Figure 33A). Tumour morphology, size and the 
presence of metastases were also evaluated at the end of the experiment by bioluminescence 
imagine (BLI) (Figure 33B). 
Despite the low amount of virus used for each injection, a reduction in tumour growth was 
observed in both groups treated with IAVs in comparison to the control group (PBS). Moreover, 
although there was no statistically significant difference between the groups injected with wild type 
H7N3 and the NS1-77 mutant, the animals injected with NS1-77 virus showed lower mean tumour 
volume increase at all time-points than those treated with full length NS1 virus, displaying a 
significant beneficial effect with respect to the control group (Figure 33A). 
Because the two viruses were shown to replicate at similar levels in tumour BxPC-3 cells (see figure 
30A) and to trigger equivalent cell death by 24 hours post-infection in this cell line (see figure 28B-
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C), the difference in the beneficial effect observed in comparison to the control group was unlikely 
ascribable to a higher viral growth (indeed similar level of viral RNA were detected in tumours 
infected by either virus see below). Thus, it might be due to the superior ability of the NS1-
truncated virus to stimulate innate immune response from the healthy cells surrounding the 
tumour. Indeed different publications confirmed that SCID mice, which lack T and B lymphocytes 
(Bosma et al., 1983), possess normal innate immune mechanisms including IFN-α/β expression that 
can reach levels similar to the responses of immunocompetent controls (Bray, 2001; Falk et al., 
1995; Murphy et al., 2003).  
The stimulation of type I IFN production from healthy cells might also account for the lower levels 
of vascularization observed post-mortem in tumours derived from mice infected either with full 
length or truncated NS1 influenza viruses compared to those of the control group (observation 
orally reported by Dr. Micol Silic-Benussi who performed the trial at the IOV facilities). Previous 
publications, in fact, demonstrated the role of IFN-α as a powerful angiogenesis inhibitor 
(Indraccolo, 2010; von Marschall et al., 2003). 
After all the mice were euthanized, 5 tumours and 1 lung, 1 liver and 1 kidney per group were 
collected and assessed by Real-Time PCR for influenza A virus M gene. All the lungs, livers and 
kidneys resulted negative for the viral RNAs (data not shown) confirming the absence of virus 
spreading. Conversely, all the tumours derived from mice injected with IAVs showed detectable 
virus RNA (Ct<35) (Figure 33C), which might indicate replication within the tumour site or might be 
just the result of the defective clearance derived from the lack of T and B lymphocytes in SCID mice.  
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Figure 33. Efficacy of H7N3 and H7N3 NS1-77 virus treatment in SCID mice bearing human BxPC-3Luc derived tumours. A) 
Solid tumours were established by day 9 and mice were randomly divided into 3 groups (n=5 per group). Animals in each 
group were administered at the base of the tumour with 5x104 pfu of H7N3, H7N3 NS1-77 viruses or PBS (negative 
control). The procedure was subsequently repeated 3, 7, and 10 days later for a total of four intratumoural inoculations 
for each group. Tumour size was monitored by caliper measurements and percentage of volume increase was calculated 
as described in material and methods. The groups were observed twice a week within 23 days from the beginning of the 
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experiment. Comparison of groups was done by using Two-way ANOVA followed by the Tukey’s multiple comparison 
test. B) Bioluminescence imaging (BLI) of BxPC-3Luc solid tumour from selected animals of the 3 different challenge 
groups. (*) metastasis. C) Ct (cycle threshold) results of real-time RT PCR targeting viral matrix gene (M) in tumours 
homogenates derived from SCID mice treated with H7N3, H7N3 NS1-77 or PBS. Based on diagnostic standards in place 
at IZSVe samples with Ct>35 were considered negative.  
 
3.3  Discussion and conclusion. 
In this study the oncolytic potential of an engineered avian-origin IAV has been tested for the first 
time in PDA cells characterized by deficient IFN expression. We focused our research on the BxPC-3 
cell line as it displayed high sensitivity to IAV infection, although previously shown to be resistant to 
various oncolytic viruses. We selected the avian origin H7N3 A/turkey/Italy/2962/03 isolate because 
of its high apoptotic potential in PDA cells (see paragraph 2.2.1). Aiming to increase the selectivity 
of H7N3 virus for tumour IFN-deficient cells, such as BxPC-3, the NS1 protein was modified to 
express only its N-terminal 77 amino acids (NS1-77), resulting in almost complete loss of the ED, 
which predominantly mediates interactions with host-cell proteins (Figure 27A).  
Annexin V results confirmed higher selectivity of H7N3 viruses’ induced apoptosis for BxPC-3 cells 
than for HPDE6 cells in comparison to the Gemcitabine and Cisplatin treatment (Figure 28A-B), 
which is likely due to the capability of the benign cells to express IFN and activate specific IFN-
stimulated genes following infection (see paragraph 2.2.2). Interestingly, progression of tumour cell 
death occurred faster with the H7N3 NS1-77 virus than for the wild type strain but cells infected by 
either virus reached the same final SCD (Figure 28C). The finding is consistent with an anti-apoptotic 
role for the NS1 ED (Li et al., 2006; Liu et al., 2010; Shin et al., 2007b).  
The H7N3 NS1-77 virus was no longer able to counteract IFN expression in IFN-competent cells, as 
shown by several reporter based assays (Figure 29A-B). However, when the same truncation was 
engineered into a different viral genetic backbone, that of H1N1 A/Puerto Rico/8/34 (PR8), it did 
not result in significant differences in the ability to antagonize IFN mediated antiviral response 
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(Figure 29A-B), confirming the strain-specific IFN-antagonistic properties of different NS1 proteins 
(Figure 29C).  
The inability to block host cell IFN expression during replication did not impair the growth of H7N3 
NS1-77 virus in IFN-deficient BxPC-3 cells or in IFN-impaired 7 day-old ECE, (Figure 30A-C). Because 
the replication of the wild type virus in IFN competent HPDE6 cells was already very low, likely due 
to the activity of IFN and ISGs following infection, the effect of the truncation in this cell line was 
difficult to discern since released virus titres were almost at the limit of detection. Nevertheless, the 
H7N3 NS1-77 virus showed significant lower growth over time than the full length NS1 virus in 
HPDE6 cells (Figure 30B) and its reduced replication efficiency in IFN competent systems was 
further confirmed in 14 day-old ECE (Figure 30C).  
In addition to an albeit small effect on improving virus selectivity compared to the wild type virus, 
the loss of the ability to counteract the innate immune response and the consequent increase in 
IFNs production from healthy cells appeared to enhance H7N3 NS1-77 cancer cell killing activity at 
appropriate M.O.I. Indeed, our results suggest that in a clinical situation, a limited amount of H7N3 
NS1-77 virus infection of IFN-expressing healthy cells should not result in efficient virus replication 
(Figure 30B), but rather in stimulation of high levels of IFN-β expression (Figure 29B and 31B), which 
would then increase the killing of neighbouring uninfected BxPC-3 cells (Figure 31C) and thus 
improving the oncolytic potential of the virus compared to the wild type (Figure 32B and 33A). 
Furthermore, the presence of IFNs, such as IFN-α, in the tumour microenvironment might 
contribute to the inhibition of angiogenesis as previously reported (Indraccolo, 2010; von Marschall 
et al., 2003). 
In conclusion, we generated an H7N3 NS1-77 avian origin IAV which was as efficient at inducing 
apoptosis as the parental strain in infected BxPC-3 cells but which overall possesses greater 
oncolytic activity than the wild type virus because of the superior ability to mediate the killing of 
uninfected cancer cells by stimulating IFN expression from neighbouring healthy cells. 
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Chapter 4. PB1-F2 mutation: looking for an optimal balance 
between apoptosis induction and virus replication in PDA cells.  
 
4.1  Introduction  
The H7N3 A/turkey/Italy/2962/03 avian-origin influenza virus was selected as oncolytic candidate 
for the present study due to its superior ability to trigger apoptosis in PDA cells compared to other 
isolates (Kasloff et al., 2014). The NS1-77 truncation was introduced to improve the specificity of 
virus for replication in IFN deficient cells (i.e. tumour cells) vs healthy cells. However, the overall 
replication of either wild type or NS1-77 H7N3 viruses was generally low, which might ultimately 
preclude the efficacy of the virus as single-shot treatment. Indeed, without high levels of virus 
replication, which can support rapid intra-tumoural spread, a single-shot administration of IAV 
would probably have modest or even innocuous effect on PDA in vivo. 
As previously discussed (see paragraph 1.5.4 and 1.5.5), a proper timing between apoptosis delay 
and induction appears of paramount importance for optimal virus replication and packaging. As 
such, the highly efficient induction of apoptosis by the H7N3 virus might actually limit its replication 
if cell death were triggered too early during infection to allow onwards virus propagation. Thus in 
this chapter we were interested to explore what effect manipulating the extent of apoptosis 
induction triggered by the recombinant H7N3 virus would have on its efficacy as oncolytic agents.  
Our caspase 9 results (see paragraph 2.2.3) showed that the H7N3 virus triggered apoptosis in 
BxPC-3 infected cells mainly by affecting the intrinsic apoptotic pathway. Based on the genetic 
aberration previously reported (Table 3) and on the expression profile of different apoptosis-related 
protein in untreated BxPC-3 cells presented in the following paragraph, the activation of this 
pathway appeared due to the direct effect of viral pro-apoptotic factors rather than represent the 
result of the host antiviral response to infection. Because the intrinsic pathway originates from the 
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mitochondria we investigated the role of pro-apoptotic protein PB1-F2 (see paragraph 1.5.5) and 
manipulated this gene in the context of recombinant virus in an effort to find an optimal balance 
between apoptosis induction and virus replication in PDA cells. 
 
4.2 Results 
4.2.1 The intrinsic apoptosis pathway in BxPC-3 cells.  
As shown in paragraph 2.2.2, the lack of IFN and ISG expression might, at least partially, explain why 
BxPC-3 cells are more sensitive than HPDE6 cells to IAV infection and are subject to increased cell 
death. However, the reason why the H7N3 isolate displayed higher levels of apoptosis compared to 
other IAV strains in this PDA cell line is still unclear. As previously described (see paragraph 1.5.4), 
during influenza virus infection, apoptosis can be considered a host defence mechanism to limit 
pathogen spreading but also a condition promoted by the virus to enhance its genome replication 
and new virion release. In line with this bivalent effect, IAVs possess different proteins able to 
modulate host cell death by targeting cellular factors and thereby exerting either anti-apoptotic 
(Gaur et al., 2012; Zhirnov et al., 2002) or pro-apoptotic function (Chen et al., 2001; Halder et al., 
2011; Schultz-Cherry et al., 2001; Tripathi et al., 2013).  
The H7N3 A/turkey/Italy/2962/03 virus triggered cell death in BxPC-3 cells mainly as the result of 
activation of the intrinsic (or mitochondrial) apoptotic pathway (see paragraph 2.2.3). To elucidate 
whether the activation of this pathway might be the result of the host antiviral mechanism or a 
direct effect of viral pro-apoptotic proteins, the expression profile of 35 apoptosis-related proteins 
in untreated BxPC-3 and HPDE6 cell lysates was compared using a proteome profiler (Human 
Apoptosis Array Kit - R&D Systems).  
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In comparison to the “benign” HPDE6 cells, the expression profile of apoptosis-related proteins 
revealed up-regulation of p53 and Clusterin in BxPC-3 cells, two proteins with pivotal roles in the 
mitochondrial apoptotic pathway (Figure 34). 
The p53 is a tightly regulated tumour suppressor protein that acts by stopping cell-cycle 
progression or promoting apoptosis when cells are exposed to stress stimuli such as oncogene 
activation or DNA damage. Having a short half-life, p53 is normally maintained at low levels in 
unstressed cells through continuous ubiquitylation and subsequent degradation, primarily due to 
the interaction with the RING-finger ubiquitin E3 ligase MDM2 (also known as HDM2) (Friedman et 
al., 1993). In response to genotoxic or cellular stress, p53 ubiquitylation is suppressed and the 
protein accumulates in the nucleus where it forms a homotetrameric transcription factor (Friedman 
et al., 1993; McLure and Lee, 1998) which regulates the expression of a wide variety of genes 
involved in cell-cycle arrest, apoptosis, DNA repair senescence, and differentiation (Ashcroft et al., 
2000).  
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Figure 34. Apoptosis-related protein profiles of untreated BxPC-3 (A) and HPDE6 (B) cell lysates. Cell lysates were diluted 
and incubated on nitrocellulose membrane spotted in duplicate with captured antibodies for 35 apoptosis-related 
proteins. Overexpression of Clusterin (Red arrow) and heavy levels of p53 expression and post-translational 
phosphorylation (green, purple and blue arrows) were observed in BxPC-3 compared to HPDE6 cells. 
 
In PDA cells, the vast majority (≈80%) of TP53 gene mutations resulted in alterations of the protein 
DNA-binding domain (see table 3 – paragraph 2.2.1) that can lead to loss of the tumour-suppressor 
function of p53 or to the accumulation of an oncogenic mutant version of p53. The mutation of just 
one allele of TP53 is potentially oncogenic since mutant p53 proteins are still capable of 
tetramerization but fail to bind efficiently to the specific DNA-binding motifs targeted by tetrameric 
wild-type p53 and can thus act in dominant negative fashion (Herskowitz, 1987). Post-translational 
phosphorylation of specific serines and/or threonines residues at the N- and C-termini of the 
protein has been reported to increase the stability of the tetramer and thus in the case of mutant 
p53 to enhance the inhibitory effect on wild-type p53. In agreement with previous publications, 
reporting the phosphorylation patterns of mutant p53 in different cancer cells (Minamoto et al., 
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2001), the proteome profile of BxPC-3 cells revealed hyper-phosphorylation of p53 protein at serine 
15 and serine 392 (S15; S392). Phosphorylation of the p53 regulatory C-terminal domain at S392, in 
particular, has been shown to regulate the oncogenic function of mutant p53 (Furihata et al., 2002; 
Yap et al., 2004) by inducing conformational changes within the tetramerization domain which 
increase its stability (Sakaguchi et al., 1997) and thereby contribute to dominant-negative effects 
and progression of tumours. Because of this effect, S392 phosphorylation has been suggested as a 
prognostic marker in patients with advanced-stage tumours (Matsumoto et al., 2006).  
The other apoptosis-related protein overexpressed in BxPC-3 cells in comparison to HPDE6 is 
Clusterin (CLU), also known as testosterone-repressed prostate message-2 (TRPM-2), sulfated 
glycoprotein-2 (SGP- 2), apolipoprotein J (Apo J) or SP40, which is a ubiquitous heterodimeric 
glycoprotein of 75–80 KDa normally secreted to protect the cell in response to cellular stressors 
that may induce apoptosis. CLU exerts its chaperone-like activity (Loison et al., 2006) by interfering 
with the oligomerization of pro-apoptotic protein Bax (Zhang et al., 2005) ( Bax itself is up-regulated 
by the tumour suppressor protein p53 (Miyashita et al., 1994; Miyashita and Reed, 1995) ), which 
otherwise would lead to the release of cytochrome c from mitochondria and caspase 9 activation 
(see paragraph 1.5.3). Due to its activity, up-regulation of CLU can enhance tumorigenesis. Indeed, 
overexpression of CLU has been previously reported in numerous advanced stage and metastatic 
cancers (Bi et al., 2010; Redondo et al., 2000; Xie et al., 2005) and has been indicated as a key 
contributor to chemoresistance to anticancer agents (Koltai, 2014; Redondo et al., 2009; Springate 
et al., 2005; Tang et al., 2012; Zellweger et al., 2001; Zellweger et al., 2002). 
Thus, due to the genetic aberration previously described in table 3 (see paragraph 2.2.1) and in the 
light of the proteome profiler results (Figure 34), the normal execution of the intrinsic 
(mitochondrial) apoptotic pathway appears to be tampered with at different levels in BxPC-3 cells. 
Based on these observations, together with the lack of IFN and MxA gene expression reported in 
paragraph 2.2.2, it is likely that the high level of cell death observed following H7N3 infection in 
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BxPC-3 cells was triggered by the direct activity of viral pro-apoptotic factors rather than represent 
the result of cellular antiviral mechanisms.   
Different IAV proteins have been ascribed with pro-apoptotic activity. Recently, IAV nucleoprotein 
(NP) was shown to induce apoptosis by interacting with the host anti-apoptotic factor CLU 
weakening its association with Bax (Tripathi et al., 2013). Interestingly, overexpression of CLU was 
demonstrated to mitigate cell death induced by NP expression or IAV infection, whereas, siRNA-
mediated knockdown of CLU enhanced the apoptosis triggered by the viral protein (Tripathi et al., 
2013). Thus, in the light of the up-regulation of CLU observed in BxPC-3 cells, together with the high 
levels of conservation of the NP protein among avian species, we hypothesized that a viral protein 
other than NP was probably responsible for the apoptotic levels observed in the case of H7N3 
A/turkey/2962/03 virus infection. 
The influenza A virus matrix protein (M1) has also been associated with pro-apoptotic function by 
sequestering the chaperone heat shock protein 70 (Hsp70) from its binding to Apaf-1 complex, 
which prevents the formation of a functional apoptosome (Halder et al., 2011). Nevertheless this 
effect by itself is not sufficient to trigger apoptosis as it relies on previous mitochondria 
permeabilization and cytochrome c release. Therefore, although it was not possible to exclude the 
synergistic activity of other viral proteins, we hypothesized that the viral pro-apoptotic protein PB1-
F2, which is able to directly target the mitochondria causing permeabilization of the MM and 
cytochrome c release (see paragraph 1.5.5), was the main determinant of apoptosis in BxPC-3 cells. 
 
4.2.2 H7N3 PB1-F2 Mitochondrial Targeting Sequence (MTS) L75H mutation. 
As previously discussed (see paragraph 1.5.5), PB1-F2 promotes apoptosis, usually during late stage 
of infection, by targeting and permeabilizing the MM. This in turn results in depolarization of 
membrane potential (ΔΨm), release of cyt c and activation of the caspase-9-mediated intrinsic 
apoptotic pathway (Gibbs et al., 2003; Lowy, 2003; Zamarin et al., 2005). Specific hydrophobic 
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residues within the PB1-F2 C-terminal MTS (minimal MTS aa 69-82 (Gibbs et al., 2003)) are essential 
for mitochondrial targeting. Indeed, Gibbs et al. reported that mitochondrial targeting was 
completely abolished by substituting specific non polar amino acids within the MTS with residues 
bearing electrically charged side chains (Gibbs et al., 2003). More recently, Chen et al. (Chen et al., 
2010) demonstrated that the introduction of leucine (Leu/L) in positions 69 (Q69L) and 75 (H75L) of 
H5N1 A/Hong Kong/156/1997 PB1-F2 drove a 40.7% increase in the protein localization on the MM 
compared to the wild-type, strengthening the idea that a Leu-rich sequence in the C-terminus is 
important for mitochondrial targeting. In line with these observations, Schmolke M. et al (Schmolke 
et al., 2011), reported that the HPAI A/Viet Nam/1203/2004 (H5N1) PB1-F2, which does not contain 
the essential leucines at position 69 (69Q) and 75 (75R), did not predominately co-localize with the 
mitochondria in infected murine and duck cells. 
Sequence analysis of the H7N3 A/turkey/Italy/2962/03 PB1-F2 MTS revealed a Leu in position 75 
where other influenza viruses isolates, with lower ability to induce apoptosis but higher virus 
replication rates (Kasloff et al., 2014), had amino acids with electrically charged side chains 
(Histidine/H or Arginine/R) (Figure 35). We hypothesised that by targeting the MM very efficiently, 
the H7N3 PB1-F2 was triggering apoptosis prematurely during infection. Thus, we speculated that 
removal of Leu from this specific position might reduce PB1-F2 mitochondria targeting, and in turn 
enhance virus replication efficiency either by providing more time for replication (Gibbs et al., 2003) 
or by increasing the localization of PB1-F2 and co-localization of PB1 into the nucleus (Mazur et al., 
2008). Thus, in order to study the effects of the L75H mutation on properties of the PB1-F2 protein 
itself we cloned the wild type or L75H mutated PB1-F2 ORF into the expression plasmids pCAGG. 
Next, seeking an optimal balance between apoptosis induction and virus replication, we generated 
two novel recombinant influenza viruses mutated at residue 75 of PB1-F2 in either the wild type 
H7N3 background or in combination with the NS1-77 truncation described in the previous chapter: 
H7N3 PB1-F2 L75H and H7N3 NS1-77 PB1-F2 L75H viruses.  
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Figure 35. Comparison of PB1-F2 MTS between H7N3 A/turkey/Italy/2960/03 (red arrow) and other avian IAV strains 
previously characterized. In position 75 (red box) the H7N3 virus presents a Leu (hydrophobic) compared to His or Arg 
(positively charged) possessed by the other strains. For comparison we included also (under the dashed line) the PB1-F2 
MTS of H5N1 A/Viet Nam/1203/2004 (green arrow) and H5N1 A/Hong Kong/156/97 (blue arrow) viruses, which do not 
display predominant co-localization with mitochondria in infected cells (Chen et al., 2010; Schmolke et al., 2011). 
Sequence alignment was performed using MEGA (version 6.06) software. 
 
4.2.3 Mutation PB1-F2 L75H decreases H7N3 virus ability to counteract IFN via 
interaction with MAVS. 
In the absence of antibody with which to detect the localization of PB1-F2, we chose to assess the 
effect of the L75H mutation on activities of PB1-F2 associated with its mitochondrial localization. In 
addition to triggering apoptosis from its mitochondrial localization, PB1-F2 protein has also been 
attributed with an ability to interfere with RLR pathway by interacting at the mitochondria level 
with MAVS (see paragraphs 1.5.1).  
As previously discussed (see paragraph 1.5.5), PB1-F2 exerts IFN antagonist function by 
permeabilizing the MM and dissipating the membrane potential (ΔΨm) required for the activity of 
MAVS. Thus, any decrease of PB1-F2 mitochondrial targeting should reduce the inhibition of MAVS 
and increase IFN expression by the cell during infection. To test whether PB1-F2 L75H was 
compromised for inhibition of MAVS activity compared with wild type protein, 293T cells were co-
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transfected with different pCAGG/PB1-F2 (H7N3) plasmids, which direct expression of SV5 epitope 
tagged PB1-F2, together with MAVS expression plasmid (MAVS+) that contains a flag tag for 
detection (Figure 36A). Overexpression of MAVS automatically triggers the induction of IFN. Cells 
were also transfected without MAVS plasmid (MAVS-) to evaluate the basal level of IFN expression. 
IFN-Luc was used as a reporter plasmid in which the luciferase gene was downstream of an IFN-β 
promoter (Hayman et al., 2006), while renilla luciferase (Renilla-Luc) was used to normalize the 
transfection (as described previously in chapter 3 to assess NS1 function – see paragraph 3.2.2). At 
16 hours post-transfection the cell lysates were tested for luciferase activity. Firefly luciferase signal 
was an indirect measure of IFN expression triggered by MAVS. 
Without MAVS plasmid (MAVS-) no luciferase signal was observed in any of the transfections 
(Figure 36A). Conversely, in presence of MAVS (MAVS+) the luciferase signal corresponding to IFN 
expression was modulated by co-expression of PB1-F2. Wild type PB1-F2 inhibited MAVS activity 
significantly more than PB1-F2 L75H. A western blot using an antibody to the flag and C-terminal 
SV5 epitope tag confirmed the expression of both MAVS and PB1-F2 constructs respectively (Figure 
36B). 
To appraise whether the effects of PB1-F2 L75H mutation would be altered in the presence of NS1 
protein ( as would be the case during virus infection) the previous experiment was repeated co-
transfecting also H7N3 NS1, NS1-77 or empty pCAGG expression plasmids (Figure 36C). Full length 
H7N3 NS1 (pCAGG/NS1) strongly counteracted IFN expression induced by MAVS (Figure 36C) 
regardless of the PB1-F2 construct co-transfected. The truncation of the H7N3 NS1 ED 
(pCAGG/NS1-77) reduced this capability, as previously shown (see paragraph 3.2.2), but in this 
situation PB1-F2 could contribute to antagonize IFN expression triggered by MAVS (pCAGG/PB1-F2 
vs pCAGG) and this effect was greater for wild type PB1-F2 than for the L75H mutant. In the 
absence of any NS1 construct (pCAGG) the single effect of different PB1-F2 proteins on MAVS and 
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IFN activity was again visible and PB1-F2 L75H showed higher levels of IFN expression than the 
corresponding wild type protein. 
Taken together these results confirm that substitution L75H within the MTS affects H7N3 PB1-F2 
ability to inhibit IFN expression probably by altering its localization. 
 
Figure 36. Mutation within the MTS of PB1-F2 modulates IFN induction at level of MAVS. A) 293T cells were transfected 
with an IFNLuc reporter encoding the firefly luciferase gene driven by the IFN-β promoter, a pCMV5-flag-MAVS (MAVS+) 
plasmid to direct overexpression of MAVS protein inducing the IFN-β reporter and one of the following: pCAGG/PB1-F2 
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H7N3, pCAGG/PB1-F2 L75H H7N3 or pCAGG expression plasmids. A renilla plasmid was also transfected to normalise the 
luciferase signal. Control 293T cells (MAVS-) were transfected without including pCMV5-flag-MAVS plasmid to appraise 
the basal level of IFN-β expression. B) Western blot targeting flag of pCMV5-flag-MAVS and SV5 tag of pCAGG/PB1-F2 
plasmids were performed to confirm protein expression, while vinculin and β-actin were used as a loading control. C) The 
experiment described above was repeated including also pCAGG/NS1 H7N3, pCAGG/NS1-77 H7N3 or pCAGG expression 
plasmids to appraise the synergetic IFN antagonistic effect of NS1 and PB1-F2 proteins. All data represent means ± 
standard deviations (SD) of one representative experiment (n=3). Statistical significance was determined using Two-way 
ANOVA followed by Bonferroni post-test. 
 
4.2.4 Mutation L75H within PB1-F2 MTS affects H7N3 virus replication and apoptosis. 
To evaluate whether the decrease in the number of leucines within the MTS could change the 
apoptotic potential displayed by H7N3 A/turkey/Italy/2962/03 virus, annexin V staining was 
performed in BxPC-3 and HPDE6 cells infected with H7N3 PB1-F2 L75H and H7N3 NS1-77 PB1-F2 
L75H viruses. Incubation of the cells with Gemcitabine and Cisplatin was included as positive control 
for apoptosis and Specific Cell Death (SCD) was measured at 16 and 24 hours post-infection as 
described in material and methods. 
Consistently with previous results (see paragraphs 2.2.1-2.2.2 and 3.2.1), both viruses induced 
higher levels of apoptosis in BxPC-3 than in HPDE6 cells, and in tumour cells infected with the NS1 
truncated virus, apoptosis progression occurred faster than in the case of full length NS1 virus 
infection (data not shown). 
Analysis of the annexin V results for H7N3 and H7N3 PB1-F2 L75H (Figure 37A) or H7N3 NS1-77 and 
H7N3 NS1-77 PB1-F2 L75H (Figure 37B) showed that mutation L75H within the MTS of PB1-F2 
decreased the levels of apoptosis at the earlier stages of infection compared to influenza viruses 
bearing wild type PB1-F2 protein. However, the same levels of cell death were reached at 24 hours 
post-infection, suggesting slower progression of apoptosis in the L75H mutant virus-infected cells. 
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Figure 37. Annexin V results for H7N3 PB1-F2 L75H viruses at 16 and 24 hours post-infection. Comparison of annexin V 
results between wild type and PB1-F2 L75H viruses bearing either full length (A) or truncated NS1 protein (B). All data 
represent means ± standard deviations (SD) of three independent experiments. Statistical significance was determined 
using Two-way ANOVA followed by Tukey’s multiple comparison test. 
 
To confirm the lower levels of apoptosis observed following infection with PB1-F2 L75H mutants, 
western blot targeting the 89 KDa fragment derived from cleavage of poly(ADP-ribose) polymerases 
(PARP), a classical hallmark of apoptosis (see paragraph 1.5.3), was performed on BxPC-3 cell 
lysates collected at 8, 16 and 24 hours post-infection with the different H7N3 viruses (Figure 38A). 
PARP results confirmed that (i) NS1-77 truncated virus triggers higher levels of apoptosis at earlier 
time points compared to the corresponding wild type NS1 viruses (see paragraph 3.2.1) and that (ii) 
PB1-F2 L75H viruses shows reduced levels of apoptosis compared to the respective wild type PB1-
F2 viruses.  
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In order to evaluate whether the variation in apoptosis induction might be associated with 
differences in replication activity, IAV Matrix (M) gene Real-Time PCR was performed on the 
supernatants derived from the infection described above (Figure 38B). Results showed a time 
related increase in M gene copy numbers for all the viruses, although different levels of replication 
were observed. In conjunction with full length or NS1-77 truncation, mutation L75H in PB1-F2 
increased levels of replicated M gene.  
 
Figure 38. PB1-F2 L75H mutation slows apoptosis promoting higher levels of virus replication. A) Western Blot targeting 
cleaved PARP 89 KDa fragment in BxPC-3 cells at 8, 16 and 24 hours post-infection with H7N3, H7N3 PB1-F2 L75H, H7N3 
NS1-77 and  H7N3 NS1-77 PB1-F2 L75H viruses (M.O.I.= 0.1). B) Quantitative real-time PCR targeting conserved M gene 
of type A influenza virus was applied on supernatants derived from BxPC-3 infected cells. All data represent means ± 
standard deviation (SD) of one representative experiment (n=3). Statistical significance was determined using Two-way 
ANOVA followed by Tukey’s multiple comparison test. 
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PB1-F2 has been suggested to play a role in polymerase function, perhaps by interacting with the 
PB1 subunit (Mazur et al., 2008).Therefore, it was possible that the L75H mutation was affecting 
viral M gene accumulation by enhancing viral polymerase activity. To assess this possibility a 
minireplicon assay was performed (Figure 39A). The minireplicon assay is based on plasmid 
expression of H7N3 A/turkey/Italy/2962/03 polymerase subunits PB1, PB2, PA, NP and a virus-like 
minigenome RNA molecule of negative polarity, containing a luciferase reporter gene, which mimic 
a viral genomic segment. In this assay pCAGG/PB1-F2 H7N3, pCAGG/PB1-F2 L75H H7N3 or empty 
pCAGG plasmids were also included and constituted the only variable. Therefore, differences in the 
expression of the reporter gene were an indirect measure of the reconstituted influenza virus 
polymerase activity, which was dependent on the ability of the different PB1-F2 to modulate 
replication. In the experiment PB1-F2 ORF of the PB1 gene was not silenced; therefore the PB1 
plasmid retained the ability to also express wild type PB1-F2 protein. As such, there was no 
significant difference in the minireplicon assay performed using the wild type PB1-F2 or the empty 
pCAGG plasmid, suggesting that the additional expression of wild type PB1-F2 had little effect on 
the polymerase activity (Figure 39A). However, co-expression of PB1-F2 L75H construct showed 
significantly higher luciferase activity in comparison to co-expression of wild type PB1-F2, 
suggesting that the L75H protein was better able to support the viral polymerase activity. To test 
whether this effect translated to an increased virus yield, growth curves were performed in BxPC-3 
cells using the recombinant viruses. The ability of the wild-type and PB1-F2 mutant H7N3 IAVs to 
replicate in BxPC-3 cells was monitored over a 72 hour time-course (Figure 39B). Due to the general 
low levels of IAVs replication previously reported in BxPC-3 (see chapter 3.3.3), it was possible to 
confirm a significant superior growth of H7N3 PB1-F2 L75H virus only at the latest time point. 
Nevertheless, the data show that the mutation L75H within the PB1-F2 MTS improves H7N3 
replication likely by both decreasing apoptosis induction and simultaneously enhancing virus 
polymerase activity. 
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Figure 39. PB1-F2 L75H mutation enhances virus polymerase activity and virion production. A) Minireplicon assay results 
for different PB1-F2 constructs. 293T cells were transfected with five plasmids, encoding PB2, PB1, PA, NP and either 
PB1-F2 or PB1-F2 L75H proteins derived from avian influenza virus H7N3 A/turkey/Italy/2962/03. A sixth plasmid 
directing the expression of a virus-like firefly luciferase reporter RNA minigenome, which mimic a viral genome segment, 
was co-transfected. At 24 h post-transfection, cells were lysed and firefly luciferase activity measured. Results are shown 
as raw data and expressed as RLU (relative light units). All data represent means + standard deviations (SD) of one 
representative experiment (n=3). Statistical significance was determined using One-way ANOVA followed by Bonferroni 
multiple comparison test. B) Replication kinetics of H7N3 and H7N3 PB1-F2 L75H influenza A viruses in BxPC-3 cell line. 
Cells were infected at an M.O.I of 0.001 and virus titres of the supernatants were determined via plaque assay on MDCK-
NPro cells at 24, 48 and 72 hours post-infection. Results represent means ± standard deviation (SD) of one 
representative experiment (n=3). Statistical significance was determined using Two-way ANOVA followed by Sidak’s 
multiple comparison test. 
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4.2.5 Efficacy of H7N3 NS1-77 PB1-F2/L75H virus in SCID mice bearing BxPC-3Luc-
derived tumours. 
Although the differences in the viral growth between the PB1-F2 L75H virus and the correspondent 
wild type virus in BxPC-3 cells were modest (see figure 39B), the results presented in the course of 
this chapter suggested that a H7N3 NS1-77 PB1-F2 L75H virus might possess a better balance 
between attenuation, replication efficiency and apoptosis induction. As such, this virus was further 
tested for its oncolytic activity in SCID mice bearing BxPC-3 derived solid tumours.  
The luciferase expressing line BxPC-3Luc, derived from the original BxPC-3 cells and generated as 
part of this project, was used. An equal number of BXPC-3Luc cells were injected subcutaneously 
into the right flank of SCID mice. After 9 days the mice developed palpable tumours and they were 
divided equally into four groups (n=5). A control group received intratumoral (IT) injections of PBS 
whilst the other three groups received a 5x104 pfu/50 µl IT injections of H7N3, H7N3 PB1-F2 L75H 
or H7N3 NS1-77 PB1-F2 L75H respectively. The IT injections were repeated four times as described 
in material and methods. The mice were monitored for signs of distress and tumour size was 
measured twice a week from the beginning of the treatment using a microcaliper and 
bioluminescence imagine (BLI) (Figure 40).  
All the viruses tested showed an effect in comparison to the group treated with PBS, with the H7N3 
NS1-77 PB1-F2 L75H virus producing the most significant reduction in tumour growth. The virus 
harbouring full length NS1 and PB1-F2 L75H mutation also displayed a significant effect in reducing 
tumour volume. Although there was no statistically significant difference in the control of tumour 
volume between the wild type H7N3 and the PB1-F2 mutant, tumour size of mice treated with PB1-
F2 mutant was lower at all time-points (Figure 40). 
To appraise whether sustainable virus replication levels were occurring within the tumours the 
animals were maintained alive until thirty-three days after the beginning of the experiment. The 
mice were then euthanized and 5 tumours and 2 lungs per group were collected and assessed by 
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Real-Time PCR for influenza virus M gene. All the lungs tested were negative for the virus (data not 
shown) confirming the absence of viral spreading. Despite the oncolytic effect achieved in animals, 
only two tumour samples collected from the groups treated with H7N3 PB1-F2 L75H (Ct=33.91) and 
with H7N3 NS1-77 PB1-F2 L75H (Ct=32.75) had detectable virus presence at 10 days after the last 
viral administration. 
 
Figure 40. Efficacy of H7N3 reverse genetics viruses in SCID mice bearing human BxPC-3Luc derived tumors. Solid tumours 
were established by day 9 and mice were randomly divided into 4 groups (n=5 per group). Animals in each group were 
administered IT with 5x10
4
 pfu of H7N3 A/turkey/Italy/2962/V03, H7N3 PB1-F2 L75H, H7N3 NS1-77 PB1-F2 L75H viruses 
or PBS (negative control). The procedure was subsequently repeated 3, 7, and 10 days later for a total of four 
intratumoural inoculations for each group. Tumour sizes were monitored by caliper measurements and bioluminescence 
imaging (BLI). Tumour volume and percentage of volume increase were calculated as described in material and 
methods. The groups were observed twice a week within 23 days from the beginning of the experiment. Comparison of 
groups was done by using Two-way ANOVA followed by the Tukey’s multiple comparison test. 
 
4.3  Discussion and conclusion 
Previously, Kasloff et al. (Kasloff et al., 2014) showed that the H7N3 A/turkey/Italy/2962/03 virus 
triggered higher levels of apoptosis but achieved lower titres in PDA cells compared to other strains 
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tested. Immunocytochemistry (ICC) results confirmed the ability of H7N3 virus to induce high levels 
of apoptosis in BxPC-3 cells by directly affecting the intrinsic apoptotic pathway (see paragraph 
2.2.3). We speculated that the virus was promoting apoptosis prematurely during infection limiting 
its own replication and that this might ultimately decrease its oncolytic potential as single-shot 
treatment in vivo.  
The apoptosis-related protein profile (Figure 34) of untreated tumour BxPC-3 cells revealed that 
these cells were aberrant at various levels along the mitochondrial pathway. The up-regulation of 
anti-apoptotic cellular proteins together with the lack of expression of IFNs and other ISGs (see 
paragraph 2.2.2) suggested that the apoptosis process seen in virus infected cells was likely the 
result of viral pro-apoptotic factors rather than the consequence of activation of the cellular 
antiviral mechanism. Thus, in the attempt to rebalance apoptosis induction in favour of virus 
replication, we investigated the influenza virus pro-apoptotic protein PB1-F2. Based on previous 
studies demonstrating the importance of specific leucine residues within the MTS for mitochondrial 
targeting (see paragraph 4.2.2), L75H substitution was introduced to decrease PB1-F2 MM 
localization and delay apoptosis induction during infection thus enhancing virus rescue. 
An indirect measure of the decrease in mitochondrial targeting was the reduced ability of PB1-F2 
L75H to affect the mitochondrial antiviral-signalling protein (MAVS) (Figure 36A-C), which led to 
higher host IFN expression and might contribute to enhance even further the selectivity of H7N3 
virus for IFN-deficient cells. 
Besides having an effect on the activity of MAVS, the reduction of mitochondrial targeting also 
modulated the timing of apoptosis in infected PDA cells. Indeed, in the annexin V assay, which 
measures early-stage of apoptosis (see paragraph 1.5.3), PB1-F2 L75H mutant viruses showed lower 
but steady progression of BxPC-3 cell death compared to the corresponding viruses bearing a wild 
type protein (Figure 37A-B). Analysis of cleaved PARP (Figure 38A), a late stage signature of 
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programmed cell death (see paragraph 1.5.3), also showed that apoptosis induced by the PB1-F2 
L75H viruses was decreased at early time points.  
The data obtained are consistent with an effect of the L75H mutation on the potency of the MTS. 
While the wild-type protein would predominantly target the MM, priming the intrinsic apoptotic 
pathway early during infection, the L75H mutation would decrease the accumulation of PB1-F2 at 
the mitochondria level. This in turn would determine lower levels of apoptosis coupled with higher 
influenza M gene copy numbers (Figure 38B) resulting from deferring the induction of apoptosis 
during infection and/or enhancing the viral polymerase activity (Figure 39A). It is likely that these 
factors synergistically contributed to increase virion production in tumour cells (Figure 39B), 
although it was difficult to show enhanced replication of the mutated virus in BxPC-3 cells that were 
rather poorly permissive for multiple cycles of influenza infection under laboratory conditions. 
Nonetheless, the H7N3 PB1-F2 L75H virus displayed a higher therapeutic effect than the wild-type 
virus in xenograft model (Figure 40). In line with the findings presented in chapter 3 (see paragraph 
3.3.5), the effect of the treatment was further increased by NS1 truncation. 
Although intra-tumoural replication levels of the H7N3 virus might be promoted in some PDA 
patients suffering with pre-existing chronic pancreatitis (see paragraph 1.2.2) as the result of auto-
activation of trypsinogen and chymotrypsinogen within the pancreas (see paragraph 1.1.2), the low 
viral growth displayed in BxPC-3 cell lines and BxPC-3 derived solid tumours by wild-type and PB1-
F2 L75H mutant virus suggests that they could be cleared very rapidly in immune competent 
systems. Based on these considerations, we decided not to incorporate the mutation PB1-F2L75H 
within the H7N3 NS1-77 virus so far developed in order to maintain the highest levels of apoptosis 
of the oncolytic candidate with the aim of using it in a multiple injection treatment. 
Nevertheless, the results obtained confirm the involvement of viral protein PB1-F2 in modulating 
IFN expression and apoptosis during infection. Furthermore, our data show that it may be possible 
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to tune the strain specific characteristics of IAV by manipulating its genome to obtain optimal 
apoptosis/replication balance. 
 
 
Chapter 5. Enhancing safety of the treatment: generation of a 6:2 
recombinant virus. 
 
5.1  Introduction 
Although the low pathogenicity H7N3 A/turkey/Italy/2962/03 NS1-77 influenza virus displays 
restricted replication in benign human cells (see paragraphs 2.2.1-2.2.2-3.3.3) due to specific 
proteases-limiting conditions, species barrier factors and antiviral mechanisms which can prevent 
virus spreading outside the site of injection, the use of an avian strain for cancer treatment might 
still carry potential threats. Indeed, as previously discussed (see paragraph 1.6.1), the possibility of 
“antigenic shift” with circulating human strains is an important concern. Although 16 HA subtypes 
have been identified in wild birds, only H1, H2 and H3 have been stably introduced into the human 
population. Therefore, the H7N3 virus belongs to an avian subtype for which the human population 
is almost completely naïve and thus its use for cancer treatment carries risk of further 
recombination within a treated patient that might result in new potentially pandemic strains. 
Furthermore, despite being a rare event, the spontaneous introduction of basic amino acids into 
the haemagglutinin cleavage site, which can determine the passage to a “highly pathogenic” (HP) 
phenotype, can occur naturally within the H7 subtype (see paragraph 1.4.4.1). This feature allows 
ubiquitous HA activation and permits the virus to evade restriction associated to trypsin-like 
proteases availability (Klenk et al., 1975; Lazarowitz and Choppin, 1975) thus conferring to it 
potential systemic spread which might cause an acute generalized disease.  
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Based on these considerations, we generated a reassortant virus containing the 2 genes expressing 
surface antigens haemagglutinin (HA) and neuraminidase (NA) of the well characterized human 
strain H1N1 A/Puerto Rico/8/1934 and the 6 gene segments encoding the internal viral proteins 
(PB2, PB1, PA, NP, M and NS) of the H7N3 A/turkey/Italy/2962/03 NS1-77 virus (Figure 41). The 
properties of the 6:2 reassortant virus, named PR8 H1/N1-2962 NS1-77, were then compared with 
those of the H7N3 viruses bearing either full length or truncated NS1 proteins. 
 
 
Figure 41. Use of reverse genetics to generate 6:2 recombinant influenza A virus. The HA and NA genes from well 
characterized human strain H1N1 A/Puerto Rico/8/34 were transfected together with the 6 genes (PB2, PB1, PA, NP, M, 
NS) encoding the internal viral proteins of the avian origin H7N3 A/turkey/Italy/2962/03 NS1-77 to generate the 
recombinant PR8 H1/N1-2962 NS1-77 virus. Adapted from (Palese, 2004). 
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5.2 Results 
5.2.1 PR8 H1/N1-2962 NS1-77 virus retains growth and apoptotic skills similar to those 
of H7N3 viruses. 
To evaluate whether the new HA and NA proteins might have affected the receptor binding 
efficiency of the recombinant virus and hence its ability to infect pancreatic cancer cells, growth 
curves were performed for H7N3 and PR8 H1/N1-2962 NS1-77 in different benign and cancer cell 
lines (Figure 42). According to previous results (see paragraphs 2.2.1-3.3.3), although IFN-
competent HPDE6 cells produced the lowest viral growth among the cell lines tested, PR8 H1/N1-
2962 NS1-77 virus reached lower titres than the full length NS1 H7N3 isolate. Conversely, in IFN 
deficient PDA cell lines both viruses produced similar titres at any given time post-infection showing 
higher growth in BxPC-3 and Mia Paca-2 than in CFPAC-1 cells (Figure 42 B-C-D).  
Based on these results the introduction of exogenous surface glycoprotein genes had no effect on 
the virus growth in PDA cell lines. However, to rule out a decrease in the level of virus mediated 
apoptosis caused by the reassortant compared to the parental strain the amount of cytoplasmic 
histone-associated DNA fragments (see paragraph 1.5.3) were measured in BxPC-3 and benign 
HPDE6 cells following infection with PR8 H1/N1-2962 NS1-77, H7N3, H7N3 NS1-77 or H1N1 PR8 
viruses (Figure 43). 
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Figure 42. Replication kinetics of H7N3 and PR8 H1/N1-2962 NS1-77 IAVs in human pancreatic cell lines. H7N3 and PR8 
H1/N1-2962 NS1-77 virus replication was monitored over a 72 hour time-course in HPDE6 (A), BxPC-3 (B), CFPAC-1 (C) 
and Mia Paca 2 (D) cell lines. Cells were infected at an m.o.i of 0.001 and virus titres of the supernatants were 
determined via plaque assay on MDCK-NPro cells at 24, 48 and 72 hours post-infection. Results represent means plus 
standard deviation (SD) of three independent experiments.  
 
Consistently with previous data (see paragraphs 2.2.1), lower apoptosis was measured in HPDE6 
cells than in the tumour BxPC-3 cell line. In addition, in the benign cell line both NS1 truncated 
viruses triggered less cell death than the full length NS1 H7N3 and H1N1 PR8 viruses. According 
with earlier findings (see paragraph 2.2.1), in BxPC-3 cell line the H7N3 isolate induced higher 
apoptosis compared to the human H1N1 PR8 strain. However, both PR8 H1/N1-2962 NS1-77 and 
H7N3 NS1-77 viruses displayed levels of cell death similar to those observed for the avian isolate 
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bearing full length NS1 protein. Taken together, these data confirm that the superior apoptotic 
skills displayed by the H7N3 virus are not the result of the virus’ ability to bind PDA cells more 
efficiently than other strains (i.e. dependent on the HA) but rather they reside in the intrinsic 
capability of the avian isolate to promote apoptosis during infection (i.e. dependent on pro-
apoptotic factors expressed by virus internal genes). 
 
Figure 43. Enrichment of nucleosomes in the cytoplasm of BxPC-3 and HPDE6 cells at 24 hours post-infection with H7N3, 
H7N3 NS1-77, PR8 H1/N1-2962 NS1-77 and H1N1 PR8 viruses (M.O.I=1). Cell Death Detection ELISAPLUS (Roche) results 
are represented as mean enrichment factors [Abs sample/ Abs mock] ± standard deviations (SD) of one representative 
experiment (n=2). Statistical significance respect the H7N3 virus was determined in each cell line using Two-way ANOVA 
followed by Dunnett’s multiple comparison test. 
 
5.2.2 PR8 H1/N1-2962 NS1-77 retains the IFN stimulatory ability of the H7N3 NS1-77 
truncated virus. 
Since the loss of ability to counteract IFN in healthy cells has been shown to improve the oncolytic 
potential of the H7N3 NS1-77 virus by contributing to both selectivity (see paragraph 3.3.3) and 
killing of uninfected cancer cells (see paragraph 3.3.4), we investigated whether the incorporation 
of PR8 HA and NA gene segments was detrimental for this feature. Thus, we compared the 
stimulation and the production of IFN-β in monolayers of different PDA cell lines and HPDE6 cells 
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infected with H7N3, H7N3 NS1-77, PR8 H1/N1-2962 NS1-77 viruses (M.O.I=0.1) or mock infected. 
Twenty-four hours post infection supernatants were collected and tested using the human IFN-β 
ELISA kit as described in material and methods. In line with earlier papers (Moerdyk-Schauwecker et 
al., 2012; Murphy et al., 2012), HPDE6 was the only cell line among those tested to mount an 
efficient IFN response to infection (Figure 44). Coherently with our previous results (see paragraph 
3.2.2), HPDE6 cells produced higher levels of IFN-β following both NS1-77 truncated virus infections 
than for the H7N3 virus bearing full length NS1. The fact that H7N3 NS1-77 and PR8 H1/N1-2962 
NS1-77 viruses induced similar production of this cytokine in the supernatants of infected HPDE6 
cells confirmed that the new surface glycoprotein did not affect the ability of the recombinant virus 
to enter the benign cells and induce a powerful innate immune response.  
 
 
Figure 44. IFN-β ELISA kit results for supernatants derived from different pancreatic cell lines infected with H7N3, H7N3 
NS1-77 and PR8 H1/N1-2962 NS1-77 viruses or mock infected. For each group absorbance values at 450 nm are 
represented (left Y axis) and the correspondent IFN-β concentration (pg/ml) can be obtained by comparison with the 
standard curve values (right Y axis). All values represent means ± standard deviations (SD) of one representative 
experiment (n=2). 
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5.3  Discussion and conclusion 
Although in previous chapters we demonstrated that the H7N3 NS1-77 virus is attenuated in IFN 
competent systems, the use of an H7 avian influenza A virus strain for tumour treatment would 
face several concerns due to the possibility of (i) recombination with circulating human strains 
which might result in a potentially new pandemic virus and/or (ii) evolution to an highly pathogenic 
phenotype.  
To address these safety issues we generated a 6:2 recombinant virus, named PR8 H1/N1-2962 NS1-
77, possessing the backbone of the previously tested H7N3 A/turkey/Italy/2962/03 NS1-77 virus but 
the HA and NA genes from the well characterized human strain H1N1 A/Puerto Rico/8/1934. 
The change of the surface glycoproteins, which represents the major antigens of IAV (Wang et al., 
2010), altered neither the PR8 H1/N1-2962NS1-77 virus growth (Figure 42) nor its apoptotic 
potency (Figure 43) compared to the parental H7N3 NS1-77 strain. These results confirm that the 
marked ability of H7N3 virus to trigger PDA cell death does not depend on the HA binding and 
fusion activity, strengthening the idea that it rather resides in the effect of internal pro-apoptotic 
genes as discussed in chapter 4.  
Furthermore, the PR8 H1/N1-2962 NS1-77 virus also retained the interferon-stimulatory properties 
displayed by the H7N3 NS1-77 virus (Figure 44) that can contribute to improve the final outcome of 
the treatment by allowing the killing of uninfected PDA cells (see paragraph 3.3.4-3.3.5).  
Although the 6:2 recombinant does not show any enhancement in its oncolytic potential compared 
to the parental virus, its safety for therapeutic use is strongly improved as it presents a human 
origin H1 glycoprotein which (i) has never been associated to a highly pathogenic phenotype and (ii) 
is not completely new to human population (indeed since the pH1N1 2009 virus emerged, many 
people have antibodies that may cross protect against PR8 virus (Skountzou et al., 2010)). Thus in 
case of antigenic shift with other circulating human strains, the PR8 H1N1-2962 NS1-77 virus would 
represent a limited risk in terms of both systemic spreading and pandemic threat.  
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Furthermore, if a recombination occurred, several internal genes provided by the PR8 H1/N1-2962 
NS1-77 virus could also contribute to curb the replication of the new virus in healthy mammalian 
cells. Indeed, as a turkey isolate without prior adaptive passages in mammals, the H7N3 virus 
presents internal genes characterized by typical avian signatures which have been associated to low 
transmission from birds to mammals and between mammals (for the sequence of all the virus 
segments please refer to materials and methods section). Examples of these signatures are those 
within the H7N3 PB2 gene, which has a pivotal role in the adaptation process of avian IAV to 
mammals (see paragraph 1.6.2.2). As previously discussed, glutamic acid to lysine change at 
position 627 (E627K) or an aspartic acid to asparagine change at position 701 (D701N) are key 
adaptive mutations for efficient replication of avian-origin IAVs in human cells. In the absence of 
PB2-627K or 701N, replacement of the highly conserved glutamine at position 591 with lysine 
(Q591K) or substitution of threonine at position 271 with alanine (T271A)  can facilitate mammalian 
adaptation in the context of an avian-type PB2 protein (Yamada et al., 2010). Because the PB2 gene 
shared by H7N3 NS1-77 and PR8 H1/N1-2962 NS1-77 presents a typical avian signature without any 
of the above substitutions, the incorporation of this segment in a recombinant virus would result in 
limited replication in human cells and low transmissibility within the human population.  
Besides PB2, avian NP has also been previously reported to contribute to the species barrier due to 
its high sensitivity to the antiviral activity exerted by human MxA protein (see paragraph 1.6.2.3). 
Conversely human IAV are often able to cope with Mx gene product thanks to mutation within 
specific recognition sites on the NP. Indeed, presence of isoleucine at position 100 (100I), proline at 
position 283 (283P) and tyrosine at position 313 (313Y) have been associated with the ability to 
escape MxA binding, while asparagine at position 52 (52N) has been shown to partially compensate 
the absence of some of the previous amino acids (Riegger et al., 2015). Because the H7N3 NP 
protein displays a typical avian signature (100R, 283L, 313F and 52Y), which makes it sensitive to 
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the antiviral activity exerted by human MxA (see paragraph 2.2.2), the integration of PR8 H1/N1-
2962 NS1-77 NP gene into a recombinant virus would contribute to limit viral fitness in human cells.  
Finally, besides the factors associated with the species barrier, NS1-77 truncation would also 
strongly reduce the risk associated with the use of PR8 H1/N1-2962 NS1-77 virus as proven by the 
fact that different IAVs with truncated or modified NS1 proteins have been proposed as attenuated 
vaccines (Ngunjiri et al., 2015; Richt and Garcia-Sastre, 2009). 
In conclusion to address issues related to the potential risk of antigenic shift and systemic spreading 
we generated a 6:2 recombinant virus which preserves the oncolytic properties previously shown 
by the parental H7N3 NS1-77 virus but which is safer for therapeutic use. 
 
 
Chapter 6. “Arming” the virus: expression of granulocyte colony-
stimulating factor (GM-CSF). 
 
6.1 Introduction. 
The immune system can identify and destroy nascent tumour cells in a process termed cancer 
immunosurveillance, which plays an important role in the defence against neoplasm (Vesely et al., 
2011; Zitvogel et al., 2006). As with foreign tissues or infectious pathogens, following recognition of 
transformed cells, our immune cells secrete signal proteins that travel to the bone marrow where 
they promote proliferation of hematopoietic stem cells and subsequently their maturation and 
differentiation into leukocytes. One of the most important proteins in this process is the 
granulocyte macrophage colony-stimulating factor (GM-CSF, also known as CSF2), which stimulates 
blood stem cells to produce granulocytes and monocytes (Metcalf et al., 1986; Smith, 1990). GM-
CSF leads to protective immunity, mainly by stimulating the recruitment, maturation, and function 
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of dendritic cells (DCs) (Dranoff, 2003; Li et al., 2009), the most potent antigen-presenting cell (APC) 
(Huang et al., 1994), which can activate the immune system against tumour-specific antigens 
(Dranoff, 2004).  
The ability of the immune system to fight tumour cells has been used in the development of cancer 
immunotherapy treatments based on enhancing host antitumor responses (Dougan and Dranoff, 
2009). Sipuleucel-T (trade name Provenge), as an example, is an autologous dendritic cell-based 
vaccine in which DCs are loaded with a fusion protein (PA2024) consisting of two parts: the antigen 
prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells, and the GM-CSF 
that helps the APCs to mature. Reinfusion of such activated cells (APC8015) into the prostate cancer 
patients showed a 4-month benefit relative to the control group in randomized phase III clinical 
trials (Kantoff et al., 2010; Le et al., 2010). In addition, as previously discussed (see paragraph 1.3.1-
1.3.1.4), clinical outcomes for the oncolytic vaccinia virus JX-594 (Pexa-Vec) and more recently for 
the herpes virus talimogene laherparepvec (T-Vec), both of which are armed with GM-CSF, 
confirmed that superior beneficial effect can be achieved when localized oncolytic activity is 
coupled with immune cell recruitment (Donnelly et al., 2013; Goins et al., 2014; Heo et al., 2013).  
Based on these successful examples, to enhance the therapeutic activity of the PR8 H1/N1-2962 
NS1-77 virus, we further engineered the viral NS segment to express the human GM-CSF gene. 
Expression of this cytokine during PR8 H1/N1-2962 NS1-77 GM-CSF virus infections was then tested 
in comparison to the parental strains.   
 
6.2 Results 
6.2.1  Design of NS1-77/2A/GM-CSFV5/NSend plasmid for reverse genetics.  
Successful insertion of exogenous genes into the IAV genome has been previously achieved by 
different groups (Manicassamy et al., 2010; Pena et al., 2013; Shinya et al., 2004; Strobel et al., 
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2000). The choice of the viral segment in which to insert the foreign gene depends on several 
factors. Increasing the length of the segment may have a detrimental effect on the packaging of the 
viral genome into new virus progeny. The segment may encode multiple viral proteins through 
splicing or frame shifts, as a result co-expression of the foreign gene might alter the expression 
levels of or even abrogate the correct production of the authentic viral genes with detrimental 
effect on virus fitness.  
Based on its small size and on the low number of proteins currently known to be co-encoded, the 
segment 8 (NS) is often an easy choice for insertion of exogenous genes in the IAV genome (Figure 
45A). Indeed, many publications demonstrated the possibility to express different non-viral proteins 
(e.g. GFP and luciferase) by fusing their ORF with the NS1 gene on segment 8, which has the 
advantages of being directly transcribed by a continuous RNA sequence and being expressed at very 
high levels during infection (see paragraph 3.1).  
Segment 8 encodes two viral proteins NS1 and NEP. The NEP is produced following mRNA splicing 
and the levels of its expression are tightly controlled because the splice consensus sites are 
suboptimal so that NEP only slowly accumulates during infection (Chua et al., 2013). Nonetheless 
manipulation of segment 8 by abrogating this splicing mechanism has been adopted to allow 
expression of foreign proteins from the viral segment. 
Although different strategies have been used to insert an exogenous gene into the NS1 ORF, many 
of them exploited the incorporation of a 2A autoproteolytic cleavage sequence within the NS 
segment. This sequence provides the opportunity to engineer in either whole proteins or domains 
that can be cleaved co-translationally with high efficiency (Ryan and Drew, 1994). In fact, during 
translation, the small 2A peptide interacts with the exit tunnel of the ribosome to induce the 
"skipping" of its last peptide bond. Crucially, the ribosome is able to continue translating the 
downstream gene, after releasing the first protein fused in its C-terminus to 2A (Ryan et al., 2002).  
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The first successful use of the foot-and-mouth disease virus (FMDV) 2A sequence to stably express 
a foreign protein from a recombinant influenza A virus was shown by Barclay et al. (Percy et al., 
1994). Much later Basler et al. (Basler et al., 2001) used a similar strategy to express functionally 
active NS1 and NEP from a single polyprotein by (i) placing the FMDV 2A autoproteolytic cleavage 
site downstream of NS1 ORF, (ii) restoring the whole NEP ORF downstream the FMDV 2A sequence 
and (iii) silencing the NS splicing acceptor (SA) site (Figure 45B).  
Extending this work, Manicassamy et al. (Manicassamy et al., 2010) designed a NS segment 
expressing the NS1-GFP and NEP as a single polyprotein with a 19 aa porcine teschovirus–1 (PTV-1) 
2A autoproteolytic cleavage site (Kim et al., 2011) between them in order to allow NEP release from 
the upstream NS1-GFP fusion protein during translation (Figure 45C). Also in this study, silent 
mutations were introduced in the SA site to prevent unnecessary splicing of NS mRNA.  
A different strategy was used by Pena et al. (Pena et al., 2013) who cloned the FMDV 2A 
autoproteolytic cleavage site sequence downstream of a truncated NS1 ORF (1–99) and then placed 
after it the transgene of interest (i.e. GFP, or luciferase). The NEP sequence, in this case, was 
deleted from segment 8 and re-introduced within segment 2, which was modified such that a 
FMDV 2A sequence separated the PB1 and the NEP ORF (Figure 45 D). Finally, in both segments 2 
and 8, the vRNA specific packaging signals (see paragraph chapter 1.4.5.3) were reconstituted after 
the 3’ end of the inserted gene sequences. 
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Figure 45. Different strategies adopted to express exogenous genes from the IAV NS segment. A) Schematic representation 
of IAV NS segment structure and mRNAs expressed. B) In the NS1–2A-NEP constructs (Basler et al., 2001), the NS1 and 
the NEP coding sequences do not overlap. In addition the two coding sequences are separated by the foot-and-mouth 
disease virus (FMDV) 2A autoprotease and are expressed as a single polyprotein. At the ribosome level, the polyprotein is 
then cleaved into two peptides: an NS1 with 16 additional 2A-derived amino acids at its carboxy terminus and an NEP 
with a single 2A-derived proline at its amino terminus. C) Schematic representation of IAV NS segment expressing NS1-
GFP fusion protein (Manicassamy et al., 2010). NS1 is fused to GFP via a GSGG linker and then followed by PTV-1 2A 
autproteolytic cleavage site and the whole NEP coding sequence. The NS splice acceptor (SA) site is mutated to prevent 
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mRNA splicing. D) Schematic representation of rearranged influenza viruses generated from Pena et al.  (Pena et al., 
2013). Exploiting the FMDV 2A autoproteolytic sequence, NEP is expressed from a single ORF downstream of the PB1 
gene, whereas the foreign gene of interest (GFP) is expressed downstream of a C-terminal truncated NS1 gene 
translating only the first 99 amino acids. The packaging signals span both the untranslated region (UTR) and part of the 
ORF at both ends of each RNA segment. (*stop codon/s) 
 
Although all the strategies described successfully allow the generation of viruses expressing 
exogenous genes, it has to be noted that while in wild type IAV infected cells the steady-state 
amount of spliced NEP mRNA is only approximately 10% that of unspliced NS1 mRNA (Herz et al., 
1981; Lamb and Lai, 1980; Lamb et al., 1980), in all the designs mentioned above, due to the shared 
ORFs, the rate of NEP expression would be the same as that of NS1 (Figure 45B-C) or PB1 (Figure 
45D) genes. This would result in overexpression of NEP, which, besides exerting a central role in 
exporting vRNPs outside the nucleus, has also been implicated in the polymerase switch between 
viral transcription and replication (see paragraph 1.4.5.2). This might result in important changes in 
the behaviour of the virus compared to the parental strain as shown by Chua et al. (Chua et al., 
2013). Since IAVs are not able to grow with high efficiency in PDA cells, high rates of viral genes 
production (mRNAs) would be required in order to assure significant amount of transgene 
expression. Based on these considerations we devised a novel NS segment which could retain, as 
much as possible, the original structure and preserve NEP splicing rate.  
In our design the FMDV 2A peptide (17aa) was inserted after codon 77 of NS1 protein and then 
followed by the GM-CSF gene (Figure 46). A V5 epitope tag peptide (14 aa) from the simian virus 5 
was then fused at the C-terminus of the GM-CSF gene to allow the detection of the cytokine 
without affecting its interaction sites with the GM-CSF Receptor Complex (Hansen et al., 2008). The 
remaining part of the NS segment was moved downstream of the GM-CSFV5 stop codon in the 
attempt to preserve splicing and thus the natural expression of NEP.  
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This NS design would have also assured that (i) the GM-CSF was produced at high levels by being 
encoded together with the NS1 protein that is abundantly expressed during infection (see 
paragraph 1.5.4), (ii) that the full length NS1 genotype could not be restored, an event that might 
have occurred following reversion of nonsense mutation in the previous NS1-77 constructs (see 
paragraph 3.1), and that (iii) the proper packaging signals were maintained at both ends of the 
vRNA segment (see paragraph chapter 1.4.5.3). 
 
 
 
Figure 46. Schematic representation of the NS1-77/2A/GM-CSFV5/NSend segment structure and mRNAs expressed. The 
NS1-77 and the downstream GM-CSFV5 coding sequences flank the foot-and-mouth disease virus (FMDV) 2A auto-
proteolytic motif and are expressed as a single polyprotein. The sequence from NS1 codon 78 until the C terminus of the 
original segment 8 is moved downstream of the GM-CSFV5 stop codon. Both splice donor (SD) and acceptor (SA) sites 
are preserved to allow mRNA splicing and production of NEP. (* stop codon). 
 
6.2.2 Analysis of expression of NS1-77/2A/GM-CSF polyprotein. 
To generate the structure desired the human GM-CSF gene, consisting only of the exon coding 
sequences, was obtained in pEx-A2 vector from Eurofins MWG - Operon. Using PCR overlapping 
and restriction enzymes, as described in material and methods (see paragraph 8.2.1.8), the first 
part of the NS segment, consisting of NS1-77/2A/GM-CSF sequence, was inserted into a pCAGG 
plasmid, which permits the fusion of the expressed protein with a V5 tag.  
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To evaluate the production of GM-CSF from the construct, 293T cells were transfected with the 
pCAGG/NS1-77/2A/GM-CSF and the previously generated pCAGG/NS1 H7N3 and pCAGG/NS1-77 
H7N3 expression plasmids (see paragraph 3.2.2) (Figure 47A). At twenty-four hours post-
transfection supernatants and cells were collected and protein expression was evaluated by 
western blot using Anti-V5 tag antibody (Lifetechnologies) (Figure 47B).  
The western blot confirmed that transfection efficiently occurred in 293T, as both positive controls 
(pCAGG/NS1 and pCAGG/NS1-77) displayed intense signals in the cell lysates, additionally the 
higher expression levels of NS1-77 protein compared to the full length one reiterated the loss of the 
truncated protein’s ability to inhibit the activity of CPSF30 (see paragraph 3.2.2). Consistent with 
the nuclear and cytoplasmic localization reported for NS1 (Hale et al., 2008), the signals for both 
the truncated and the full length proteins were detected only in the cell lysates. 
Human GM-CSF codes for a protein of 144 amino acids, with a N-terminal leading peptide of 17 
amino acids which is essential for protein targeting to the endoplasmic reticulum (ER) membrane 
and entry into the translocon (Walter and Johnson, 1994). In addition, GM-CSF undergoes heavy 
glycosylation which can target two N-linked glycosylation sites and four potential O-linked 
glycosylation sites (Kaushansky et al., 1987). Because of these different degrees of glycosylation the 
apparent molecular mass of the mature GM-CSF proteins can vary producing a broad band on SDS-
Page between 18 and 30 KDa (Wong et al., 1985).  
Although a continuous signal consistent with variations in glycosylation was observed, in the pellet 
of 293T cells transfected with pCAGG/NS1-77/2A/GM-CSF plasmid two major bands were visible. 
Based on molecular weight prediction the 144 aa non-glycosylated precursor form of human GM-
CSF should have migrated in SDS-page around 16 KDa. However, the cytokine generated from the 
pCAGG plasmid was fused at its C-teminus with 16 amino acids consisting of the 2 aa-long Mlu I 
restriction site and the 14 aa-long V5 tag (see chapter 9 – Appendix for the detailed sequence and 
structure of the construct). As such, the final length of the GM-CSFV5 protein expressed from the 
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plasmid was 160 aa with an expected molecular weight around 18 KDa. Thus, we ascribed the lower 
band in the pellet (column 3 - blue arrow) to the expression of the non-glycosylated GM-CSFV5 
precursor protein. As for the upper band (column 3 - red arrow) located above the signal for NS1 
protein (≈26 KDa), although heavy post-translational glycosylation can further increase the 
molecular weight of GM-CSFV5 up to 30 KDa (Wong et al., 1985), we cannot rule out the possibility 
that this band might correspond to an uncleaved form of the NS1-77/2A/GM-CSFV5 polyprotein 
(predicted molecular weight ≈28.5 KDa) derived from sub-optimal cleavage of the 2A sequence. 
In contrast with the NS1 and NS1-77 proteins, due to the presence of secretory signal peptide at its 
N-terminus, the human GM-CSF protein was also abundantly detected in the supernatant of 
transfected cells (column 6). In line with previous data (Wong et al., 1985), the heavy post-
translational glycosylation on both O-linked and N-linked sites produced a heterogeneous 
population of mature GM-CSFV5 proteins in the supernatants that migrated as a broad band 
between 18 and 30 KDa. The presence of GM-CSF in the supernatants derived from pCAGG/NS1-
77/2A/GM-CSF transfection was further confirmed using the Human GM-CSF ELISA kit (Thermo 
ScientificTM) (Figure 47C).  
The detection of the cytokine in the supernatants was an indirect evidence of the proteolytic 
cleavage of the NS1-77/2A/GM-CSFV5 polyprotein. If the cleavage had not occurred the GM-CSF 
signal peptide would have been embedded within the polyprotein and hence the cytokine could not 
have been secreted (Futatsumori-Sugai and Tsumoto, 2010; Rapoport, 1992).  
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Figure 47. Expression of human GM-CSF from pCAGG/NS1-77/2A/GM-CSF plasmid. A) Schematic representation of the 
pCAGG plasmids used for transfection of 293T cells. B) Western Blot analysis targeting V5 tag in pellets (Column 1-3) and 
supernatants (column 4-6) derived from 293T transfection with pCAGG/NS1 H7N3 (columns 1 and 4), pCAGG/NS1-77 
H7N3 (columns 2 and 5) and pCAGG/NS1-77/2A/GM-CSF (columns 3 and 6) plasmids. Expected protein sizes: NS1≈ 26 
KDa, NS1-77≈ 9 KDa, hGM-CSFV5 precursor form (nonglycosylated)≈ 18 KDa [blue arrow], NS1-77/2A/GM-CSFV5 ≈ 28.5 
KDa [red arrow], hGM-CSFV5 mature form (glycosylated) ≈ 18-30 KDa. C) Human GM-CSF ELISA kit quantitative results 
for the supernatants derived from pCAGG/NS1-77/2A/GM-CSF and pCAGG/NS1-77 transfections. For each group mean 
absorbance (n=2) (Abs 450-550nm) is represented (left Y axis) + standard deviation (SD) and the correspondent 
concentration (pg/ml) can be obtained by comparison with the standard curve values (right Y axis). 
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6.2.3  Generation of RF483-NS1-77/2A/GM-CSFV5/NSend plasmid for reverse 
genetics. 
A series of overlapping PCRs were then performed to obtain the final NS1-77/2A/GM-CSFV5/NSend 
construct (see chapter 9 – Appendix for the detailed sequence and structure of the construct), 
which was eventually inserted into the rescue plasmid RF483 as described in materials and methods 
(see paragraph 8.2.1.8). The RF483 rescue plasmid, derived from the pHW2000 plasmid previously 
generated by Hoffmann et al. (Hoffmann et al., 2000) (see paragraph 1.6.3), allows synthesis of the 
same viral RNA species produced during virus infection by using a RNA  pol I–pol II transcription 
system (Figure 48A).  
We next tested the capability of the new reverse genetics construct to produce NEP mRNA 
following splicing of the full length NS mRNA in transfected cells. Thus, semi-confluent monolayers 
of 293T cells were transfected in a 24 well plate with RF483-NS1-77/2A/GM-CSFV5/NSend plasmid 
at concentration of 1 µg/well. As positive controls for segment 8 mRNA splicing, the rescue 
plasmids RF483-H7N3 NS and RF483-H7N3 NS1-77, previously used for the generation of H7N3 and 
H7N3 NS1-77 viruses respectively, were also transfected (Figure 48B). Forty-eight hours post-
transfection, the media was removed and the cells pelleted at 12000 g x 5 minutes. Total RNA was 
extracted from cell lysates using the Nucleospin RNA extraction kit (Macherey-Nagel) and then 
mRNAs were isolated trough the PolyATtract mRNA Isolation Systems (Promega). Using the primers 
H7N3 NEP Fw1-23 and H7N3 NEP Rv322-344, which target the NS1 and NEP shared mRNA 
sequences (Figure 48B), RT-PCR was performed to investigate the expression of the mRNAs 
produced from NS1-77/2A/GM-CSFV5/NSend construct. 
Visualization of PCR products in agarose gel (Figure 48C) confirmed production of a different NS1 
mRNA species from the NS1-77/2A/GM-CSFV5/NSend segment when compared to the NS and NS1-
77 reverse genetics plasmids. Indeed, in line with the construct design, NS1-77/2A/GM-
CSFV5/NSend segment generated longer NS1 mRNAs (PCR product ≈ 1347nt) than the wild type 
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segment (PCR product ≈ 693nt). Nevertheless, all the plasmids tested produced an additional band 
of the same size and similar intensity which migrated at a molecular weight compatible with the 
NEP mRNAs (PCR product ≈ 344nt). Purification of the bands from agarose gel and subsequent 
sequencing confirmed the identity of the NEP mRNAs (data not shown). Taken together these 
results show that the structure of the new construct does not affect the ability of NS segment to 
undergo splicing and that NEP production occurs at similar rates as for the original segment. 
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Figure 48. Detection of mRNA species produced from RF483-NS1-77/2A/GM-CSFV5/NSend rescue plasmid. A) Schematic 
representation of RF483 dsDNA pol I–pol II transcription system for synthesis of vRNAs and mRNAs to generate reverse 
genetics viruses. The cDNA of each of the eight influenza virus segments is inserted between the RNA pol II promoter (pol 
II) and the polyadenylation signal (Poly A). This pol II transcription unit is flanked by the RNA pol I promoter (pol I) and 
the pol I terminator (T) in the opposite orientation (-). After transfection of the plasmid, two types of molecules are 
synthesized. From the human pol I promoter, negative-sense vRNA(-) is synthesized by cellular pol I. The synthesized 
vRNA contains the noncoding regions (NCR) at the 5′ and 3′ ends. Transcription by pol II yields mRNAs with 5′ cap 
structures and 3′ poly(A) tails; these positive-sense mRNAs (+) are translated into viral proteins. B) Schematic 
representation of RF483-NS1-77/2A/GM-CSFV5/NSend, RF483-H7N3 NS and RF483-H7N3 NS1-77 rescue plasmids used 
in the experiment and their corresponding mRNA products. Red and green arrows represent the forward and reverse 
primers respectively used to target shared NS1 and NEP mRNA sequences in the RT-PCR reaction. Expected sizes of PCR 
products are reported below each mRNA species. C) Left - upper panel: agarose gel visualization of PCR amplified mRNA 
products transcribed from NS1-77/2A/GM-CSFV5/NSend (1), wild type NS (2) and NS1-77 (3) segments. Left - lower 
panel: Beta-actin was also tested as loading control. Right panel: agarose gel visualization of purified PCR products 
confirming the expected size of the different mRNA species. 
 
6.2.4  PR8 H1/N1-2962 NS1-77 GM-CSF virus rescue and propagation. 
Although mRNA transcribed from the NS1-77/2A/GM-CSFV5/NSend segment was able to support 
NS1-77, GM-CSF and NEP expression in mammalian cells following transfection, we still had to 
confirm that (i) the corresponding vRNA could be packaged into the virion and (ii) that it could be 
efficiently transcribed by the viral RNA polymerase complex. Thus, to address these points, we 
tested whether PR8 H1/N1-2962 viruses could be rescued by reverse genetics using the new NS 
segment.  
Human embryonic kidney cells (HEK) 293T were transfected with the seven reverse genetics 
plasmids used for the production of the PR8 H1/N1-2962 virus (H7N3 PB2/PB1/PA/NP/M and PR8 
HA/NA) (see paragraph 5.1) plus the RF483-NS1-77/2A/GM-CSFV5/NSend plasmid to generate the 
novel PR8 H1/N1-2962 NS1-77 GM-CSF virus. Transfections with the RF483-NS1-77/2A/GM-
CSFV5/NSend or pCAGG/NS1-77/2A/GM-CSF plasmids alone were also performed as controls. 
Twenty four hours post-transfection aliquots of the supernatants were collected and tested for the 
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presence of GM-CSF protein using the Human GM-CSF ELISA kit. The ELISA assay confirmed the 
expression of the cytokine from all the transfections except the mock (Figure 49A).  
To evaluate whether the NS construct was efficiently packaged into virions, a RT-PCR using a 
forward primer targeting the 5’ end of the NS1 gene and a reverse primer annealing downstream 
the GM-CSFV5 sequence was performed on supernatants derived from the eight plasmid 
transfection (Figure 49B). Supernatant derived from transfection of RF483-NS1-77/2A/GM-
CSFV5/NSend plasmid alone was also appraised as negative control. Results showed amplification of 
the NS1-77/2A/GM-CSFV5/NSend segment only in the supernatants derived from transfection with 
all the 8 plasmids suggesting efficient packaging of the NS segment into newly synthesized viruses 
released from the cells (Figure 48B). Accordingly, electron microscopy confirmed the presence in 
this supernatant of IAV particles (Figure 49C), in which subsequent RNA extraction and sequencing 
verified the presence of the NS1-77/2A/GM-CSFV5/NSend segment (data not shown).  
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Figure 49. Rescue of PR8 H1/N1-2962 NS1-77 GM-CSF virus. A) Human GM-CSF ELISA results for supernatants derived 
from 293T cells transfected with pCAGG/NS1-77/2A/GM-CSF plasmid, RF483-NS1-77/2A/GM-CSF/NSend plasmid, 
RF483-NS1-77/2A/GM-CSF/NSend plus the other segments required for the generation of PR8 H1/N1-2962 NS1-77 GM-
CSF virus or mock transfected. B) Agarose gel results for RT-PCR targeting the NS1-77/2A/GM-CSFV5/NSend segment in 
the supernatant of 293T cells transfected either with the segment alone (1) or in combination with the other 7 reverse 
genetics plasmids (2). C) Electron microscopy confirming the presence of IAV particles in the supernatant from the eight 
plasmid transfection. Magnifications: 56Kx=56000x; 71Kx=71000x. 
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Although the PR8 H1/N1-2962 NS1-77 GM-CSF virus was successfully rescued the corresponding 
titre was extremely low to perform a direct growth curve. Therefore, the virus had to undergo serial 
passages in MDCK-Npro cells, during which we monitored its ability to retain and express the 
cytokine. RT-PCR and subsequent sequencing of virus NS segment confirmed the presence of the 
NS1-77/2A/GM-CSFV5/Nsend vRNA in the supernatants of infected cells in passage 1 and 2 (Figure 
50A). The production of the human cytokine during PR8 H1/N1-2962 NS1-77 GM-CSF virus infection 
was monitored at the end of the second passage in Npro cells through a 72 hour time course 
(M.O.I=0.1) using the Human GM-CSF ELISA kit (Figure 50B). PR8 H1/N1-2962 NS1-77 virus and 
mock infection were performed as negative controls. A significant increase in the amount of human 
GM-CSF was observed within the first 48 hours post-infection, confirming the ability of PR8 H1/N1-
2962 NS1-77 hGM-CSF virus to efficiently express the exogenous gene at high rate in infected cells. 
No appreciable signals were recorded for any of the other infections. 
 
Figure 50. Ability of the PR8 H1/N1-2962 NS1-77 GM-CSF virus to mantain and express the human GM-CSF gene. A) RT-
PCR analysis of NS1-77/2A/GM-CSFV5/Nsend vRNA in the supernatants of infected Npro cells after the first (P1) and the 
second (P2) passages. RT-PCR was carried out for viral RNA isolated from cell culture supernatants by using a forward 
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primer annealing to the 5’end of NS1 gene while the reverse primer was targeting the GM-CSF/V5 overlapping region 
(expected product size ≈733nt). PCR products were separated by agarose gel electrophoresis and visualized by ethidium 
bromide staining. B) Time-course expression of human GM-CSF during PR8 H1/N1-2962 NS1-77 GM-CSF virus infection 
in Npro cells. The cells were infected with PR8 H1/N1-2962 NS1-77 GM-CSF or PR8 H1/N1-2962 NS1-77 viruses at M.O.I 
0.1 or mock infected. Supernatants were collected and analysed for human GM-CSF using the Human GM-CSF ELISA kit. 
Mean absorbance (Abs 450-550nm) values derived from one representative experiment (n=3) are represented ± 
standard deviation (SD) and the correspondent concentration (pg/ml) can be obtained by comparison with the standard 
curve values on the right Y axis. 
 
A truncation involving the major part of the human GM-CSF sequence was revealed by RT-PCR and 
sequence analysis (data not shown) at the end of the third passage in Npro cells and further 
confirmed at the end of passage 4 (Figure 51A-B). Previously, Wolschek et al. (Wolschek et al., 
2011) showed that the human interleukin-2 (IL-2) gene, co-expressed immediately downstream the 
SD site (aa 10) of the NS1 gene, was deleted from the virus after only one passage in Vero cells. 
However, the same gene was stably retained until passage five when the NS1 gene was allowed to 
express the first 125 amino acids (Kittel et al., 2005), suggesting that the introduction of a foreign 
sequence in close proximity of the SD or SA sites might compromise NS mRNA splicing due to an 
interfering RNA secondary structure (Wolschek et al., 2011). Wolschek et al. addressed this issue by 
constructing different IL-2-expressing chimeric segments endowed with specific changes in the 
sequences surrounding the splicing sites and the branch point to enhance NS mRNA splicing efficacy 
(Wolschek et al., 2011). Although this strategy improved the stability of the foreign gene 
expression, at least until passage number 5, it also entailed a change in the splicing rate of the NS 
segment. Differently to Wolschek et al., we tried to avoid affecting NEP expression by keeping intact 
the sequence surrounding the splicing sites and maintaining the natural distance between the 
splicing acceptors site and the branch point sequence within the “NSend” part of the construct. 
Nevertheless, it appears that an optimal distance between the SA and SD sequences is preferred in 
order to allow a stable propagation of the NS segment. In line with this consideration following few 
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passages the selective pressure promoted the emergence of a truncated form of segment 8 that 
likely restored a more suitable distance between the different splicing regulatory elements.   
 
 
 
Figure 51. Progressive truncation of the NS1-77/2A/GM-CSFV5/NSend segment during serial passages in Npro cells. A) RT-
PCR analysis of the novel NS segment following serial passages of the PR8 H1/N1-2962 NS1-77 GM-CSF virus in Npro 
cells. RT-PCR was carried out from viral RNA isolated from cell culture supernatants by using primers targeting 5’ and 3’ 
ends of NS1-77/2A/GM-CSFV5/NSend segment. Decrease of the size of the engineered NS segment was observed after 
passage number 3 and further confirmed at the end of passage number 4. RT-PCR product expected sizes: NS1-
77/2A/GM-CSFV5/NSend = 1347 nt; wild type NS segment= 693nt. B) Schematic representation of the truncation 
occurring within the NS1-77/2A/hGM-CSFV5/Nsend segment following serial passages in Npro cells. After agarose gel 
purification of the lowest band displayed for passage 3 and subsequent sequencing, a truncation spreading from 75nt 
after the beginning of the hGM-CSF gene to 59nt following the V5 tag stop codon was revealed. Results were further 
confirmed sequencing samples from passage number 4. The deletion affected the expression of the cytokine but not 
those of NS1-77 and NEP proteins. 
 
6.2.5  Expression of GM-CSF genes in PDA cells following infection. 
Although the expression of the exogenous gene appears compromised after multiple rounds of 
infection, this issue might represent a problem for the production of large viral stock rather than for 
the efficacy of the treatment itself. Indeed, since PDA cells do not support high growth of H7N3 
derived viruses (see paragraphs 3.3.3 – 4.2.1) and hence the virus oncolytic activity cannot rely on 
multiple cycles of infection in these cells, the loss of GM-CSF, even after few passages, would have 
unlikely a dramatic effect on the final outcome of a multiple injection treatment as long as the input 
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virus is able to express significant amount of the cytokine. Therefore, to appraise the level of human 
GM-CSF expression during a single round of infection in PDA cells, the PR8 H1/N1-2962 NS1-77 GM-
CSF virus collected in passage 2 was tested in BxPC-3 cell line. 
In order to confirm the cytokine expression in tumour cells, immunofluorescence (IF) targeting the 
V5 tag, fused to the C-terminus of GM-CSF (see Figure 46), was performed in BxPC-3 cells at 8 hours 
post-infection with PR8 H1/N1-2962 NS1-77 GM-CSF, PR8 H1/N1-2962 NS1-77 viruses (M.O.I=0.1) 
or following mock infection (negative controls). The results displayed a very strong signal only for 
the PR8 H1/N1-2962 NS1-77 GM-CSF virus, confirming the production of the V5-tagged protein 
early during infection, a data in line with the timing of NS1 gene expression with which GM-CSF is 
co-transcribed (Figure 52).  
However, higher magnification (400X) revealed that the IF signal for the V5 tag was mainly nuclear 
rather than cytoplasmic. This result would be consistent with the production of an uncleaved form 
of NS1-77/2A/GM-CSFV5 polyprotein, which was previously hypothesized on the basis of western 
blot data generated in paragraph 6.2.2 (Figure 47B). Indeed, sub-cellular localization might be 
explained because the uncleaved polyprotein would be directed to the nucleus by the nuclear 
localization signal 1 (NLS1) within the RBD (residues Arg-35, Arg-38 and Lys-41) at the N-terminus of 
NS1-77 protein (Hale et al., 2008). Due to its localization, this polyprotein would represent the main 
target of IF antibodies as the cleaved form of GM-CSFV5 protein is rapidly secreted outside the 
plasma membrane. Indeed, the successful secretion of human GM-CSF from transfected 293T cells 
reported earlier (see paragraph 6.2.2) suggests that the uncleaved and unsecreted form of GM-
CSFV5 might represent only a fraction of the whole product generated from the new NS segment. 
Since IF appraises the presence of V5-tagged protein inside the cells, we next investigated the 
amount of GM-CSF secreted in the supernatant during PR8 H1/N1-2962 NS1-77 GM-CSF infection. 
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Figure 52. Immunofluorescence (IF) targeting GM-CSFV5 in BxPC-3 cells at 8 hrs post-infection. Tumour BxPC-3 cells were 
infected with PR8 H1/N1-2962 NS1-77 GM-CSF or PR8 H1/N1-2962 NS1-77 viruses (M.O.I= 0.1) or mock infected. After 
fixation and permeabilization, BxPC-3 cells were incubated with the Mouse anti-V5 Antibody (Lifetechnologies) and then 
with the Goat anti-mouse IgG-FITC (SIGMA). Each antibody was diluted in PBS containing 1% BSA, 0.1% Tween-20 and 
0.2% Evan’s Blue contrast solution.  
 
To appraise the levels of human GM-CSF expression in benign and tumor cell lines, semiconfluent 
monolayers of HPDE6 and BxPC-3 cells were infected with PR8 H1/N1-2962 NS1-77 GM-CSF virus 
(M.O.I=0.1). PR8 H1/N1-2962 NS1-77 virus and mock infections were also performed as negative 
controls. At 24 hours post-infection supernatants were collected and tested for presence of GM-
CSF using the Human GM-CSF ELISA kit (Thermo Scientific). The results confirmed production of the 
cytokine only in the case of PR8 H1/N1-2962 NS1-77 GM-CSF virus infection in both cell lines (Figure 
53). However, while in the supernatants of tumour BxPC-3 cells GM-CSF reached values above 1500 
pg/ml, in those derived from benign HPDE6 cells the concentration was almost 2 fold lower. Indeed, 
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although the virus can infect both cell lines as no selectivity is exerted at cell entry, the ability of 
benign HPDE6 to efficiently mount an IFN-mediated antiviral response (see paragraph 2.2.2) and 
the fact that GM-CSF is encoded together with a truncated NS1-77 protein, which cannot 
counteract this response (see paragraph 3.2.2), could explain the lower levels of the cytokine in this 
cell line. 
 
Figure 53. Human GM-CSF ELISA results for BxPC-3 and HPDE6 supernatants collected at 24 hours post-infection with PR8 
H1/N1-2962 NS1-77 GM-CSF, PR8 H1/N1-2962 NS1-77 viruses (M.O.I = 0.1 ) or following mock infection. Values represent 
means of Absorbance450nm- Absorbance550nm ± standard deviations (SD) of one representative experiment (n=4). For each 
absorbance value the correspondent GM-CSF concentration (pg/ml) can be obtained by comparison with the standard 
curve values (right Y axis). Statistical significance was determined using Two-way ANOVA followed by Tukey’s multiple 
comparison test. 
 
6.3  Discussion and conclusion 
The granulocyte macrophage colony-stimulating factor (GM-CSF or CSF2) is produced by various cell 
types including macrophages, mast cells, T cells, fibroblasts and endothelial cells (Cousins et al., 
1994; Nimer and Uchida, 1995), mostly in response to immune activation and cytokines that 
mediate inflammation. Under physiological conditions, GM-CSF in the circulation is at low or even 
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undetectable levels (20-100 pg/ml) (Conti and Gessani, 2008), which can readily reach high values 
(200-7000 pg/mL) in response to immune stimuli (Shi et al., 2006). 
T cell-derived GM-CSF, which is produced by both CD4+ and CD8+ T cells after TCR (T-cell receptor) 
activation along with the appropriate co-stimulatory signals, has a particularly important role in the 
crosstalk between antigen-presenting cells and T cells (Conti and Gessani, 2008). Indeed, It has 
been shown that GM-CSF is critical for DCs development and maturation by activating different 
cellular signalling pathways such as the janus kinase/signal transducer and activator of transcription 
(JAK/STAT) pathway, the mitogen-activated protein kinase (MAPK) pathway and the 
phosphatidylinositol 3-kinase (PI3K) pathway. These pathways can act synergistically promoting 
proliferation and differentiation of DCs (van de Laar et al., 2012) which can then move by 
chemotactic (Wang et al., 1987) in the blood stream toward the site of cytokine expression and 
boost both Th1 and Th2 mediated immune response against foreign antigen or tumour associated 
antigens. 
Based on the encouraging results showed by different armed oncolytic viruses and vectors, 
demonstrating the beneficial effect of GM-CSF stimulated anticancer immunity even in the case of 
low or no replication (Andtbacka et al., 2015; Hellebrand et al., 2006; Heo et al., 2013), we decided 
to incorporate the gene encoding for this cytokine into the PR8 H1/N1-2962 NS1-77 influenza A 
virus backbone. 
Using information generated by earlier studies co-expressing exogenous genes linked with the viral 
NS1 ORF, we designed a novel NS segment in which the foot-and-mouth disease virus (FMDV) 2A 
auto-proteolytic cleavage sequence and the human GM-CSF gene fused to V5 tag were placed “in 
frame” downstream of  codon 77 of NS1 gene (NS1-77) (Figure 46). The rest of the NS segment was 
then moved downstream of the V5 tag stop codon, maintaining both splicing acceptor site and 
branch sequences with the aim to preserve splicing site selection (Corvelo et al., 2010; Taggart et 
al., 2012) for the generation of NEP mRNA.  
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Following transfection of 293T cells the construct allowed efficient production and secretion of 
human GM-CSF (Figure 47B-C) and expression of NEP at level similar to those of the original NS 
segment (Figure 48C). Moreover the elongated vRNA was packaged into novel virions since we 
were able to generate a PR8 H1/N1-2962 NS1-77 GM-CSF virus bearing the human cytokine gene 
(Figure 49B-C). Infection of cells with this virus led to secretion of GM-CSF from MDCK Npro cells 
during passage of stocks (Figure 50A-B) and after infection of tumour BxPC-3 cells (Figure 53). 
Although GM-CSF was also detected in the supernatants of infected HPDE6 cells, the efficient 
antiviral response against the truncated NS1-77 virus mounted by the benign cells (see paragraphs 
2.2.2-3.2.2) mitigated the production of the cytokine to significantly lower concentrations than in 
tumour cells (Figure 53).  
The results collected in this chapter show that the novel NS segment can “arm” the previously 
generated PR8 H1/N1-2962 NS1-77 virus to abundantly express the human GM-CSF during PDA cell 
infection. The high levels of GM-CSF expression in BxPC-3 cells (Figure 53) suggest that infection of 
PDA cells with the recombinant virus could promote recruitment of immune cell to the proximity of 
the neoplasm where tumour antigens might be present in larger number compared to normal cell 
components as results of virus preferential lytic (see paragraph 2.2.1) and immunostimulatory 
activity (see paragraph 3.3.4).  
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Chapter 7: Discussion. 
 
7.1  Why should IAV make any difference for PDA virotherapy? 
Pancreatic cancer is the fourth commonest cause of cancer related death in men. Late detection, 
early metastases, difficult surgical approach and cancer resistance for chemo and radiotherapy all 
contribute to the worst prognosis among various gastro-intestinal cancers (see paragraph 1.2.4).  
Pancreatic cell carcinogenesis develops through accumulation of mutations and genetic lesions 
which lead to activation of oncogenes and inactivation of tumour suppressor genes. Although 
characteristic patterns of genetic lesions have been revealed (see paragraph 1.2.3), accumulating 
evidence suggests that PDAs are characterized by marked genetic heterogeneity. Indeed the latest 
genomic sequencing efforts demonstrate that most of the secondary mutations occurring in PDAs 
have a prevalence of <5% (Biankin et al., 2012; Yachida and Iacobuzio-Donahue, 2013). Therefore, 
although molecular signatures of this malignancy, consisting of mutations in KRAS, CDKN2A, TP53 
and SMAD4/DPC4 genes, are pivotal in pancreatic cancer evolution, their combination with 
different secondary events may lead to diverse PDA sub-classes possessing disparate phenotypes 
and genotypes, as shown by various cancer-derived cell lines (Deer et al., 2010). This may have 
substantial implications for therapeutic responsiveness and targeted intervention strategies 
(Biankin et al., 2012; Collisson et al., 2011). 
With technological advancement, more specific cancer treatments targeted to key genetic 
aberrations are becoming available, leading the way for better care through patient-tailored 
personalized treatment. 
As previously discussed (see paragraph 1.3), virotherapy is a treatment based on oncolytic viruses, 
which exploit the genetic aberrations in tumours to selectively or preferentially infect, replicate and 
ultimately kill cancer cells with minor or no effect on the healthy cells. Although some oncolytic 
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viruses have already been thoroughly investigated and even successfully reached advanced clinical 
trials (see paragraph 1.3.2), due to the genetic heterogeneity of PDA tumour cells together with the 
different replicative mechanisms adopted by each virus, virotherapy should not rely on a short list 
of possible candidates. Instead, a broad range of viruses characterized by specific cancer cell 
permissiveness would represent a better opportunity to find the best treatment for each specific 
PDA patient. As an example reovirus, a naturally occurring, replication competent oncolytic virus, 
which has shown positive results in different clinical trials across a variety of cancer types (Comins 
et al., 2008), replicates specifically in cells that have a constitutive activated KRAS pathway. Because 
of the prevalence of KRAS-mediated neoplasms associated with pancreatic cancer (see paragraph 
1.2.3), the majority of PDA cell lines results sensitive to treatment by reovirus. However, this virus 
fails to produce the same beneficial effect in BxPC-3 cells (Lee et al., Dec. 6, 2011) which carry a 
wild-type gene and do not present enhanced KRAS activity (Yip-Schneider et al., 1999). Indeed 
different publications showed that PDA cells are highly heterogeneous in their permissiveness to 
various OVs (Moerdyk-Schauwecker et al., 2012; Murphy et al., 2012; Wennier et al., 2011). 
Therefore the potent pro-apoptotic effect of IAVs in tumour PDA cells, previously shown resistant 
to other oncolytic viruses (see paragraph 2.2.1), suggested that IAV might be a useful treatment 
option for specific sub-classes of PDA and might play a role in further studies on virotherapy for 
pancreatic cancer.  
 
7.2  An engineered avian influenza A virus for PDA virotherapy. 
In the present study for the first time the oncolytic potential of engineered avian-origin influenza A 
virus (AIV) was evaluated against PDA cells. Indeed, to our knowledge, no IAV of any origin has been 
appraised so far for PDA treatment and the relative small number of previous investigations 
concerning the use of this virus for virotherapy were focused on the well characterized human 
strain H1N1 A/Puerto Rico/8/34 (Bergmann et al., 2001; Muster et al., 2004; Sturlan et al., 2010; 
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Wolschek et al., 2011) (Table 5). However, as shown in the thesis, the choice of a particular viral 
isolate does affect the corresponding oncolytic performances as it can influence for example the 
ability to counteract host IFN response (see paragraph 3.2.2), the extent of apoptotic induction (see 
paragraphs 2.2.1 – 2.2.2) or the sensitivity to host ISGs (see paragraph 1.6.2.3). As such, the 
possibility to select a virus strain from the diverse natural avian reservoir on the basis of its inherent 
oncolytic potency in PDA cells and, through engineering, improve its safety and debulking activity 
represents a novel approach for IAV therapy.  
 
Table 5. Novel aspects of the present study (blue line) in comparison to previous publications on IAV as an oncolytic virus 
(white lines). delNS1, lack of NS1 gene expression; NS1-99/NS1-80/NS1-77, NS1 gene express only the N-terminal 99, 80 
or 77 amino acids, respectively; IL-15, Interleukin-15; hGM-CSF, human granulocyte macrophage colony-stimulating 
factor. 
 
Publications IAV backbone  (origin) Genetic changes Tumour cells 
Bergmann et al., 2001 
 
H1N1  
A/Puerto Rico/8/34 
(human) 
 
 delNS1 
Ras-transfectant  
cell line 518-L1 
 
Muster et al., 2004 
H1N1  
A/Puerto Rico/8/34 
(human) 
 delNS1 or NS1-99 
 
Human melanoma  
cell lines 
 
Sturlan et al., 2010 
H1N1  
A/Puerto Rico/8/34 
(human) 
 NS1-80 
 
Human colon cancer  
cell lines 
 
van Rikxoort et al., 
2012 
H1N1  
A/Puerto Rico/8/34 
(human) 
 
 delNS1 
 Armed with IL-15, 
(based on NS design from 
Wolschek et al., 2011). 
 
Human melanoma  
cell lines 
 
Present work 
 
H7N3 
A/turkey/Italy/2962/03 
(avian) 
 
 NS1-77 
 PB1-F2 L75H 
 H1-N1 (PR8)  
 Armed with hGM-
CSF 
 Novel NS design 
 
Human pancreatic 
ductal adenocarcinoma 
(PDA) cell lines 
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Specific targeting of cancer cells is the conditio sine qua non for oncolytic virotherapy since it 
contributes to enhance both safety and efficacy of the treatment. Some viruses, such as reovirus, 
Newcastle disease virus and mumps virus have a natural preference for cancer cells, while others 
such as measles, adenovirus, vesicular stomatitis virus (VSV), vaccinia and herpes simplex virus 
(HSV) can be adapted to make them cancer specific (Russell et al., 2012).  
Among the different strategies to improve cancer selectivity (see paragraph 1.3.1.2) oncolytic 
viruses can be engineered to exploit the defective antiviral defences of tumour cells (Naik and 
Russell, 2009). Like many types of cancer cells, the majority of PDA cells are deficient in IFN alpha 
and beta gene expression (see paragraph 1.2.3). As such, it is possible to enhance preferential 
replication in these cells by decreasing the virus’ ability to counteract IFN-mediated antiviral 
response in the healthy cells. In case of IAV this strategy involves the impairment of the NS1 
protein, which is the major viral antagonist of host IFN expression during infection (see paragraph 
1.5.4). Thus, to further increase selectivity for IFN-deficient PDA cells, the low pathogenicity avian 
influenza virus H7N3 A/turkey/Italy/2962/03 (see paragraph 2.2.1) was mutated to express a 
truncated NS1-77 protein (see paragraph 3.1). 
The NS1 deletions or truncations have most often been described in the literature as potential 
novel attenuated influenza virus vaccines (Ngunjiri et al., 2015; Pica et al., 2012; Wacheck et al., 
2010). In addition the previous works developing the PR8 strain of IAV as an OV also turned to NS1 
deletion or truncation for improving the selectivity of the virus to replicate in IFN deficient tumour 
cells (Muster et al., 2004; Sturlan et al., 2010). However none of these previous studies had 
described the bystander effect that we directly tested here whereby H7N3 NS1 truncation 
significantly enhanced the killing of uninfected PDA cells, through stimulation of IFN expression 
from the healthy cells (see paragraph 3.3.4).  
In order to further enhance the potency for tumour killing by giving the virus more time for genome 
replication within each round of PDA infection, we next attempted to engineer mutations to the 
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virus that might delay induction of apoptosis by mutating the viral PB1-F2 protein, which normally 
exerts a pro-apoptotic function. However, the increase in virus yield following the PB1-F2 L75H 
mutation was extremely modest compared to the wild type H7N3 PB1-F2 virus. The overall titre of 
the mutated virus might have been limited by the availability of proteases in the cell culture system 
that are required for activation of influenza HA to support multiple rounds of replication. Although 
previous studies showed that trypsin-like protease endogenously expressed in different PDA cell 
lines were sufficient to allow multi-cycle replication of lentogenic Newcastle disease virus (NDV) 
(Buijs et al., 2014), under our experimental conditions vRNA replication did not appear to correlate 
with a proportional increase of infectious virus titres (see chapters 2 and 4). In other words the in 
vitro system we use to measure virus replication might not support multicycle replication and that 
makes it difficult to test whether engineered mutations really do enhance replication or not. These 
effects might be more readily seen in vivo in the orthotropic pancreatic tumour mouse model 
because of an excess of activating trypsin that may result from pancreatitis often associated with 
tumour progression that could support more efficiently multiple rounds of infection.  
Since the stimulation of the immune system is often detrimental for pathogen replication and viral 
gene expression, the development of antitumor immune-based strategies and oncolytic viruses 
(OVs) have occurred on separate tracks for long time. However, it has become increasingly clear 
that the immune responses play a critical role on the clinical benefit of virotherapy such that, in 
some models, virus replication and direct oncolysis are not even necessarily required for therapy 
(Prestwich et al., 2009).  
The granulocyte macrophage colony-stimulating factor (GM-CSF) is the immune gene most usually 
inserted into clinically advanced OVs (Andtbacka et al., 2015; Heo et al., 2013). This preference for 
GM-CSF derives from its potent ability to generate systemic adaptive antitumour immunity in vivo 
after expression in cancer cells, (Dranoff et al., 1993) which is associated with the recruitment and 
differentiation of activating DC in the tumour microenvironment. Coupling virus infection with 
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concomitant expression of an immunostimulatory signal, able to boost anti-tumour immunity, 
appears a suitable strategy to improve the oncolytic performances of a virus which displays low 
replication but high lysis in PDA cells. Thus, oncolytic IAV H1/N1-2962 NS1-77 virus was “armed” to 
express the human GM-CSF gene during infection (chapter 6). Although the use of 2A 
autoproteolytic sequence has been widely reported by different authors for the expression of 
polyprotein mRNAs (see paragraph 6.2.1), we devised a novel NS segment which (i) allows high 
levels of GM-CSF expression and secretion, (ii) retains the natural production of NEP by preserving 
both splicing sites and (iii) further enhances the safety of the virus by eliminating the possibility of 
reversion to the full length NS1 genotype. 
Of course a possible downside of coupling oncolytic activity with immune cell recruitment might be 
that the activated immune system may also act prematurely to suppress therapeutic virus 
replication. However, as previously reported (see paragraphs 3.3.3 – 4.2.1), the avian origin IAV 
displayed moderate replication in PDA cells and thus its use as oncolytic agent in these cells does 
not rely (at least at the moment) on multiple rounds of infection. Moreover, the direct method of 
administration (IT), the quickly ability of the H7N3-derived viruses to trigger high level of cell death 
(see paragraph 3.2.1) and to express significant levels of GM-CSF in PDA cells (see paragraph 6.2.5) 
together with the possibility to exploit HA exchange with other human IAV subtypes (H1, H2, H3) 
preserving the original apoptotic properties (see paragraphs 5.2.1), may allow the virus to perform 
its lytic and immunostimulatory activity before adaptive immunity could promote pathogen 
clearance.  
Although immunodeficient animal models (e.g. SCID mice) are suitable for the evaluation of 
effective replication in and destruction of human tumours by OVs, they cannot assess the complete 
safety and efficacy profile of the virus in normal tissue, nor do they permit evaluation of the impact 
of adaptive immunity on overall virus potency, which is especially important when such virus is 
armed with immunomodulatory transgenes. However, the cost associated with generating or 
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buying and housing immunocompetent mice are prohibitive and tumour latency and progression to 
invasive diseases are also highly variable (Tseng et al., 2010). In addition, in our specific case, the 
use of immunocompetent pancreatic cancer mouse models would have also required the injections 
of murine PDA cell lines and the insertion into the viral NS segment of the murine variant of GM-
CSF, which shares modest structural homology at the level of the nucleotide (70%) and amino acid 
(56%) sequences with the human gene (Shi et al., 2006).  
An alternative to common immunocompetent mouse models may be represented by humanized 
mice, which are immunodeficient mice that have been engrafted with human primary 
haematopoietic cells and tissues that generate a functional human immune system. These models 
address many of the limitations of translating discoveries in rodents into clinical applications for 
studies of human hematopoiesis, immunity, cancers, and infectious diseases (Shultz et al., 2012). 
With respect to oncology, humanized mice have already been used to study human tumours in vivo 
(Shultz et al., 2007), to characterize tumour biology (Barabe et al., 2007) and to study anti-tumour 
therapies (Wege et al., 2011). Nevertheless, there are still a number of limitations in the currently 
available humanized mouse models as investigators are continuing to identify molecular 
mechanisms underlying the remaining defects in the engrafted human immune system and are 
generating "next generation" models to overcome these final deficiencies (Brehm et al., 2013; 
Shultz et al., 2012). 
Due to all these issues the oncolytic activity of the GM-CSF “armed” IAV was not tested in 
immunocompetent PDA mouse model during this project. Therefore, future studies will be 
necessary to appraise the timing and the extent of GM-CSF expression and the corresponding 
overall oncolytic activity of the PR8 H1N1-2962 NS1-77 GM-CSF virus in the more complex context 
of an immunocompetent system. In addition, infection of appropriate immunocompetent system 
should also preclude overexpression of GM-CSF, which has been previously associated with 
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pathological changes mainly due to autoimmune response (Biondo et al., 2001; Hamilton and 
Anderson, 2004; Johnson et al., 1989). 
Nevertheless, taken together, our work demonstrates the possibility to improve the oncolytic 
potential of an influenza A virus isolate, chosen on the basis of its strain-specific apoptotic potency 
in PDA cells, by enhancing its selectivity (see chapter 3) and safety (see chapter 5) and by combining 
its tumour debulking activity via direct viral lysis (see chapter 2) with the possible activation of 
innate (see chapter 3) and adaptive (see chapter 6) immune responses (Figure 54). Based on all 
these considerations, we believe that the study hereby presented is novel and is an example of how 
to develop information from current literature to solve difficult medical problems. 
 
Figure 54. Graphical abstract of the main findings of the present work. The wild type avian influenza virus H7N3 
A/turkey/Italy/2962/03, which was selected for its strain-specific apoptotic potency in PDA cells (upper panel), was 
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further improved by engineering. The resulting reverse genetics virus, named PR8 H1/N1-2962 NS1-77 GM-CSF (lower 
panel) preserves the apoptotic potential of the parental strain in PDA cells, but possesses enhanced selectivity, safety 
and oncolytic potential.  
 
In addition, the project also generated useful reagents and findings. We generated a BxPC-3 cell line 
stably expressing the luciferase gene (BxPC-3Luc), which might be a useful tool to monitor both 
tumour growth and virotherapy beneficial effect in future in vivo studies. We also contributed to 
the characterization of the PDA cells in terms of (i) sialic–acids receptor distribution (see paragraph 
2.2.1), (ii) IFN and ISG genes expression (see paragraph 2.2.2 and 5.2.2) and (iii) apoptosis related 
protein activation (see paragraph 4.2.1). Although these data may represent important information 
especially for further investigation in oncology and virotherapy, they are also relevant for 
interpreting basic virological studies. Indeed, since many cell lines used for virological experiments 
are either immortalized or derived from tumours, they might possess genetic aberrations which 
might affect the final outcome of the research. Therefore a better characterization of the cell lines 
in laboratory use can improve the study of the virus determinants and their interaction with the 
host cell pathways.  
Finally, in light of an increasing level of criticism about the lack of reproducibility in modern 
scientific publications, it is worth noting that our results also consolidate previous findings, 
including those confirming the strain-specific ability of NS1 protein to counteract IFN mediated 
antiviral response (see paragraph 3.2.2) or the data supporting the lack of IFN expression and the 
sensitivity to exogenous IFN of different PDA cell lines (see paragraph 3.3.4).  
 
7.3  Future developments.  
Oncolytic viruses can constantly be subjected to improvement, refinement and perfection through 
engineering efforts. For example surface markers that are expressed selectively by specific tumour 
181 
cells can be targeted by engineering viruses to use them as receptors for virus entry (Cattaneo et 
al., 2008). Besides increasing the efficacy of the treatment, this transductional targeting can also be 
used to eliminate toxicities, particularly when the oncolytic virus binds a ubiquitous receptor. VSV, 
for example, was pseudotyped with the surface glycoprotein from a non-neurotropic lymphocytic 
choriomeningitis virus or retargeted measles virus, thereby eliminating its neurotoxicity without 
compromising its ability to infect and kill cancer cells (Ayala-Breton et al., 2012; Muik et al., 2011). 
Modification of the hypervariable loop of the adenovirus hexon protein ablated the ability of that 
virus to infect normal hepatocytes but not tumour cells (Shashkova et al., 2009).  
Further modifications to enhance specific PDA targeting, thus increasing its anti-tumour effect and 
reducing undesirable tropism, might be introduced also into the PR8 H1/N1-2962 NS1-77 GM-CSF 
virus. Indeed, IAV infection begins with a specific interaction between the viral hemagglutanin (HA) 
and a sialic acid (SA)-containing host cell receptor (see paragraph 1.4.5.1). The degree of receptor 
affinity is further influenced by oligosaccharide length, sulfation, fucosylation, and specific 
subterminal residues of the SA-containing glycoconjugate, all affecting the interaction at the HA 
receptor binding site (RBS) (Nicholls et al., 2008). Sialyl Lewis x (SLex)-related antigens, which 
contain fucose adjacent to the terminal SA, have been found in the majority of pancreatic cancer 
tissues while absent from normal tissues, and correlate with poor patient prognosis in the clinical 
setting (Kim et al., 1988; Mas et al., 1998; Perez-Garay et al., 2010). Thus to increase IAV specific-
targeting of PDA cells, the HA RBS might be mutated to optimize binding with tumour-associated SA 
species, creating a PDA-specific virus with lowered affinity for cells from the normal pancreas. A 
possible way to engineer viruses with altered preferences for different silaic acid species has 
recently been pioneered using an experimental evolution approach (Imai et al., 2012). Here random 
mutations were introduced into the region of HA encoding the globular head, which includes the 
receptor-binding pocket, of IAV HA to generate a virus library from which mutants that displayed 
enhanced binding for particular sialic acids were enriched. In our case such a library would be 
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screened by panning for PDA cell binding (Imai et al., 2012) or by using synthetic Sialyl lewis glycans 
(Stencel-Baerenwald et al., 2014). De-targeting or re-targeting the virus could be pivotal to success, 
especially in the case of the treatment of the pancreas, where, an undesired tropism could cause 
pancreatic disorders. Indeed, a possible viral involvement in the aetiology of type I diabetes (T1D), 
for example, has been suggested by several authors (Filippi and von Herrath, 2008; Richer and 
Horwitz, 2008; von Herrath et al., 1998). Viruses associated with human type I diabetes include 
enterovirus such as Coxsakievirus B (CVB) (Hyoty and Taylor, 2002; Jaidane and Hober, 2008; Yin et 
al., 2002), but also measles, congenital rubella, mumps, cytomegalovirus and influenza B (Hyoty et 
al., 1993; Lindberg et al., 1999; Sano et al., 2008). Viral infections such as Coxsackie B 4 (CVB4) 
(Coleman et al., 1973; Jaidane et al., 2009), rotavirus (Honeyman et al., 2000), and reovirus 
(Onodera et al., 1978) have shown to be diabetogenic in mice. Therefore, although pancreatitis and 
T1D might likely be pre-existing conditions in patient suffering PDA (see paragraph 1.2.2), the re-
targeting of IAV HA to specific tumour cell receptors could be essential to decrease the likelihood of 
undesired side effects and increase the safety of the treatment. 
Once the issue of unwanted toxicity is addressed, further engineering could take the virus closer to 
the goal of a single-shot virotherapy (Russell et al., 2012), which might enhance the beneficial effect 
of the treatment and reduce the stress of multiple interventions for the patients. Indeed, without 
rapid, destructive intra-tumoural spread, a single-shot administration of IAV for PDA virotherapy 
would probably have a modest or even innocuous effect. Thus, to enhance efficacy, further 
engineering of the viral HA could be performed, to increase its activation only in the environment of 
the pancreatic tumour. A second key event in the IAV infection process is the cleavage of HA by 
host proteases from its inactive precursor, HA0, to its functionally active forms HA1 and HA2 (see 
paragraph 1.4.5.1). The amino acid sequence of the HA cleavage site determines the proteases 
capable to process it, and, thus its tropism based on the protease distribution in different organs 
(see paragraph 1.4.4.1). Previous publication showed that the IAV HA cleavage site can be modified 
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to host novel proteolytic sites, making virus replication dependent on the presence of specific 
proteases (Stech et al., 2005). Alterations of protease production and secretion are well-
documented in cancers, such as over-expression of matrix metalloproteinases (MMPs) in numerous 
types of tumours, including PDA (Kinoh et al., 2004; Schneider et al., 2003; Springfeld et al., 2006; 
Vartak and Gemeinhart, 2007). Therefore, modification of the HA cleavage site to render it specific 
for tumour-associated proteases could provide a further mechanism to increase viral replication 
specifically in the tumour cells (Cattaneo, 2010; Springfeld et al., 2006; Szecsi et al., 2006).  
 
7.4  Personal considerations 
Because the research described in this thesis contributed not only to generate scientific data but 
also to my vocational training, I would like to conclude with a personal remark. When I began my 
PhD I considered this project a fantastic opportunity to improve my knowledge concerning two 
extremely interesting area of science to me: virology and oncology. I still do. Nonetheless, as with 
many projects, in the following years I had to face diverse scientific, technical and financial 
challenges. In solving them when I could, or bypassing them through the devising new experiments 
and strategies when I could not, I developed as a scientist. Although a very straightforward project 
would have been appreciated, I am thankful for the challenges and problems that I encountered as 
they correspond to the moments where I learnt the most and sometimes I had the chance to 
surprise myself with some good ideas. I do not know if what I adsorbed during these years is 
enough but I am aware of what I knew at the beginning of this thesis and what I know now about 
IAV and pancreatic cancer. Looking back I would have done some things differently but I will value 
this experience as preparation for the next challenges that I will face in my scientific career. 
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Chapter 8. Materials and Methods 
 
8.1 Materials 
8.1.1 Cell lines 
Table 6. Cell lines used in this study. 
Cell line Origin / Modification Source 
293T  Human embryonic kidney cells expressing large T antigen of SV-40 ATCC 
A549- IFNLuc  
Human lung cell line stably expressing Firefly luciferase reporter 
gene under the control of IFN-β promoter 
Barclay Lab 
MDCK-NPro 
Madin Darby Canine Kidney cells expressing the NPro gene of 
Bovine Viral Diarrhea Virus (BVDV) 
Barclay Lab 
BxPC-3 Human pancreatic ductal adenocarcinoma cell line ATCC 
BxPC-3Luc BxPC-3 cells stably expressing Firefly luciferase reporter gene. This study 
AsPC-1 Human pancreatic ductal adenocarcinoma cell line ATCC 
CFPAC-1 Human pancreatic ductal adenocarcinoma cell line ATCC 
MIA PaCa-2 Human pancreatic ductal adenocarcinoma cell line ATCC 
PANC-1 Human pancreatic ductal adenocarcinoma cell line ATCC 
HPDE6 
Human pancreatic ductal cells from normal pancreatic ducts 
immortalized by transfection with the E6 gene of human 
papilloma virus (HPV). 
Dr. Lorenzo Piemonti 
(HSR - Milan) 
 
8.1.2 Animals 
Table 7. Animal species used in this study. 
Species Age/Use Source 
Embryonated Chicken Eggs (ECE)  7 and 14-days / Virus infection  Charles River Laboratories 
SCID-B17 mice 
6 weeks/ Evaluation of the treatment in 
xenograft model 
Dr. Vincenzo Ciminale 
Instituto Oncologico Veneto 
(IOV) 
 
8.1.3 Viruses 
Table 8. Viruses used in this study. 
Viruses Genome Source 
H1N1 A/Puerto Rico/8/34 (PR8) Reverse genetics virus based on wild type strain. 
Fouchier lab 
Erasmus Medical Centre 
PR8 NS1-77 
PR8 genetic backbone bearing the NS1-77 gene 
truncation. 
This study 
H7N3 A/turkey/Italy/2962/03 Reverse genetics virus based on wild type strain. This study 
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H7N3 NS1-77 
H7N3 genetic backbone bearing the NS1-77 gene 
truncation. 
This study 
H7N3 PB1-F2 L75H 
H7N3 genetic backbone bearing L75H substitution 
in the PB1-F2 gene. 
This study 
H7N3 NS1-77 PB1-F2 L75H 
H7N3 genetic backbone bearing NS1-77 gene 
truncation and L75H substitution in the PB1-F2 
gene. 
This study 
(PR8) H1/N1-2962 NS1-77 
Internal gene segments (PB2, PB1, PA, NP, M, NS) 
from the H7N3 NS1-77 virus and HA and NA genes 
from H1N1 PR8.  
This study 
(PR8) H1/N1-2962 NS1-77 GM-CSF 
PB2, PB1, PA, NP, M gene segments from H7N3 
virus, HA and NA from H1N1 PR8 and novel NS1-
77/2A/GM-CSFV5/NSend segment. 
This study 
 
8.1.4 Plasmid vectors  
All plasmids used in this study contain genetic antibiotic resistance to Ampicillin unless otherwise 
stated. 
 
Table 9. List of plasmid vectors used in this study. 
Plasmid Description Use Source 
pI.18 ⁄ VN1194 HA 
Express the HA from the influenza H5N1 virus 
isolate A ⁄ Viet Nam⁄ 1194 ⁄ 2004 (Genbank: 
AY651333). 
Generation of 
pseudotypes 
Prof. N.J. 
Temperton, 
University of Kent 
pI.18 ⁄ VN1194 NA 
Express the NA from the influenza H5N1 virus 
isolate A ⁄ Viet Nam⁄ 1194 ⁄ 2004 (Genbank: 
AY651445).  
Generation of 
pseudotypes 
Prof. N.J. 
Temperton, 
University of Kent 
 pCMV-Δ8.91 Express HIV- type 1 (HIV-1) gag-pol construct. 
Generation of 
pseudotypes/ 
lentivector 
Prof. N.J. 
Temperton, 
University of Kent 
pCSFLW Reporter plasmid expressing firefly luciferase. 
Generation of 
pseudotypes 
Prof. N.J. 
Temperton, 
University of Kent 
VSV-G 
Express the Vesicular Stomatitis Virus G 
protein. 
Generation of 
pseudotypes/ 
lentivector 
Prof. N.J. 
Temperton, 
University of Kent 
pRRL-Firefly Reporter plasmid expressing firefly luciferase. 
Generation of 
pseudotypes/ 
lentivector 
Olivier Moncorgé 
Barclay Lab 
pCMV-Victoria-PB2  Express human influenza Victoria PB2 protein  
Helper plasmid for 
reverse genetics 
virus rescue 
Barclay Lab 
pCMV-Victoria-PB1 Express human influenza Victoria PB1 protein  
Helper plasmid for 
reverse genetics 
virus rescue 
Barclay Lab 
pCMV-Victoria-PA  Express human influenza Victoria PA protein  
Helper plasmid for 
reverse genetics 
virus rescue 
Barclay Lab 
pCMV-Victoria-NP Express human influenza Victoria NP protein  
Helper plasmid for 
reverse genetics 
virus rescue 
Barclay Lab 
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RF483- PR8 PB2 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 1 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Centre 
RF483- PR8 PB1 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 2 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 PA 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 3 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 HA 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 4 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 NP 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 5 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 NA 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 6 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 M  
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 7 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 NS 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 8 cDNA. 
Reverse genetics 
Fouchier lab 
Erasmus Medical 
Center 
RF483- PR8 NS1-77 
Pol I-Pol II vector containing H1N1 A/Puerto 
Rico/8/34 (PR8) Segment 8 cDNA modified to 
express a NS1 protein of 77 amino acids (NS1-
77), without affecting NEP ORF. 
Reverse genetics This study 
RF483- H7N3 PB2 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 1 cDNA. 
Reverse genetics This study 
RF483- H7N3 PB1 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 2 cDNA. 
Reverse genetics This study 
RF483- H7N3 PB1-F2 L75H 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 2 cDNA 
mutated to create L75H amino acid changes, 
without affecting PB1 and N40 ORFs. 
Reverse genetics This study 
RF483- H7N3 PA 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 3 cDNA. 
Reverse genetics This study 
RF483- H7N3 HA 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 4 cDNA. 
Reverse genetics This study 
RF483- H7N3 NP 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 5 cDNA. 
Reverse genetics This study 
RF483- H7N3 NA 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 6 cDNA. 
Reverse genetics This study 
RF483- H7N3 M 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 7 cDNA. 
Reverse genetics This study 
RF483- H7N3 NS 
Pol I-Pol II vector containing H7N3 
A/turkey/Italy/2962/03 Segment 8 cDNA. 
Reverse genetics This study 
RF483- H7N3 NS1-77 
Pol I-Pol II vector containing H1N1 
A/turkey/Italy/2962/03 Segment 8 cDNA 
modified to express a NS1 protein of 77 amino 
acids (NS1-77), without affecting NEP ORF. 
Reverse genetics This study 
RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend 
Pol I-Pol II vector containing H1N1 
A/turkey/Italy/2962/03 Segment 8 cDNA 
engineer to express a NS1 protein of 77 amino 
acids (NS1-77) and human GM-CSF, without 
affecting NEP ORF. 
Reverse genetics This study 
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pCAGG/NS1 PR8 pCAGG vector expressing PR8 NS1 protein 
Protein 
expression 
This study 
pCAGG/NS1 H7N3 pCAGG vector expressing H7N3 NS1 protein. 
Protein 
expression 
This study 
pCAGG/NS1-77 H7N3 
pCAGG vector expressing H7N3 NS1-77 
protein. 
Protein 
expression 
This study 
ISG54Luc  
Reporter plasmid expressing the firefly 
luciferase gene driven by the inducible 
promoter ISG54. 
Protein 
expression 
Barclay Lab 
RenillaLuc Reporter plasmid expressing renilla luciferase 
Protein 
expression 
Barclay Lab 
pCAGGLuc  Expression of firefly luciferase 
Protein 
expression 
Barclay Lab 
pCAGG/PB1-F2 H7N3 
pCAGG vector expressing H7N3 PB1-F2 
protein. 
Protein 
expression 
This study 
PCAGG/ PB1-F2 L75H H7N3 
pCAGG vector expressing H7N3 PB1-F2 L75H 
protein. 
Protein 
expression 
This study 
pCMV5-FLAG-MAVS Expressing MAVS adaptor protein 
Protein 
expression 
Barclay Lab 
IFN-Luc  
Reporter plasmid expressing the firefly 
luciferase gene driven by the IFN-β promoter. 
Protein 
expression 
Barclay Lab 
pCAGG/PB2 H7N3 pCAGG vector expressing H7N3 PB2 protein. 
Protein 
expression 
This study 
pCAGG/PB1 H7N3 pCAGG vector expressing H7N3 PB1 protein. 
Protein 
expression 
This study 
pCAGG/PA H7N3 pCAGG vector expressing H7N3 PA protein. 
Protein 
expression 
This study 
pCAGG/NP H7N3 pCAGG vector expressing H7N3 NP protein. 
Protein 
expression 
This study 
pHuman-PolI-Firefly 
Negative-sense firefly luciferase-expressing 
plasmid used as reporter to measure the 
polymerase activity 
Minireplicon 
assay 
Olivier Moncorgé 
Barclay Lab 
pEX-A2-2AhGM-CSF 
pEX-A2 vector for gene synthesis containing 
the human GM-CSF gene without introns 
sequences. 
Cloning 
Eurofins-MGW 
Operon 
pCAGG/ NS1-77/2A/GM-CSF 
pCAGG vector expressing H7N3 NS1-
77/2A/GM-CSF polyprotein. 
Protein 
expression 
This study 
 
8.1.5 Oligonucleotides 
Oligonucleotide primers were synthesised by MWG Eurofins and stock solutions of 100 pmol/μl 
were made using sterile water. 
 
Table 10. List of the main oligonucleotides used in this study. 
Primer Sequence Use 
mpFUS-PB2H7N3f CCGAAGTTGGGGGGGAGCGAAAGCAGGTCAAATA 
To generate RF483-H7N3 PB2 
reverse  genetics plasmid 
abFUS-PB2-r GGCCGCCGGGTTATTAGTAGAAACAAGGTCGTTTTTA 
To generate RF483- H7N3 PB2 
reverse  genetics plasmid 
abFUS-PB1-G-f CCGAAGTTGGGGGGGAGCGAAAGCAGGCAAAC 
To generate RF483- H7N3 PB1 
reverse  genetics plasmid 
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abFUS-PB1-r GGCCGCCGGGTTATTAGTAGAAACAAGGCATTTTTTC 
To generate RF483- H7N3 PB1 
reverse  genetics plasmid 
mpFUS-PAH7N3f CCGAAGTTGGGGGGGAGCGAAAGCAGGTACTGATC 
To generate RF483- H7N3 PA 
reverse genetics plasmid 
abFUS-PA-r GGCCGCCGGGTTATTAGTAGAAACAAGGTACTTTTTTGG 
To generate RF483- H7N3 PA 
reverse genetics plasmid 
abFUS-H7-A-f CCGAAGTTGGGGGGGAGCAAAAGCAGGGGATACG 
To generate RF483- H7N3 HA 
reverse genetics plasmid 
abFUS-HA-r GGCCGCCGGGTTATTAGTAGAAACAAGGGTGTTTTTTC 
To generate RF483- H7N3 HA 
reverse genetics plasmid 
abFUS-NP-A-f CCGAAGTTGGGGGGGAGCAAAAGCAGGGTAGATAAT 
To generate RF483- H7N3 NP 
reverse genetics plasmid 
abFUS-NP-r GGCCGCCGGGTTATTAGTAGAAACAAGGGTATTTTTCTT 
To generate RF483- H7N3 NP 
reverse genetics plasmid 
mpFUS-NAH7N3f CCGAAGTTGGGGGGGAGCAAAAGCAGGTGCGAG 
To generate RF483- H7N3 NA 
reverse genetics plasmid  
mpFUS-NAH7N3r GGCCGCCGGGTTATTAGTAGAAACAAGGTGCTTTTTTC 
To generate RF483- H7N3 NA 
reverse genetics plasmid 
abFUS-MA-A-f CCGAAGTTGGGGGGGAGCAAAAGCAGGTAGATATTG 
To generate RF483- H7N3 M 
reverse genetics plasmid 
abFUS-MA-r GGCCGCCGGGTTATTAGTAGAAACAAGGTAGTTTTTTACT 
To generate RF483- H7N3 M 
reverse genetics plasmid  
abFUS-NS-A-f CCGAAGTTGGGGGGGAGCAAAAGCAGGGTGACA 
To generate RF483- H7N3 NS 
reverse genetics plasmid 
mpFUS-NSH7N3r GGCCGCCGGGTTATTAGTAGAAACAAGGGTGTTTTTTATC 
To generate RF483- H7N3 NS 
reverse genetics plasmid 
PR8/NS1-77fw  AATCCGATGAGGCACTTTAAATGACCATGGCCTCT 
Mutagenic primer to introduce a 
stop codon (TAA) in the H1N1 
A/Puerto Rico/8/34 NS1 ORF after 
77 amino acids. 
PR8/NS1-77rv  AGAGGCCATGGTCATTTAAAGTGCCTCATCGGATT 
Mutagenic primer to introduce a 
stop codon (TAA) in the H1N1 
A/Puerto Rico/8/34 NS1 ORF after 
77 amino acids. 
H7N3/NS1-77fw 
GGAGGAAGAATCTGATGAGGCACTTTAATAGACTATTACT
TCAGTGCCG 
Mutagenic primer to introduce two 
stop codons (TAATAG) after 77 
amino acids in the H7N3 
A/turkey/Italy/2962/03 NS1 ORF 
(NS1-77). 
H7N3/NS1-77rv 
CGGCACTGAAGTAATAGTCTATTAAAGTGCCTCATCAGAT
TCTTCCTCC 
Mutagenic primer to introduce two 
stop codons (TAATAG) after 77 
amino acids in the H7N3 
A/turkey/Italy/2962/03 NS1 ORF 
(NS1-77). 
H7N3/PB1-F2_L75H_fw CAGGGATCTTTGAAAACTCATGTCTTGAAACGATGGAAG 
Mutagenic primer to introduce 
PB1-F2 L75H amino acid changes, 
without affecting PB1 and N40 
ORF. 
H7N3/PB1-F2_L75H_rv CTTCCATCGTTTCAAGACATGAGTTTTCAAAGATCCCTG 
Mutagenic primer to introduce 
PB1-F2 L75H amino acid changes, 
without affecting PB1 and N40 
ORF. 
H7N3/NS1NotIF TATGCGGCCGCAGCAAAAGCAGGGTGACAAAAACA 
To clone the H7N3 NS1 and NS1-77 
into pCAGGS plasmid  
SAMR TCCTCATCAGTATGTCCGGGAAGAGAAGGTAATGG 
PCR mutagenesis was used to 
remove the splice acceptor site 
(AG) from the H7N3 NS1 coding 
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sequence in pCAGG plasmid. 
SAMF CCATTACCTTCTCTTCCCGGACATACTGATGAGGA 
PCR mutagenesis was used to 
remove the splice acceptor site 
(AG) from the H7N3 NS1 coding 
sequence in pCAGG plasmid. 
H7N3/NS1MluIR GCGACGCGTAACTTCTGACTCAATTGTTCTCGCCA 
To clone the H7N3 NS1 into pCAGG 
plasmid. 
H7N3/NS1-77MluIR GCGACGCGTAAGTGCCTCATCAGATTCTTCCTCC 
To clone the H7N3 NS1-77 into 
pCAGG plasmid. 
H7N3/PB1-F2NotIF TATGCGGCCGCCATACAGCCATGGAACAGGAAC 
To clone the H7N3 PB1-F2 into 
pCAGG plasmid. 
H7N3/PB1-F2MluIR GCGACGCGTGTTTGTCCACTCTTGTTTGCTG 
To clone the H7N3 PB1-F2 into 
pCAGG plasmid. 
H7N3 PB2 NotIF 
 
TATGCGGCCGCGTCAAATATATTCAATATGGAGAG 
To clone the H7N3 PB2 into pCAGG 
plasmid. 
H7N3 PB2 MluIR 
 
GCGACGCGTATTGATGGCCATCCGAATTC 
To clone the H7N3 PB2 into pCAGG 
plasmid. 
H7N3 PB1 NotIF 
 
TATGCGGCCGCCATTTGAATGGATGTCAATCCG 
To clone the H7N3 PB1 into pCAGG 
plasmid. 
H7N3 PB1 MluIR 
 
GCGACGCGTTTTTTGCCGTCTGAGCTCTTC 
To clone the H7N3 PB1 into pCAGG 
plasmid. 
H7N3 PA NotIF 
 
TATGCGGCCGCTCCAAAATGGAAGATTTTGTGCG 
To clone the H7N3 PA into pCAGG 
plasmid. 
H7N3 PA MluIR 
 
GCGACGCGTTTTCAGTGCATGTGTGAGGAAG 
To clone the H7N3 PA into pCAGG 
plasmid. 
H7N3 NP NotIF 
 
TATGCGGCCGCATCAGCATCATGGCGTCTCAAG 
To clone the H7N3 NP into pCAGG 
plasmid. 
H7N3 NP MluIR 
 
GCGACGCGTATTGTCATACTCCTCTGCATTG 
To clone the H7N3 NP into pCAGG 
plasmid. 
2A/NS1-77 rv1 GGTCAAAATTAAGTGCCTCATCAGATTCTTCC 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
2A/NS1-77 rv2 GCAAGTTTAAGAAGGTCAAAATTAAGTGCCTC 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
2A rv1 TCGACGTCTCCCGCAAGTTTAAGAAGGTC 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
2A rv2 GTTGGACTCGACGTCTCCCGCAAG 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
IIMluI/GM-CSF rv2 ATATACGCGTCTCCTGGACTGGCTCC 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
II2A fw2 AGACGTCGAGTCCAACCCTGGG 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
MluI/GM-CSF rv TATACGCGTCTCCTGGACTGGCTCCCAGCAGTCAAAG 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend and 
pCAGG/ NS1-77/2A/GM-CSF 
plasmids. 
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V5/stops rv GAAGTAATAGTCTATTACGTTGAGTCGAGTCCCAG 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend plasmid. 
Stops/NSend fw TGGGACTCGACTCAACGTAATAGACTATTACTTCAG 
To generate RF483- H7N3 NS1-
77/2A/GM-CSFV5/NSend plasmid. 
H7N3 NEP Fw1-23 ATGGATTCCAACACTGTGTCAAG 
NS1-77/2A/GM-CSF and NEP 
mRNAs amplification 
H7N3 NEP Rv322-344 GTTCTTATCTCTTGCTCCACTTC 
NS1-77/2A/GM-CSF and NEP 
mRNAs amplification 
VG 150 GCAAAGACCTGTACGCCAACA β-actin mRNA amplification  
VG 151 CCTCGGCCACATTGTGAAC β-actin mRNA amplification 
 
8.1.6  Antibodies  
Table 11. List of antibodies used in this study. 
Antibody Description Source 
Mouse ANTI-V5 tag antibody Mouse monoclonal antibody against SV5 tag AbD Serotec 
Monoclonal ANTI-FLAG antibody produced 
in mouse 
Monoclonal ANTI-FLAG antibody produced 
in mouse 
Sigma 
Cleaved PARP (Asp214) Rabbit monoclonal 
antibody 
Rabbit monoclonal antibody against 89KDa 
cleaved PARP fragment. 
Cell Signalling Technology 
Goat anti-mouse IgG horseradish peroxidase 
linked whole antibody 
Secondary antibody conjugated to HRP GE Healthcare 
Goat anti-rabbit IgG HRP-linked Antibody Secondary antibody conjugated to HRP Cell Signalling Technology 
Goat anti-vinculin (N-19) antibody Goat monoclonal antibody against Vinculin Santa Cruz Biotechnology 
Donkey anti-goat IgG-HRP antibody Secondary antibody conjugated to HRP Santa Cruz Biotechnology 
Mouse monoclonal to beta Actin Mouse monoclonal antibody against B-actin abcam 
Mouse anti-V5 Antibody Mouse monoclonal antibody against SV5 tag Lifetechnologies 
Goat anti-mouse IgG-FITC  Secondary antibody conjugated to FITC Sigma 
Alexa Fluor® 647 Annexin V conjugate   Analysis of apoptosis in infected cells Invitrogen 
 
8.1.7 Buffers and culture media  
Table 12. List of Buffers and culture media used in this study. 
Solution Recipe Use 
DMEM  
Dulbecco's Modified Eagle Medium (DMEM) (Gibco)  
Fetal Bovine Serum 10% (v/v) (Biosera)  
Non-essential amino acids (NEAA) 1% (v/v) (Sigma)  
Penicillin and Streptomycin (P/S) 1% (v/v) (Gibco)  
Maintence of 293T, PANC-1 
and MIA PaCa-2 cell lines 
DMEM G-418 
Dulbecco's Modified Eagle Medium (DMEM) (Gibco)  
Fetal Bovine Serum 10% (v/v) (Biosera)  
Non-essential amino acids (NEAA) 1% (v/v) (Sigma)  
Penicillin and Streptomycin (P/S) 1% (v/v) (Gibco) 
Geneticin (G-418) (Gibco) (0.5 mg/ml) 
Maintence of Npro-MDCK 
and A549 IFN-Luc cell lines 
RPMI 1640  
RPMI 1640 (Gibco)  
Fetal Bovine Serum 10% (v/v) (Biosera)  
Non-essential amino acids (NEAA) 1% (v/v) (Sigma)  
Penicillin and Streptomycin (P/S) 1% (v/v) (Gibco) 
Maintence of BxPC-3, BxPC-
3Luc, AsPC-1, HPDE6 cell lines 
Iscove Iscove’s medium (Gibco) Maintence of CFPAC-1 cell 
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Fetal Bovine Serum 10% (v/v) (Biosera)  
Non-essential amino acids (NEAA) 1% (v/v) (Sigma)  
Penicillin and Streptomycin (P/S) 1% (v/v) (Gibco) 
line.  
Phosphate Buffered 
Saline (PBS)  
155 mM NaCl  
1 mM KH2PO4  
3 mM Na2HPO4  
Cell washes  
Cell trypsin  
2x solution  
200ml PBS (Gibco)  
4ml 2.5% (10x) Trypsin solution (Gibco)  
0.5mM EDTA  
Cell passage  
Virus plaque assay 
overlay  
100 ml 10 x Earle’s minimal essential medium (EMEM)  
28 ml 7.5% BSA  
1% glutamine (200mM)  
20 ml 7.5% NaHCO3  
10 ml 1M HEPES  
5 ml 1% DEAE Dextran (Sigma)  
1% penicillin-streptomycin (5000IU/ml)  
2% Agarose (Oxoid)  
Virus plaque assays  
2,5% Avicel  
2,5 g of Avicel powder (FMC Corporation) 
100 ml distilled water 
Virus plaque assay 
Crystal violet solution  
100 ml Crystal violet stock solution  
300 ml ethanol  
1.6 l water  
Virus plaque assay - cell 
monolayer staining  
TAE Buffer  
40mM Tris-acetate pH 8  
1mM EDTA  
DNA gel electrophoresis  
Lysogeny Broth (LB)  
1% Oxoid tryptone  
0.5% Oxoid yeast extract  
0.5% NaCl  
0.1% glucose  
Culturing transformed 
bacterial cells  
SOC Medium  
2% Oxoid tryptone  
0.5% Oxoid yeast extract  
10mM NaCl  
2.5mM KCl  
10mM MgCl2  
10mM MgSO4  
20mM glucose  
Recovery medium used 
during transformation of 
Escherichia coli DH10B cells  
6X DNA loading dye  
0.25% Bromophenol blue  
40% (w/v) sucrose.  
DNA gel electrophoresis  
Dissociation buffer 
50 mM Tris-Cl pH 6.8 
5% β-mercaptoethanol 
2% SDS 
0.1% bromophenol blue 
10% glycerol 
 
Cell lysis 
6X protein loading dye  
375 mM Tris-HCl pH 6.8  
6% SDS 
30% glycerol  
9% 2-Mercaptoethanol 
0.03% bromophenol blue  
Protein gel electrophoresis  
SDS-Page running 
buffer 
25 mM Tris 
250 mM glycine 
0.1% SDS 
Protein gel electrophoresis 
Western Blot transfer 
buffer 
39 mM glycine 
48mM Tris base 
0.037% SDS 
20% methanol 
Protein gel electrophoresis 
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8.2 Methods  
8.2.1 Molecular biology 
8.2.1.1 Reverse Transcriptase and Polymerase Chain Reaction (PCR). 
Reverse transcriptase PCR reactions were performed either using Qiagen OneStep RT-PCR kit or a 
two steps reaction consisting of cDNA synthesis followed by PCR.  
 
Qiagen OneStep RT-PCR 
RT-PCRs were carried out in a total volume of 25 μl. Reaction mixture contained 1 pg – 2 
μg/reaction of template RNA, 5x QIAGEN OneStep RT-PCR Buffer, dNTP Mix (final concentration 400 
μM of each dNTP), 1 μM of sense and anti-sense oligonucleotides, RNase Inhibitor (8U/reaction), 
1U/reaction of OneStep RT-PCR Enzime Mix. OneStep PCR conditions are presented in Table 13.  
 
Table 13. Qiagen OneStep PCR thermal cycling conditions. 
Passage Temperature  Time  Reaction 
1 50°C 30 min Reverse transcription 
2 94°C 15 min Initial PCR activation step 
3 94°C 1 min Denaturation 
4 55°C 1 min Annealing 
5 68°C 1-2 min Extension 
6 Go to step 3, repeat 34-39 times    
7 68°C 7 min Final extension 
8 4⁰C  Hold  
 
cDNA 
Complementary DNA (cDNA) was synthesised through two sequential reactions: (i) annealing of 
random primer mix (RF671) to RNA and then (ii) reverse transcription. The reaction mixture for the 
first reaction consists of 0.1 µM random oligonucleotides (RF671 -Operon), 0.5mM dNTPs Mix, 20U 
rRNAsin (Promega), 1 pg – 2 μg/reaction template RNA. After 5 minutes incubation at 65°C the 
reaction mixture was cooling down on ice for 5 minutes and ten mixed with a second reaction 
mixture containing 1X RT buffer (Invitrogen), DTT 0.005M, rRNAsin 20U, SuperScript III RT 200U 
(Invitrogen). The final reaction mixture was incubated at 25°C for 5 minutes and then at 60°C for 50 
minutes to obtain cDNA. 
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PCR  
PCR for sequencing and DNA insert construction was performed using a reaction mix containing 50-
100 ng of cDNA, PFU Buffer 1X (Stratagene), dNTPs Mix 0.25 M, 0.2 μM of sense and anti-sense 
oligonucleotide primers, 1.75 U of Turbo PFU (Stratagene). PCR conditions are presented in Table 
14.  
Table 14. PCR thermal cycling conditions. 
Passage Temperature Time Reaction 
1 95°C 2 min Initial Denaturation 
2 95°C 45 sec Denaturation 
3 55-65°C 1 min Annealing 
4 72°C  2 min Extension 
5 Go to step 2 and repeat 39 times   
6 72°C 10 min Final extension 
7 4⁰C  Hold  
 
8.2.1.2 Agarose gel electrophoresis  
DNA fragments were separated on 1% or 2% agarose gels diluted with 0.5X TAE buffer and 
supplemented with 1x gel red (Cambridge Bioscience). DNA was loaded with 5x Gel loading dye 
(Qiagen). Gels were run in 0.5X TAE buffer. Samples were run alongside markers at 80-120V until 
the bands had sufficiently separated. DNA was visualised using a UV trans-illuminator. 
 
8.2.1.3 DNA purification  
DNA fragments were cut from the agarose gel under UV light, and DNA extracted using a QIAquick 
Gel extraction kit (Qiagen) following manufacturer’s instructions. Similarly, digestion products or 
PCR product (directly) were purified using the Gel extraction kit. DNA fragments were eluted with 
35-50 μl sterile water. 
 
8.2.1.4 Double restriction enzyme digest  
In order to clone genes into the pCAGG vector, the NotI and MluI restriction enzymes were utilized. 
Double digests were performed in 40 μl total volume using 4 μl of the 10X NEB buffer 3, 2 μl of each 
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NotI and MluI enzyme (NEB), 4 μl of 10X NEB BSA and 28 μl of PCR purified DNA or purified plasmid 
DNA in nuclease free water. All reactions were carried out at 37°C for 2 - 3 hours. 
 
8.2.1.5 DNA ligation  
Constructs were ligated into the pCAGG vector using T4 DNA Ligase kit (Promega) as recommended 
by the manufacturer’s guidelines. Typically, DNA ligation was performed in a total volume of 20 μl 
using a 1:3 vector:insert ratio and 2 hours incubation at room temperature (RT).  
 
8.2.1.6 Transforming competent bacterial cells  
1 to 3 μl of the DNA ligation (or ~50ng of plasmid) was mixed with 50μl OneShot®TOP10 chemically 
competent E.coli. (Invitrogen) and incubated on ice for 30 minutes. Cells were heat shocked for 30 
seconds at 42°C and replaced on ice for 2 minutes. 250μl of pre-warmed S.O.C. media (Invitrogen) 
was added to the mix and incubated for 1 hour at 37°C in a shaking incubator, after which a suitable 
volume was spread on to pre-warmed LB agar plates containing 1% Ampicillin and incubated 
overnight at 37C for colony formation. Colonies were screened by PCR, and grown in 5ml LB 
supplemented with Ampicillin (100μg/ml). 
 
8.2.1.7 Plasmid purification  
Small scale. Bacterial cells grown in 5ml LB (100μg/ml Ampicillin) were pelleted by centrifugation at 
3000xg for 5 minutes. The supernatant was discarded and DNA purified by the QIAprep Spin 
Miniprep kit (QIAGEN) following the manufacturers guidelines. DNA was eluted with 50μl warm 
sterile water and stored at -20°C.  
Large scale. 250ml of LB supplemented with 100μg/ml Ampicillin was inoculated with 200μl 
bacterial cells and incubated at 37°C for 16 hours. Cells were pelleted by centrifugation at 3000xg 
for 5 minutes. The supernatant was discarded and DNA purified by the QIAfilter Plasmid Maxi kit 
(QIAGEN) following the manufacturers guidelines. The DNA pellet was resuspended with 500-1000 
μl of nuclease free water and stored at -20°C. The concentration and quality of DNA was measure 
using a NANODROP spectrophotometer. Good quality DNA was considered such with a A260/A280 
ratio of 1.7-2.0. 
 
8.2.1.8 Plasmid constructs  
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The empty RF483, which is derived from the pHW2000 plasmid previously generated by Hoffmann 
et al. (Hoffmann et al., 2000), and the virus PR8 rescue plasmids were supplied by Dr. R. Fouchier, 
Erasmus University, Rotterdam, Netherlands. 
Viral RNA segments from A/turkey/Italy/2962/03 (H7N3) were extracted by using RNA extraction kit 
NucleoSpin RNA II (Macherey-Nagel) according to manufacturer’s instructions and circularized to 
sequence their Non-Coding Regions (NCR) as previously described (de Wit et al., 2007). Based on 
the NCR sequences sense and antisense primers were designed according to the In-Fusion® Dry-
Down PCR Cloning Kit recommendations (Clontech) for subsequent amplification of the viral genes 
by reverse transcription-PCR (RT-PCR). cDNA copies of viral RNAs were sequenced in order to very 
their fidelity to the original segments and inserted into RF483 vector by using In-Fusion® Dry-Down 
PCR Cloning Kit (Clontech). Plasmids obtained were propagated in One Shot® TOP10 Chemically 
Competent E. coli (Invitrogen), purified by EndoFree® Plasmid Maxi Kit (Qiagen) and confirmed by 
sequencing. Mutations of interest in the NS1 and PB1-F2 genes (segment 8 and 2 respectively) were 
introduced by PCR using QuikChange Site-Directed Mutagenesis kit (Stratagene) as follows:  
 
 RF483 - PR8 NS1-77 
A single nucleotide mutation A232T was introduced in segment 8 of H1N1 A/PR/8/34 using 
PR8/NS1-77fw and PR8/NS1-77rv primers in order to create a stop codon (TAA) in the NS1 ORF 
after 77 amino acids. The resulting construct was called RF483- PR8 NS1-77 and confirmed by 
sequencing. 
 
 RF483 - H7N3 NS1-77  
Using the set of primers H7N3/NS1-77fw and H7N3/NS1-77rv two stop codons (TAATAG) were 
generated by three site mutations (A232T, A235T, T236A) after 77 amino acid in the H7N3 
A/turkey/Italy/2962/03 NS1 ORF (see chapter 9 – appendix). The resulting construct was called 
RF483- H7N3 NS1-77 and was confirmed by sequencing. 
 
 RF483 - H7N3 PB1-F2 L75H  
A single nucleotide mutation T224A was introduced in the PB1-F2 gene of either full length or 
truncated NS1-77 H7N3 A/turkey/Italy/2962/03 virus using H7N3/PB1-F2_L75H_fw and H7N3/PB1-
F2_L75H_rv primers to create L75H amino acid changes, without affecting PB1 and N40 ORF (see 
chapter 9 – appendix). The resulting constructs was called RF483- H7N3 PB1-F2 L75H and was 
confirmed by sequencing. 
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The RF483-NS1-77/2A/GM-CSFV5/NSend plasmid (see chapter 9 – appendix) was generated 
through multiple steps as summarized in figure 55. Briefly, using the RF483- H7N3 NS plasmid as 
template a first PCR was performed with the H7N3 NS1NotIFw and the 2A/NS1-77rv1 
oligonucleotides to amplify the H7N3 NS1 gene sequence until codon 77. The reverse primers 
added to the final PCR product the docking sequence for further elongation of the FMDV 2A 
autoproteolytic site through a series of successive PCRs that eventually produced the NS1-77/2A 
fragment (Figure 55A). pEX-A2 vector containing the FMDV 2A sequence upstream of the human 
GM-CSF gene (without intron sequences) was obtained from Eurofins-MGW Operon and used as 
PCR template to generate the 2A/GM-CSF product (Figure 55B). Next overlapping PCR was 
performed using the two previous products as templates to obtain the NS1-77/2A/GM-CSF 
fragment bearing NotI and MluI restriction sites at its 5’ and 3’ ends respectively (Figure 55C). Using 
DNA restriction and subsequent ligation the PCR product was inserted into pCAGG plasmid, which 
allowed the fusion of the construct expressing the polyprotein with a 14-amino-acid long SV5 tag at 
its carboxyl terminus (Figure 55D). The resulting plasmid was named pCAGG/NS1-77/2A/GM-CSF 
and used to test the expression of both NS1-77 and human GM-CSF proteins. Next, using the 
pCAGG/NS1-77/2A/GM-CSF plasmid as template, the H7N3 NS1NotIFw and V5/stops rv primers 
allowed the PCR amplification of the sequence from NS1-77 until V5 tag and the introduction of two 
stop codons at the 5’ terminus (Figure 55D). Using the RF483-H7N3 NS rescue plasmid as template 
another PCR was performed to amplify the NS sequence from aa position 77 on the NS1 ORF to the 
3’ UTR of the viral segment (Figure 55E). The sense oligonucleotide (Stops/NSend fw) provided two 
stop codons at 5’ of the PCR product which overlap the sequence at 3’ end of the NS1-77/2A/GM-
CSFV5 segment previously generated. Finally, overlapping PCR was performed using the sense and 
anti-sense oligonucleotides bearing the viral NS segment NCR (abFUS-NS-A-f and mpFUS-NSH7N3r), 
which were previously designed according to the In-Fusion® Dry-Down PCR Cloning Kit 
recommendations (Clontech) (Figure 55F). 
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Figure 55. Schematic representation of the steps performed to construct the pCAGG/NS1-77/2A/GM-CSF and the RF483-
NS1-77/2A/GM-CSFV5/NSend plasmids. Red box: NS1/NEP shared coding region; NS1-77: sequence encoding 77 N-
terminal aa of the H7N3 NS1 protein, 2A: FMDV autoproteolytic cleavage site; GM-CSF: human granulocyte macrophage 
colony-stimulating factor; V5: SV5 tag; ** stop codons; NSend: sequence from NS1 codon 78 until the end of the H7N3 
NS segment. For specific primers sequences refer to table 10.  
 
pCAGG/NS1 H7N3 expression construct was generated as previously described by Hayman A. et al., 
2006 (Hayman et al., 2006). Briefly, PCR mutagenesis was used to remove the splice acceptor site 
(AG) from the H7N3 A/turkey/Italy/2962/03 NS1 coding sequence (see chapter 9 – appendix). In 
PCR1 the primer pairs H7N3/NS1NotIF and SAMR (see table 10) were used, producing a ~550 bp 
amplicon. PCR2 included primers SAMF and H7N3/NS1MluIR (see table 10) and resulted in a ~ 210 
bp product. PCR1 and PCR2 were performed starting from the viral RNA as template using Qiagen 
OneStep RT-PCR kit (Qiagen). A third overlapping PCR3 was then carried out using the NS1NotIF and 
NS1MluIR primers. The 720 bp PCR3 product was then digested with NotI and MLu restriction 
enzymes (NEB, New England Biolabs) and ligated into pCAGG vector, which allow the fusion of the 
expressed protein with a 14-amino-acid long SV5 tag at its carboxyl terminus. The construct was 
then propagated in One Shot® TOP10 Chemically Competent E. coli (Invitrogen), purified by 
EndoFree® Plasmid Maxi Kit (Qiagen) and confirmed by sequencing.  
198 
A second construct pCAGG/NS1-77 H7N3, encoding the first 77 amino acids of the NS1 protein from 
H7N3 A/turkey/Italy/2962/03, was generated by PCR using the forward primer H7N3/NS1NotIF and 
the reverse primer H7N3/NS1-77MluIR. The PCR product was then cloned into the pCAGG vector 
using the NotI and MluI restriction sites as previously described. A pCAGG/NS1 PR8 construct 
containing the full length NS1 from H1N1/PR/8/34 modified to remove the splice acceptor site was 
previously generated in our laboratory. Empty pCAGG vector was used as negative control. 
Different pCAGG/PB1-F2 H7N3 and pCAGG/PB1-F2 L75H H7N3 constructs were generated by PCR 
using the forward primer H7N3/PB1-F2NotIF, the reverse primer H7N3/PB1-F2MluIR and as 
templates the wild type PB1 or PB1-F2 L75H plasmids previously employed to produce the reverse 
genetics viruses. PCR products were then cloned into pCAGG vector as described above. 
 
8.2.1.9 Sequencing of constructs 
All plasmid constructs were verified by DNA sequencing. Briefly, PCR amplification was performed 
by using specific primers (primer sequences are available on request) and then the complete coding 
sequences were generated using the Big Dye Terminator v3.1 cycle sequencing kit (Applied 
Biosystems, Foster City, CA). The products of the sequencing reactions were cleaned-up using the 
Performa DTR Ultra 96-well kit (Edge BioSystems, Gaithersburg, MD) and sequenced in a 16-
capillary ABI Prism 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequence data 
were assembled and edited with SeqScape software v2.5 (Applied Biosystems).  
 
8.2.2 Cell lines and transfection 
8.2.2.1 Cell culture 
293T, Mia Paca-2, PANC-1, Npro-MDCK that express NPro gene of Bovine Viral Diarrhea Virus 
(BVDV) thus lacking of IFN expression and A549-IFNLuc cells, which contain a stable integrate firefly 
luciferase gene driven by the IFN-β promoter, were grown in Dulbecco’s modification of Eagle’s 
medium DMEM (Gibco) supplemented with 10% Fetal Bovine Serum FBS (Biosera), 1% MEM Non-
essential amino acid solution NEAA (SIGMA) and 1% penicillin-streptomycin (P/S) (Gibco). Geneticin 
(G-418) (Gibco) was added at the concentration of 0.5 mg/ml in A549-IFNLuc and Npro-MDCK 
media. The immortalized epithelial cell line from normal human pancreatic ducts HPDE6 and the 
pancreatic ductal adenocarcinoma cell lines AsPC-1 and BxPC-3 were maintained in RPMI 1640 
(Gibco) supplemented with 10% FBS, 1% P/S solution and 1% NEAA solution. Iscove’s medium 
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(Gibco) supplemented with FBS 10%, 1% NEAA (Sigma) and 1% P/S solution (Gibco) was used to 
grow CFPAC-1 ductal adenocarcinoma cell line. All cell lines were grown in a humidified incubator at 
37°C with 5% CO2, and sub-cultured twice weekly.  
 
8.2.2.2 Transfection 
Transfections were performed using Lipofectamine 2000 reagent (Invitrogen) following 
manufacturer’s instructions. DNA:reagent ratio volumes were scaled appropriately for cell 
transfections. DNA and Lipofectamine were diluted in the appropriate volumes using OptiMEM 
(Invitrogen). Transfection of RG plasmids for RG virus generation was carried out with Fugene 6 
(Promega), as described in paragraph 8.2.2.4. 
 
8.2.2.3 Generation of BxPC-3Luc cell line. 
BxPC-3 cells stably expressing Luciferase gene (BxPC-3Luc) were generated using lentivector 
transduction (Figure 55). Briefly, semiconfluent monolayers of 293T cells were co-transfected in 10 
cm2 Petri dishes with 8 μg of HIV gag/pol construct 4 μg Vesicular Stomatitis Virus G protein (VSV-G) 
construct and 4 μg of pRRL-Firefly luciferase reporter constructs using Lipofectamine 2000 
(Invitrogen). Supernatant was harvested 48 h post-transfection, filtered through 0.45-μm filters, 
and stored at -80°C. Transduction was performed in a 12 well plate by adding 500 μl/well of 
lentivector suspension in serum free DMEM onto 10 fold dilutions of BxPC-3 cells. After 24 hours 
incubation the media were replaced with fresh media containing 3% FBS DMEM and cells were left 
at 37°C for 72h. The lentivector transduction efficiency was assessed by monitoring expression of 
luciferase in the target cells using the Luciferase Assay Reporter System (Promega). BxPC-3Luc cells 
were maintained in RPMI 1640 (Gibco) supplemented with 10% FBS, 1% Pen-Strep solution and 1% 
NEAA solution. 
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Figure 56. Lentivector transduction used to establish a BXPC-3 cell line stably expressing the firefly luciferase, termed BXPC-
3Luc.  
 
8.2.2.4 Virus rescue  
Virus rescue was carried out using a set consisting of 12 plasmids. Four expression “helper” 
plasmids with a CMV promoter directed the expression of the proteins of the viral polymerase 
complex PB1, PB2, PA, and NP from the human strain A/Victoria/3/75 (H3N2). The remaining eight 
plasmids contained cDNA copies of viral RNAs derived from the avian A/turkey/Italy/2962/03 
(H7N3) or the human A/Puerto Rico/8/34 (H1N1) inserted into the RF483 vector. The rescue 
method used was adapted from Neumann et al. (1999) (Neumann et al., 1999) as previously 
described (Elleman and Barclay, 2004). Briefly, all 12 plasmids were transfected into 293T cells in 
12-well plates using Fugene 6. To generate recombinant NS1-77 and/or PB1-F2 L75H viruses, 
different plasmids (see table 9) corresponding to mutated segment 8 and 2 RNAs were substituted 
in place of the equivalents H7N3 or human PR8 plasmids. The PR8 H1/N1-2962 NS1-77 virus was 
obtained by co-transfecting the plasmids for the surface antigens haemagglutinin (HA) and 
neuraminidase (NA) of the H1N1 PR8 virus together with the 6 plasmids expressing the internal viral 
genes (PB2, PB1, PA, NP, M and NS) of the H7N3 NS1-77 virus. To generate the PR8 H1/N1-2962 
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NS1-77 GM-CSF virus the RF483 – H7N3 NS1-77 plasmid was substituted with the RF483-H7N3 NS1-
77/2A/GM-CSFV5/NSend plasmid. After 24 hours, the transfected cells were removed from the 
wells and mixed with Npro-MDCKs and co-cultured in 25ml flasks. The first 6–8 h of the co-culture 
was carried out in DMEM media supplemented with 10% FBS after which the cells were washed 
briefly in serum-free media and the media was replaced with serum-free media containing 2.5 μg 
/ml TPCK-trypsin (Worthington). The cells were monitored daily thereafter and supernatants 
containing recombinant viruses were harvested once the cell layers were completely destroyed by 
the virus. The harvested supernatants were spun at 4000 x g at 4 °C for 20 min to remove the cell 
debris and stored in aliquots at -80 °C. Viral titres were determined by plaque assay on MDCK-Npro 
cells (Matrosovich et al., 2006). 
 
8.2.2.5 A549-IFNLuc luciferase assay 
A549-IFNLuc cells were incubated with different reverse genetics viruses diluted in serum-free 
DMEM at an M.O.I. of 1 in a 24 well plate at 37°C. After 1 hour absorption, the input viruses were 
replaced with 3% FBS DMEM and then cells were further incubated for 8 hours. Next, the cells were 
washed once with PBS and then lysed with 100 μl/well of Passive Lysis Buffer (Promega), rocking 
the plate for 15 minutes at room temperature. In order to assure the maximum release of the 
luciferase proteins from the cells the plates were frozen and thawed for 3 times at -80°C. The 
luciferase activity was measured in a luminometer using the Luciferase Assay System (Promega). 
 
8.2.2.6 ISG54 luciferase assay 
HPDE6 and BxPC-3 cells were incubated with reverse genetics viruses diluted in serum-free DMEM 
at an M.O.I of 1 pfu/cell in a 24 well plate at 37°C. After 1 h, the viruses were replaced with 3% FBS 
DMEM and the cells were incubated for further 8 hours. The supernatants were collected and 
exposed on ice to the ultraviolet radiation from a germicidal lamp for 5 minutes in order to 
inactivate any possible viral particle then they were stored at -80°C.  
Plasmids ISG54Luc, encoding the firefly luciferase gene driven by the inducible promoter ISG54 and 
RenillaLuc, encoding the renilla luciferase, were co-transfected into 293T cells using Lipofectamine 
2000 (Roche). After 8 h, the medium was replaced with the supernatans previously inactivated and 
cells were incubated at 37°C. After 24 hours 293T cells were washed once with PBS and then lysed 
with 100 μl/well of Passive Lysis Buffer (Promega), rocking the plate for 15 minutes at room 
temperature. In order to assure the maximum release of the luciferase proteins from the cells were 
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frozen and thawed for 3 times at -80°C. The firefly and the renilla luciferase activities were 
measured in a luminometer using the Dual-Luciferase Reporter Assay System (Promega).  
 
8.2.2.7 Post-transcriptional limitation of IFN-β induction 
293T cells were co-transfected with pCAGGLuc plasmid, which constitutively expresses firefly 
luciferase and one of the following plasmids: pCAGG/NS1 PR8, pCAGG/NS1 H7N3, pCAGG/NS1-77 
H7N3 and empty pCAGG (K-). After 8 hours incubation at 37°C, cells were lysed in Passive Lysis 
Buffer (Promega), rocking the plate for 15 minutes at room temperature. In order to assure the 
maximum release of the luciferase proteins the cells were frozen and thawed for 3 times at -80°C. 
The firefly luciferase activity was measured in a luminometer using the Luciferase Reporter Assay 
System (Promega). 
 
8.2.2.8 Western blot  
Cells lysates were treated in dissociation buffer for 5 minutes at 96°C and then electrophoresed in 
12% polyacrylamide gels using running buffer. Following SDS-PAGE the proteins were transferred 
from the gel onto immuno-blot Hybond-ECL membrane (GE Healthcare) by electroblotting with 
transfer buffer. Membranes were washed with PBS and then incubated overnight at 4°C in PBS 
solution containing 5% skymmed milk (Bio-rad). After further washing with PBS, membrane was 
incubated for 1 h at room temperature under constant shaking with PBS containing 0.05% Tween-
20 (Sigma), 5% skymmed milk (Bio-Rad) and mouse ANTI-V5 tag antibody (AbD Serotec), Mouse 
anti-V5 Antibody (Lifetechnologies), Monoclonal ANTI-FLAG antibody produced in mouse (Sigma) or 
Cleaved PARP (Asp214) Rabbit monoclonal antibody (Cell Signalling Technology). After incubation 
the membrane was washed again as previously described and then incubated with goat anti-mouse 
IgG horseradish peroxidase linked whole antibody (GE Healthcare) or Anti-rabbit IgG HRP-linked 
Antibody (Cell Signalling Technology). Vinculin and β-actin were detected as loading controls using 
goat anti-vinculin (N-19) antibody (Santa Cruz Biotechnology) followed by incubation with donkey 
anti-goat IgG-HRP antibody (Santa Cruz Biotechnology) and Mouse monoclonal to beta Actin 
(abcam) followed by incubation with goat anti-mouse IgG horseradish peroxidase linked whole 
antibody (GE Healthcare), respectively. Visualization of protein bands in Amersham Hyperfilm™ ECL 
(GE Healthcare) was performed using ECL Plus Western Blotting Detection System (GE Healthcare). 
 
8.2.2.9 BxPC-3 and HPDE6 cells apoptosis-related proteins profile 
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BxPC-3 and HPDE6 cells were seeded at density of 1x105 cells/well in 12 well plates. After 24 hours 
media was removed and cells were washed 3 times with PBS and then lysed in dissociation buffer. 
Cell lysates from 3 different wells for each cell line were pooled together and microcentrifuged at 
14000 g for 5 min. The supernatant was collected and the expression of 35 apoptosis-related 
proteins was evaluated using the Human Apoptosis Array kit (R&D Systems). Transfer of protein 
dots in Amersham Hyperfilm™ ECL (GE Healthcare) was performed using ECL Plus Western Blotting 
Detection System (GE Healthcare). Data analysis was performed using Gel Doc EZ system and the 
Image Lab Software (Bio-Rad). 
 
8.2.2.10  PB1-F2/MAVS luciferase assay 
PB1-F2/MAVS luciferase assay was performed in a 24-well plate transfecting 293T cells with 
pCAGG/PB1-F2 H7N3, pCAGG/PB1-F2 L75H H7N3 or empty pCAGG plasmids (1 µg/well), together 
with IFNβ-Luc plasmid (0.250 µg/well), which contain a firefly luciferase gene driven by the IFN-β 
promoter and renilla expression plasmid (0.125 µg/well). pCMV5-FLAG-MAVS plasmid, stably 
expressing MAVS adaptor protein, was added to half of the plate (1 µg/well) (MAVS+). The other 
half was transfected without pCMV5-FLAG-MAVS plasmid (MAVS-) to appraise the basal levels of 
IFN expression in 293T. At 8 hours post-transfection the media was replaced with DMEM 
supplemented with 10% FBS, 1% NEEA and 1% P/S solution and cells were incubated for further 16 
hours. At the end of the incubation, 293T cells were lysed with 300 µl of lysis buffer (Promega) then 
firefly luciferase activity was measured in a luminometer using the Dual-Luciferase Reporter Assay 
System (Promega).  
The PB1-F2/MAVS/NS1 assay was performed including also pCAGG/NS1 H7N3, pCAGG/NS1-77 
H7N3 or empty pCAGG expression plasmids in the MAVS+ condition described above, aiming to 
evaluate the synergetic effect of NS1 and PB1-F2 antagonistic effect on the IFN-mediated antiviral 
response.  
 
8.2.2.11  Minireplicon assay 
293T cells were transfected in 24-well plates with pCAGG expression plasmids encoding PB2, PB1, 
PA, NP and different PB1-F2 (wild type or L75H) proteins derived from the H7N3 
A/turkey/Italy/2962/V03 (NP, 320 ng; PB1 and PB2, 160 ng; PA, 80 ng; PB1-F2 or PB1-F2 L75H or 
empty pCAGG, 500 ng) using Lipofectamine 2000 (Invitrogen). A negative-sense firefly luciferase-
expressing plasmid (pHuman-PolI-Firefly; 80 ng) was used as reporter to measure the polymerase 
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activity. At 24 hrs post-transfection, cells were lysed with 300 µl of lysis buffer then firefly luciferase 
activity was measured in a luminometer using the Luciferase Reporter Assay System (Promega). 
 
8.2.2.12  NS1-77/2A/GM-CSFV5 and NEP mRNAs detection. 
Semi-confluent monolayers of 293T cells were transfected in a 24 well plate with RF483-NS1-
77/2A/GM-CSFV5/NSend, RF483-H7N3 NS1 or RF483-H7N3 NS1-77 plasmids at concentration of 1 
µg/well. Forty-eight hours post-transfection, the media was removed and the cells were pelleted at 
12000 g x 5 minutes. Total RNA was extracted from cell lysates using the Nucleospin RNA extraction 
kit (Macherey-Nagel) and then mRNAs were isolated using the PolyATtract mRNA Isolation Systems 
(Promega). RT-PCR was performed using the primers H7N3 NEP Fw1-23 and H7N3 NEP Rv322-344, 
which target the NS1 and NEP shared mRNA sequences, to investigate the expression of mRNAs 
produced from NS1-77/2A/GM-CSFV5/NSend construct. Amplification of β-actin mRNA was 
performed as a loading control using VG 150 and VG 151 primers previous published by Moerdyk-
Schauwecker et al. (Moerdyk-Schauwecker et al., 2012). 
 
8.2.3 Infectious studies 
8.2.3.1 Annexin-V staining 
The ability of reverse genetics influenza viruses to kill pancreatic cells via apoptosis was measured 
using annexing V staining. BxPC-3 and HPDE6 cells were infected with virus isolates at M.O.I. of 0.1 
and the inoculum was removed after one hour of absorption and replaced with 1 ml of serum-free 
media. Combination of Gemcitabine (2 mM) and Cisplatin (0.8 µM) treatment served as positive 
controls for apoptosis. FBS was added to each well one hour prior to harvesting for a final 
concentration of 10% to ensure cell membrane integrity for the labelling process. At 16 and 24 
hours post-infection, cells were harvested from two infected and one control well and incubated 
with Alexa Fluor® 647 Annexin V conjugate  (Invitrogen) (1 µl per 375,000 cells) and propidium 
iodide (PI, 2 µl per 375,000 cells) in a volume of 300 µl of media with 10% FBS for 10 minutes in the 
dark. Samples were then fixed for 15 minutes in 3.6% paraformaldehyde, spun for 5 minutes at 
1200 RPM, resuspended in 300 ul of PBS-FBS and read within 24 hours on a BD Facscalibur. The 
percentage of Specific Cell Death (SCD %) was calculated according to the formula SCD% = [(% 
annexin V positive cells (AV+) following virus infection - % AV+ not treated) / (100% - % AV+ not 
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treated)] x 100. A minimum of 5,000 events were recorded and all infections were repeated in 
three independent experiments. 
 
8.2.3.2 Expression of IFN related genes in BxPC-3 and HPDE6 cells. 
Cells were either mock-treated or infected with H7N3 A/turkey/Italy/2962/03 at M.O.I. of 0.1. Total 
RNA was extracted from cells at 16 h post-infection (p.i.) using NucleoSpin RNA II kit (Macherey-
Nagel) in accordance with manufacturer instructions. RNA (0.5 mg/reaction) was reverse 
transcribed and amplified by RT-PCR using OneStep RT-PCR kit (Qiagen). PCR was carried with the 
following conditions: reverse transcription at 50°C at 30m, denaturation at 94 °C for 15 min 
followed by denaturation at 94°C for 45 s, annealing at 57 °C for 45 s, extension at 72 °C for 45 s for 
35 cycles and a finishing step at 72 °C for 8 min. All the primers used for the PCR were previously 
published and designed to amplify cellular mRNAs (Moerdyk-Schauwecker et al., 2012). PCR 
products were electrophoresed on a 1% agarose gel with Gel Red™ Nucleic Acid Stain (Biotium) and 
photographed using a Gel Doc™ EZ Imager (Bio-Rad). 
 
8.2.3.3 Immunocytochemistry (ICC) targeting apoptotic markers. 
BXPC-3 and HPDE6 cells previously seeded on sterile glass chamber slides (BD) and high-binding 
slides were infected at M.O.I. of 1. At 16 h post-infection supernatants were removed, slides were 
air-dried under the biosafety cabinet, fixed in ice-cold acetone for 20 minutes, and then stored at -
20°C until analysis. Gemcitabine and Cisplatin treatment served as positive controls for apoptosis. 
Prior to staining, frozen slides were thawed and washed 3 times for five minutes with deionized 
water to remove residual acetone, blocked with 3% H2O2 for eight minutes at RT to remove 
endogenous peroxidases, washed 3 times with deionized water and once with PBS-Tween 20. Slides 
were then blocked for 30 minutes with 1% BSA, washed with PBS-Tween and permeabilized with 
0.1% Triton X-100 for 10 minutes. Caspase-specific primary antibodies, including anti-active/cleaved 
caspase-8 (1:50, Imgenex), anti-active-caspase-9 (1:10, BioVision), and anti-active-caspase-3 (1:30, 
Cambridge, UK) were applied for 1 hour in a humidified chamber at room temperature. 
Immunoreactivity was revealed by the avidin–biotin method (LSAB+/System-HRP, DakoCytomation 
Glostrup) using aminoetile-carbazole substrate (AEC + Substrate-Chromogen Ready-to-use, 
DakoCytomation). Carazzi’s haematoxylin was used as a counterstain and Faramount Mounting 
Medium (DakoCytomation) was used to mount coverslips on slides. Ten histological counts of 500 
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cells each were performed per cell line/treatment/time point using Nis Elements BR software 
(Nikon) to determine the percentage of caspase-positive cells.  
 
8.2.3.4 Influenza A virus M gene one step RRT-PCR.  
BxPC-3 cells were infected with H7N3, H7N3 PB1-F2 L75H, H7N3 NS1-77, H7N3 NS1-77 PB1-F2 
L75H A/turkey/Italy/2962/03 viruses at M.O.I. of 1. Total RNA was extracted from cells at 8, 16 and 
24 h post-infection (p.i.) using NucleoSpin RNA II kit (Macherey-Nagel) in accordance with 
manufacturer instructions. The isolated RNA was amplified using the published primers and probes 
from Spackman et al., 2002 (Spackman et al., 2002), targeting the conserved Matrix (M) gene of 
type A influenza virus. 5 µl of RNA were added to the reaction mixture composed of 300 nM of the 
forward and reverse primers (M25F and M124-R respectively), and 100 nM of the fluorescent label 
probe (M+64). The amplification reaction was performed in a final volume of 25 µl using the 
commercial kit QuantiTect Multiplex RT-PCR kit (Qiagen, Hilden, Germany). The PCR reaction was 
performed using the following protocol: 20 minutes at 50 °C and 15 minutes at 95 °C followed by 40 
cycles at 94 °C for 45 sec and 60 °C for 45 sec. Target RNA in vitro transcribed was obtained using 
the Mega Short Script 7 (High Yield Transcription kit, Ambion), according to the manifacturer’s 
instructions, quantified by NanoDrop 2000 (Thermo Scientific) and used to create a standard 
calibration curve for viral RNA quantification. Copy numbers of M gene were obtained through the 
extrapolation of Ct values of the test samples against the corresponding standard curve. 
 
8.2.3.5 Virus replication kinetics in pancreatic cell lines.  
The ability of H7N3 and H7N3 NS1-77 to replicate in IFN competent HPDE6 cells and IFN deficient 
BxPC-3 cells was monitored over a 72 hour time-course. Cells were seeded in a 24 well plate and 
then infected with both viruses at an M.O.I. of 0.001. After 1 hour absorption the inoculum was 
removed and replaced with 500 μl/well of serum-free RPMI 1640 media containing 0.1 μg/ml of 
TPCK-trypsin (SIGMA). At 24, 48 and 72 hours post-infection cells were scraped and for each virus 
cell suspensions from three infected wells were harvested centrifuged and then the supernatants 
were store ad -80°C. 
The ability of H7N3 and H7N3 PB1-F2 avian influenza viruses to replicate in tumour derived BxPC-3 
cells was monitored over a 72 hour time-course in  24-well plates using an MOI of 0.001. Following 
one hour of incubation the inoculum was removed and replaced with 500 μl/well of serum-free 
RPMI 1640 media containing 0.5 μg/ml of TPCK-trypsin. At 24, 48 and 72 hours post-infection cell 
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suspensions from three infected wells were harvested, centrifuged and then the supernatants were 
store ad -80°C. Viral titres were determined for all the samples within the same plaque assay 
session on MDCK-Npro cells (Matrosovich et al., 2006). 
 
8.2.3.6 Viral growth in 7 and 14-day-old embryonated chicken eggs (ECE) 
Ten specific pathogen free (SPF) embryonated chicken eggs ECE (Charles River) of both 7 and 14 
day-old were infected with 103 pfu/egg of recombinant H7N3 A/turkey/Italy/2962/03 NS1-77 or full 
length NS1 viruses. Infected eggs were incubated at 37°C and candled daily to monitor the embryo 
viability. Once the number of dead eggs in each group exceeded 50%, they were incubated at +4°C 
overnight. Allantoic fluids harvested from all eggs were screened by rapid HA and those positive in 
each group were pooled together. Viral titres of the pooled fluids were measured by 
Haemagglutination assay (HA) according to the EU Council Directive 2005/94/EC and the OIE 
diagnostic manual (COUNCIL DIRECTIVE 2005/94/EC of 20 December 2005, 2006; Office 
International des Epizooties (OIE), May 2012). 
 
8.2.3.7 Evaluation of H7N3 NS1-77 virus’ immunostimulatory activity. 
Confluent monolayers of IFN-competent HPDE6 cells were infected in 12 well plates with H7N3 and 
H7N3 NS1-77 at M.O.I=1 or mock infected. After 1 h absorption, the media were replaced with 
RPMI 1640 supplemented with 3% FBS, 1% Pen/Strep, 1% NEEA and cells were incubated for 
further 24 hours. After 24 hours supernatants were collected and exposed for 10 minutes under 
germicidal lamp to inactivate potential infectious particles in the suspension as confirmed by 
subsequent plaque assay. The VeriKine Human IFN-β ELISA kit (pbl Assay Science) was then used for 
quantitative measurement of IFN-β in the supernatants. Next different monolayers of PDA and 
HPDE6 cells in 24 well plates were incubated with the conditioned media derived from previous 
infection. After 16 hours incubation the media was discharged and cells were washed with PBS and 
tested for the presence of cytoplasmic histone-associated DNA fragments using the Cell Death 
Detection ELISAPLUS photometric enzyme immunoassay (Roche – Life Science).  
Confluent mixture of HPDE6/BxPC-3Luc cells or BxPC-3Luc cells alone were growth in 96 well-plates 
using RPMI 1640 with 10% FBS, 1% Pen/Strep, 1% NEEA. Cells were then washed 3 times with PBS 
and infected with H7N3 or H7N3 NS1-77 viruses at M.O.I=0.1; 0.01; 1 or mock infected. After 1 hour 
absorption the cells were supplemented with RPMI 1640 with 0.5% FBS, 1% Pen/Strep, 1% NEEA 
and further incubated at 37°C until 24 hours post-infection when they were washed carefully with 
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PBS and lysed in Passive Lysis Buffer (Promega). Next, 5µl of cell lysates were combined with 100ul 
of BrightGlow buffer and substrate mixture (Bright-Glo™ Luciferase Assay System, Promega). 
Luciferase signal reading was performed within 5 minutes in GloMax-Multi Detection System 
(Promega). 
 
8.2.3.8 Packaging and conservation of NS1-77/2A/GM-CSFV5/NSend segment following serial 
virus passages in Npro cells. 
Packaging (Figure 49B). Supernatants derived from transfection with RF483-NS1-77/2A/GM-
CSFV5/NSend alone or in combination with the other 7 plasmids required to generate PR8 H1/N1-
2962 NS1-77 GM-CSF virus, were tested for the presence of the novel NS segment. Total RNA was 
extracted using the Nucleospin RNA extraction kit (Macherey-Nagel) and cDNA was generated. PCR 
reaction was performed using PFU turbo polymerase (invitrogen) and H7N3/NS1NotIF and 
H7N3/NS1MluIR sense and antisense oligonucleotides. 
The conservation of the NS1-77/2A7GM-CSF segment following PR8 H1/N1-2962 NS1-77 GM-CSF 
virus passage 1 and 2 in Npro cells (Figure 50A) was evaluated through Onestep RT-PCR using 
H7N3/NS1NotIF and IIMluI/GM-CSF rv2 primers. 
Analysis of truncation of the novel segment between passage 1 and 4 in Npro cells (Figure 51A) was 
performed on RNA extracted from the supernatant of infected cells by RT-PCR using 
H7N3/NS1NotIF and H7N3 NEP Rv322-344 sense and antisense oligonucleotides. 
 
8.2.3.9 Visualisation of GM-CSF expression in PR8 H1/N1-2962 NS1-77 GM-CSF virus infected 
BxPC-3 cells.  
BxPC-3 cells were grown on slides to 80% confluence and then infected with PR8 H1/N1-2962 NS1-
77 and PR8 H1/N1-2962 NS1-77 GM-CSF viruses at an M.O.I. of 0.1 or mock infected. After 8 hours 
post-infection the supernatants were collected and cells were carefully washed with PBS and then 
fixed and permeabilized with chilled acetone (80%). Blocking was performed with PBS containing 
1% BSA and 0.1% Tween-20 (Sigma), then the cells were incubated for 1 h at 37°C in a humidified 
chamber with mouse Anti-V5 antibody (Lifetechnologies), washed 3 times in PBS and further 
incubated with goat anti-mouse IgG-FITC antibody (Sigma) in PBS containing 1% BSA and 0.2% 
Evan’s Blue. After 1 hour at 37°C the staining solution was decanted and the slides were washed 
three times and observed under UV light. 
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8.2.3.10  Human GM-CSF and IFN-β quantitative measurement. 
Quantitative measurement of GM-CSF and IFN-β in cell supernatants was performed using the 
Human Gm-CSF ELISA kit (Thermo Scientific) and the VeriKineTM Human IFN Betas ELISA kit (pbl 
assay science) following manufacturers' recommendations. 
 
8.2.3.11  In vivo tumour model 
The in vivo experimental protocol was investigated and approved by the Italian Ministry of Health 
(protocol 130/2011). Six weeks old pathogen-free SCID-B17 female mice were maintained in 
laminar flow racks and micro isolator cages under pathogen-free conditions and received 
autoclaved food and water ad libitum.  
For the experiment described in chapter 2 twelve 6-week-old female SCID mice were 
subcutaneously injected with 5x106 BxPC-3 cells in a volume of 100 µl into the right flank. Palpable 
tumours developed after 8 days, and mice were then randomly divided into two groups (n=6), one 
group receiving an intratumoral inoculation of 2.4x104 PFU of H7N3 in a volume of 100 µl and the 
other receiving 100 µl of PBS. The procedure was subsequently repeated 3, 5, and 7 days later for a 
total of four intratumoral inoculations per treatment group. The overall physical condition and 
behaviour of the mice were monitored daily, and measurements of tumour size were taken on days 
8, 15, 19, and 25 following initial injection. Caliper measurements of tumour sizes were taken at 
regular intervals throughout the experiment, and the length (L) and width (W) were recorded to 
determine tumour volumes according to the formula V = L * W2 * (π/6) (V=volume; L=length; 
W=width). At 25 days post-infection, mice were sacrificed and tumours were snap-frozen for RNA 
extraction and IAV-specific RT-PCR as described above. 
For the experiments described within chapters 3 and 4, mice were inoculated subcutaneously in the 
right flank with 100 µl of 5 x 106 BxPC-3Luc cells, stably expressing firefly luciferase gene. Palpable 
tumours developed after nine days and mice were then randomly divided into different groups (n=5 
per group), each one receiving an intratumoural (IT) inoculation of 5 x 104 pfu/50 µl of H7N3 
A/turkey/Italy/2962/V03, H7N3 NS1-77, H7N3 PB1-F2 L75H, H7N3 NS1-77 PB1-F2 L75H viruses or 
PBS (negative control). The procedure was subsequently repeated for a total of four inoculations 
per treatment group. The overall physical condition and behaviour of the mice were monitored 
daily, and caliper measurements of tumour size were performed at regular interval following initial 
injection. The percentage of volume increase from the beginning of the treatment was calculated as 
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follows: Volume increase (%) = (Vtx-Vt0)/(Vt0*100). Tumour size and presence of metastasis were 
monitored also by bioluminescence imaging (BLI).In the case of H7N3 NS1-77 PB1-F2 L75H 
experiment (chapter 4 – paragraph 4.2.5) at day 23 a fifth IT virus injection was performed to 
appraise the clearance of the virus by the animals. All animals were sacrificed at the end of the 
experiments and in any case before reaching the threshold tumour volume of 1000 mm3. Following 
post-mortem examination tumours and lungs, livers and kidneys were collected, snap-frozen and 
tested for viral RNA presence using Real-Time RT-PCR for influenza A virus M gene as described 
above.  
 
8.2.4 Bioinformatic analysis 
8.2.4.1 Sequence analysis  
The sequences of all eight influenza genome segments belonging to H7N3 
A/turkey/Italy/2962/2003 were submitted to GenBank and assigned accession numbers JX515660, 
JX515661, JX515662, JX515663, JX515664, JX515665, JX515666, DQ090062.  
Influenza plasmids and virus sequences were aligned and analysed using MEGA 6.06 software 
(Tamura et al., 2013). Sequences used for comparison were downloaded from the NCBI Influenza 
Virus Resource (Bao et al., 2008). 
 
8.2.4.2 Statistical analysis 
Analysis of data was done using GraphPad Prism 6 for Windows (GraphPad Software Inc., La Jolla, 
CA).  Symbol and meaning: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.  
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Chapter 9. Appendix  
 
Sequences and corresponding ORFs of the main plasmids used in this study. Analysis was performed 
using Geneious v5.0 software (Kearse et al., 2012). 
 
 
RF483- H7N3 NS1 and RF483-H7N3 NS1-77 
Three site mutations (red boxes) were introduced to obtain the RF483-H7N3 NS1-77 plasmids from 
the Rf483-H7N3 NS1. 
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pCAGG/NS1 H7N3  
Site specific mutagenesis (A/C) was performed on pCAGG/NS1 H7N3 plasmid to abrogate NEP 
expression. 
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RF483- H7N3 PB1-F2 and RF483-PB1-F2 L75H 
Site direct mutagenesis (red box) was used to substitute Leucine (L) in position 75 within the PB1-F2 
ORF to Histidine (H). 
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RF483-NS1-77/2A/GM-CSF/NSend  
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